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Abstract
Oestrogen is suggested to have a protective role within the cardiovascular system as
the risk of coronary heart disease in pre- menopausal women is lower than that of
age-matched males and this protection is lost following the menopause. Oestrogen is
known to act via two receptor subtypes, ERa and ER6. However, little is known as
to the role of either receptor in mediating the effects of oestrogen in the
cardiovascular system (CVS).
The aim of this thesis was to determine the distribution of ERs in the CVS and
whether this was altered under pathophysiological conditions. We hypothesised that
oestrogen acting through ERs modifies vascular function and contributes to
regulation of blood pressure. Therefore, blood pressure and vascular function were
assessed in female mice of different oestrogen status and the influence of ER8
determined by studying male ER6 knock-out (6ERKO) mice and female WT mice
treated with a novel ER6 antagonist.
Immunoreactive ERB was associated with nuclei of myocardial, endothelial (ETC)
and vascular smooth muscle cells (VSMC) of the heart, aorta and mesenteric artery
in both male and female wild type (WT) and BERKO mice. Immunoreactive ER8
was also expressed in the 6ERKO mouse, which suggests the presence of part of the
receptor. However it was shown not to function as native WT ER6 protein as the
ovarian phenotype of the 6ERKO was consistent with loss of function. The
distribution of ER8 in mouse models of atherosclerosis and myocardial infarction
(MI) were not different to that of normal mice.
Mean arterial blood pressure (MABP) measured in young and aged WT and BERKO
mice, by implantation of a Millar catheter into the left carotid artery, was found to
increase with age. However, there was no difference in MABP between BERKO and
age- matched WT animals. The aorta isolated from these animals demonstrated that
the loss of functional ERB led to increased sensitivity to the ai- adrenoceptor agonist,
phenylephrine (PE) relative to their age- matched WT controls. Incubation with an
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inhibitor of nitric oxide (NO) synthase suggests that this may be due to a reduction in
the basal release of NO in the 8ERKO. The endothelium- dependent and -
independent relaxation responses were not different between 6ERKO mice and age-
matched WT controls.
MABP of female WT mice, as measured by radiotelemetry suggested that both
endogenous and exogenous oestrogen increased MABP. Treatment of female mice
with an ER8 antagonist resulted in an increase in MABP in sham ovx mice whilst
MABP was reduced in mice which were of ovx+E. Mesenteric vessels isolated from
sham ovx and ovx+E showed that chronic E treatment increased the sensitivity to PE.
Treatment of sham ovx animals with an ER antagonist did not alter vascular
function. Whilst treatment of ovx+E mice with the ER8 antagonist, led to a reduction
in the sensitivity to PE and an increase in both endothelium- dependent and -
independent vasodilatation.
In conclusion, ERB is widely expressed in the CVS, of both male and female mice
and was not altered in animal models of MI or atherosclerosis. In the vasculature of
both male and female mice ER8 modulated vascular function. The loss of ER6
function, in female mice with endogenous oestrogen, led to an increase in MABP
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In pre-menopausal females the principal site for oestrogen biosynthesis are the
ovaries. The ovaries have the ability to synthesise C19 precursors and to produce and
secrete oestradiol, Figure 1.1, following stimulation by the gonadotrophins, follicle
stimulating hormone (FSH) and lutenizing hormone (LH). At specific points in the
oestrous cycle, FSH and LH are released from the anterior pituitary in response to
gonadotrophin releasing hormone (GnRH) which is released from the hypothalamus,
Figure 1.2. FSH acts directly on granulosa cells to stimulate follicular growth by
synthesising androgens which are converted to oestrogen, this is known as the
follicular phase which terminates at ovulation. LH contributes to follicular growth by
acting on theca cells within the ovary to synthesis androgens which are then
converted to oestrogen via aromatase in granulosa cells. The surge in LH
concentrations, due to the positive feedback of moderate levels of oestrogen, results
in ovulation and the transformation of remaining granulosa and theca cells of that
follicle into the corpus luteum which secretes oestrogen and progesterone which act
on the hypothalamus to suppress the release of GnRH and subsequently FSH and
LH, this is known as the luteal phase.
However, in post- menopausal women, when the ovaries have ceased to synthesis
oestrogen and also in men, significant amounts of oestrogens are produced in a
number of extragonadal sites. Such sites of oestrogen biosynthesis include
mesenchymal cells of adipose tissue, osteoblasts of bone ana vascular endothelial as
well as aortic smooth muscle cells (reviewed in Simpson et al, 2000). However, in
these cells the process of oestrogen biosynthesis differs to that of the ovary as these
tissues are dependent on circulating C19 androgenic precursors as they are unable to
convert cholesterol to C19 precursors. Although the amounts of oestrogens
synthesised at these sites may be low the local tissue concentrations are likely to be
high and produce physiological effects either by acting in a paracrine or autocrine
manner. The importance of extragonadal synthesis of oestrogen and its role in males
was highlighted by the finding that men with a mutation in the gene coding for
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aromatase had reduced bone mass and their bones were incapable of epiphyseal

















Figure 1.2 Activation of oestrogen biosynthesis in the ovary by
hypothalamic and pituitary hormones.
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1.2 Structure of oestrogen receptors and mechanisms of
oestrogen receptor signalling
1.2.1 Oestrogen receptor structure
Oestrogen exerts its effect by binding to classical steroid hormone receptors, the
oestrogen receptor (ER) a (Green et al, 1986) and the more recently described ER8
(Kuiper et al, 1996). Similar to other receptors within the steroid hormone receptor
superfamily, ERa and 8, which share a high degree of homology, consist of three
functional domains; the N- terminal (A/ B domains), the DNA binding domain
(C domain) and the ligand binding domain or C-terminal (E/ F domain) (reviewed in
Nilsson et al, 2001, Kuiper et al, 1996; Kuiper and Gustafsson, 1997b), Figure 1.3.
The N-terminal domain, in which there is the greatest degree of sequence diversity
between ERa and ER8, contains the ligand-independent activation function (AF-1)
site which is a target site for receptor phosphorylation, is involved in protein-protein
interactions and is the site at which other transcription factors interact with the
receptor (reviewed in Nilsson et al, 2001). The N-terminus of ER8 is well conserved
between species implying that there is a degree of evolutionary constraint and
suggests that this receptor is of functional importance. The structural differences
between these receptors may explain the differences observed between the
transcriptional activation properties of these receptors. Delaunay et al, demonstrated,
by fusing the amino terminus of the ER8 protein to a heterologous yeast DNA
binding domain, that synergism between the amino and carboxyl terminus of ER8
was required for transcriptional activation (2000). This was in contrast to ERa, of
which the amino terminus was sufficient for transcription in certain cell types
(Metzger et al, 1995). Furthermore, although 178-oestradiol binds to both receptors
with similar affinity (Kuiper et al, 1997) the transcriptional response of ERa in some
cell types was greater than that of ER8 (Mclnemey et al, 1996). 4-hydroxytamoxifen
which was shown to be an ER8 antagonist, is an agonist for ERa on a promoter on
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The DNA binding domain (DBD) is the region in which ERa and ER(3 share the highest
degree of homology (86%). The DBD is important for receptor dimerisation and binding
to specific pallindromic DNA sequences, oestrogen response elements (ERE) located
within target genes (reviewed in Nilsson et al, 2001). Therefore ERa and ER8 will
interact with ERE of various genes with similar affinity and specificity.
The ligand binding domain (LBD) is the region of the oestrogen receptor which binds
hormone or ligand. This region of the receptor also mediates receptor dimerisation (either
forming homodimers or heterodimers between receptors), nuclear translocation of the
receptor (reviewed in Nilsson et al, 2001 and Hall et al, 2001) and recruitment of and
interaction with coregulators via AF-2. ERa and ERp share 58% homology in the primary
amino acid sequence in the LBD with high homology in the ligand binding cavity of both
ERs (Brzozowski et al, 1997). However, some ligands have been reported to bind with a
higher affinity to ERa than ERP and vice versa (Kuiper et al, 1997). It was suggested that
this was due to differences in the tertiary structure of the ligand binding cavity of ERa and
ERp despite sharing homology in their primary amino acid sequences. The gene
modulatory effect of the ER after ligand binding depends in part on the conformational
change in the LBD of the receptor leading to the formation of a hydrophobic groove,
known as AF-2, which enables cofactors to bind (reviewed Ruff et al, 2000). The
conformational change in the ER following ligand binding promotes and stabilises ER
cofactor interaction which subsequently stabilises ER ligand interaction which thereby
slows the rate of dissociation. Cofactors can either be co-activators or co-repressors
(reviewed Nilsson et al, 2001). Co-activators are implicated in transcriptional activation of
the target gene and can bridge the ER to either histones, or components of basal
transcription or both. Alternatively, co-repressors either associate with the ER in the
presence of antagonist or attenuate transcription of target genes by competing with co-
activators for binding with AF-2. Similar to the differences that exist between ERa and
ERp in the affinity for different ligands (Kuiper et al, 1997) there also exist differences in
the binding affinity of the AF-2 domain for specific cofactors between both receptors
(reviewed Nilsson et al, 2001). One such example is that ERa is less efficient than ERp in
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recruiting the co-activator complex TRAP/DRIP, which connects directly to basal
transcription machinery. This suggests that the ligand binding cavity and the AF-2 domain
may provide a site for the targeting of ER specific agonists/ antagonists.
1.2.2 Oestrogen receptor signalling
For many years it was believed that oestrogen only signalled through the classical ligand-
dependent and genomic pathway. Recently however, several other signalling pathways
have been suggested. These include an ERE-independent mechanism where the activated
ER can alter transcription of other response elements by binding DNA-bound transcription
factors at AF-1 binding sites. Alternatively, there may be non-genomic signalling where
the ER homo or heterodimers is present in, or close to, the cell plasma membrane, which
upon ligand binding leads to the activation of intracellular signalling cascades (reviewed
in Kelly and Levin, 2001 Mendelsohn 2002).
1.2.2.1 Classical ER signalling pathway.
In the classical signalling pathway, it was believed that ERs were rapidly transferred to the
nucleus only upon ligand binding. However, it is now confirmed that ER are
predominantly nuclear proteins and are located in the cell nucleus whether or not it is
bound with a ligand (Parker, 1995). The ER is stored in the nucleus in the inactive state
(King and Greene, 1984), bound to a heat shock protein which dissociates on binding of
the ligand and activation of the receptor. The binding of the agonist leads to homo- or
hetero- dimerisation of ERs and induces a conformational change such that the DBD of
the ER dimers bind to ERE in the promoter region of target genes, (reviewed in Hall et al,
2001), Figure 1.4. As described in section 1.2.1, the conformational change upon ligand
binding allows and stabilises the binding of coactivators to AF-2 within the carboxy
terminal, which subsequently stabilises ER- ligand binding (Gee et al, 1999) such that it
may result in maximal transcriptional activity. The importance of coactivators in steroid
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hormone function was highlighted in mice which were lacking steroid receptor
coactivator-1, which demonstrated decreased response to hormones in the prostate and
uterus (Xu et al, 1998). Opposite to the function of coactivators are corepressors, such as
repressor for oestrogen activity (REA), which function to silence the activity of ERs
(Montano et al, 1999). Therefore, coactivators and corepressors expressed in a given cell
type may determine the extent of transcriptional activity of the ligand activated ER.
1.2.2.2 Nongenomic actions of oestrogen
The observation that oestrogen treatments could produce effects that were too rapid for the
activation of RNA and protein synthesis suggested that oestrogen may have nongenomic
effects, Figure 1.4.
The non-genomic effects of oestrogen have been disputed as ER do not express sequences
that could code for a hydrophobic, transmembrane spanning region. However, it is
possible that ERs undergo post-translational modification such that they can be
transported and localised in the cell membrane. It was shown in Chinese hamster ovary
cells that were transfected with ERa and ER8 that both of these receptors were located in
the nucleus and cell membrane (Razandi et al, 2000). Although ERs lack myristoylation
and palmitoylation sites, which could anchor them to the plasma membrane, they may be
tethered to the membrane by glycophosphatidly- inositol (GPI) links or be localised to
caveolae, which are signalling transduction and vesicular trafficking domains in the
plasma membrane (reviewed in Kelly and Levin, 2001). Oestrogen rapidly activated
eNOS in cultured endothelial cells in which ERa reportedly coprecipitated with
endothelial cell caveolae (Shaul et al, 1996, Shaul et al, 1998). This was shown to be ER
mediated as the rapid activation of eNOS was completely inhibited by the ER antagonist
ICI 182 780. The exact signalling pathway by which ERa activates eNOS has yet to be
fully determined. However, ERa has been shown to activate eNOS in a non-genomic
manner via interaction with the phosphatidylinositol 3-OH kinase pathway and the
MAPkinase pathway in endothelial cells (reviewed in Simoncini et al, 2002 and Ho and
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Liao, 2002). Furthermore, a recent study by Song et al, demonstrated that ERa interacts
with the adaptor protein She such that it forms a complex with IGF-1R. This complex can
then be translocated to the cell membrane and induce the phosphorylation of MAPkinase
and subsequent downstream signalling. (Song et al, 2003).
Although evidence suggests that oestrogen may produce rapid effects via ERa, whether
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1.3 Oestrogen receptor function
By 1996 it was clear that two receptor molecules for oestrogen existed, both of
which shared a high degree of homology, specifically within regions of the LBD
(reviewed in Nilsson et al, 2001). Studies to date aimed at elucidating the role(s)
played by ERa and ER6 induced changes in gene expression have been hampered by
the lack of subtype specific receptor antagonists.
However, this was overcome firstly, by gene deletion techniques by which ER
subtype specific knock out mice were generated; ERa knock-out (ERKO, Lubhan et
al, 1993) and ER8 knock-out, (BERKO, Krege et al, 1998). The generation of these
mice provided a useful tool in studying the effects of oestrogen mediated via these
individual receptors. Secondly, by the recent development of ER subtype specific
agonists and antagonists as a result of improved understanding of the structure and
function of the individual regions of the ERs. Examples of such drugs are ERa
agonist, propyl pyrazole (PPT, Stauffer et al, 2000) and diarylpropionitrile (DPN,
Meyers et al, 2001), a selective ERB agonist. These drugs have a 410 fold and 70
fold higher binding affinity for ERa and ERB respectively.
1.3.1 ER knock out mice
Studies on the reproductive systems of ER knock-out mice have demonstrated that
both of these receptors are of physiological importance in maintaining normal
fertility. Both sexes of the ERKO mouse were shown to be infertile (Lubhan et al,
1993). The ovary of the ERKO females was enlarged, hemorrhagic and consisted of
cystic follicles (Schomberg et al, 1999). The ovaries from these mice also lacked
corpus luteum which suggests that the ovaries are incapable of spontaneous
ovulation. Additional studies suggested that the ovarian phenotype of the ERKO
mouse, was exacerbated by the elevated levels of gonadotrophins that existed in
these animals (Sharkey et al, 1999). The testes of the male ERKO were reduced in
size and male infertility was attributed to a defect in their ability to resorb fluid
within the efferent ductules which affected sperm motility such that these sperm
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were unable to fertilise wild-type oocytes in- vitro (reviewed in Couse and Korach,
1999). In contrast, female 6ERKO mice are capable of producing litters although the
number of litters and the number of pups were substantially fewer than that of wild-
type animals. The subfertility of 6ERKO females may be due to an increase in early
atretic follicles and a reduction in the number of corpus luteum (Krege et al, 1998).
In contrast to the ERKO, BERKO males were found to be fully fertile.
Mice in which the ER genes have been modified have been used to study the role of
these receptors in mediating the effects of oestrogen in the cardiovascular system and
this will be discussed later in this chapter.
1.3.2 ER selective agonists
ER selective agonists have been described in the literature (Harrington et al, 2003)
but have only recently become commercially available. To daie only limited research
has been published using ER selective agonists as tools to study the roles of the
different ER subtypes in mediating the effects of oestrogens. The advantage in using
selective agonists over 'knock-out animals' is that 'knock-out' animals have passed
through all stages of development without the presence of the respective receptor.
Therefore, the 'knock out' mouse cannot be considered different to the wild-type
mouse only in the lack of expressing the receptor, as some compensatory
mechanisms during development cannot be excluded. Furthermore, the method of
gene deletion employed to generate the ERKO and 6ERKO animals can result in
aberrant splicing of the disrupted gene and therefore the 'knock-out' generated may
not be a complete null. Literature has reported that such variants were detected in
both ERKO and BERKO mice (Couse et al, 1995, Krege et al, 1998). However, the
variants expressed in these models were not found to be the same as transcribed
wild-type mRNA
Early studies using the ER selective agonists have demonstrated that activation of
ERB in the uterus by DPN downregulates the expression of the progesterone receptor
(PR, Frasor et al, 2003). These findings are consistent with results of a study using
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6ERK0 mice in which expression of PR mRNA in the uterus was upregulated
following chronic oestrogen treatment (Weihua et al, 2000), this suggests that ER8
attenuates the expression of PR. The selective ERa agonist, PPT has also been
shown to have effects in vivo-, treatment caused an increase in PR expression in the
cerebellum showing PPT is capable of crossing the blood brain barrier (Harris et al,
2002). Other studies using DPN have demonstrated that neuroprotection provided by
oestradiol following global ischaemia is likely to be mediated by ER8 (Carswell et
al, 2004).
Few studies have been published in the literature reporting the effects of ER selective
agonists in the cardiovascular system. This is an area of research that needs to
expand over the next few years in order to improve the safety and efficiency of
oestrogens in cardiovascular disease. Studies published to date have demonstrated
that in spontaneously hypertensive rats (SHR) treatment with an ERa agonist
prevented endothelial dysfunction, and that stimulation of ERa increased eNOS
protein expression and vasodilator-stimulated phosphoprotein phosphorylation
(Widder et al, 2003).
1.3.3 ER in the cardiovascular system
In 1996 when ER6 was identified and immediately thereafter, research rapidly
opened up in the areas of both genomic and non-genomic effects of oestrogen and
the role of oestrogen receptors in mediating those effects in the cardiovascular
system. In addition, a number of studies were undertaken to determine the
distribution of both receptors in the cardiovascular system of both humans and
animals models.
1.3.3.1 ER distribution.
Oestrogen action is dependent upon the presence of specific ligand-activated
receptors in target tissues. Therefore prior to determining the effects of oestrogen on
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target cells, studies in receptor distribution can provide data as to whether cells are
likely to provide a future therapeutic target.
Following the identification of ERa and ERG (Green et al, 1986, Kuiper et al, 1996),
immunohistochemical and molecular biological techniques were employed to
determine their distribution in the cardiovascular system (Orimo et al, 1993,
Leiberman et al, 1990, Karas et al, 1994, Iafrati et al, 1997). ERa was reported to be
expressed in rat aortic smooth muscle cells (Orimo et al, 1993) and also human
vascular smooth muscle cells (Bausero et al, 2000). However, it became apparent
that expression of ERa varied with both the species and vascular bed studied.
Although expressed in both human and rat vascular smooth muscle cells, it was
reported that VSMC of both the carotid artery and aorta of the guinea-pig lacked
immunoreactive ERa (Leiberman et al, 1990). It is possible that the variation in
expression of ERa in the vasculature may account for some of the differences
reported between species in the functional effects of oestrogen. For example, there
have been reports of differences in vascular responses between rabbit and rat
(Paredes-Carbajal et al, 1995). Therefore determining the e-pression of ERs in the
animal model and vascular model being studied may be crucial so that appropriate
comparisons may be made between reports in the literature. Literature published on
the distribution of ERa in the cardiovascular system has mainly involved the use of
whole tissue extracts combined with Western analysis or detection of mRNA.
Determination of mRNA expression using whole blood vessels means that whether
ERa is specifically expressed in vascular smooth muscle or endothelial cells is not
known. Where immunocytochemistry has been applied, it was to cultured cells,
either smooth muscle or endothelial cells. Although cellular localisation of the
protein to the nucleus was demonstrated compatible studies on intact tissue were not
undertaken. Studies to assess the presence of ERa in coronary arteries of monkeys
and humans have shown that nuclei of both endothelial cells and vascular smooth
muscle cells express ERa (Diano et al, 1999). However, the vascular bed studied
may result in differing results as studies in the vascular endothelium of human and
non-human primate endometrium have shown that these cells express ER6 but not
ERa (Critchley et al, 2001).
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Immunocytochemical analysis of female rat vascular beds localised the expression of
ER6 protein in the nuclei of vascular smooth muscle and endothelial cells of the
aorta, tail and uterine arteries (Andersson et al, 2001). Several studies have reported
the expression of mRNA for ER8 in the blood vessels of rat and mice (Lindner et al,
1998, Makela et al, 1999). However, despite the use of mice, in particular ERKO and
BERKO mice as tools to extrapolate the influence of oestrogen and the mechanisms
by which these effects are produced, it is only very recently that literature has
reported the expression of ERs in the mouse vasculature. Initial studies by Lang et al,
reported that ER6 but not ERa was expressed in the mouse aorta (Liang et al, 2001).
Both ERa and ER8 are known to be expressed in the nuclei of cardiomyocytes and
coronary arteries of both rat and rabbit hearts (Lou et al, 1998, Saunders et al, 1997,
Neudling et al, 2001) as studied using whole tissue and cultured rat cardiomyocytes.
However, the expression of ERs, either RNA or protein, in ^ardiomyocytes has not
yet been reported in the mouse.
1.4 Influence of oestrogen in the cardiovascular system.
1.4.1 Early observations and clinical trials
The role of oestrogen is not restricted to the reproductive system but also extends to
masculinisation of the brain, closure of epiphyseal plates and the function of the
cardiovascular system (reviewed in Nilsson et al, 2001).
Oestrogen was suggested to have a protective role in the cardiovascular system as
women suffer less from cardiovascular disease during their reproductive life than
age-matched men (Benetos et al, 1999). In addition to the described benefits of
oestrogen on coronary heart disease and stroke, one other beneficial effect of
oestrogen was believed to be on the regulation of blood pressure. It was suggested
that oestrogen lowered blood pressure as premenopausal women had a lower systolic
and diastolic blood pressure than those women that had either undergone natural or
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surgically induced menopause (Stassen et al, 1989, Seely et al, 1999, Cagnacci et al,
1999). Furthermore, this apparent protection gradually declines after the menopause
as circulating oestrogen levels fall.
Oestrogen therapy was used as a treatment for menopausal symptoms from the late
1940s and since then its effects out with the reproductive system have been observed.
Observational studies reported that women receiving oestrogen replacement therapy
had a 50% reduction in the incidence of secondary heart attacks (Sullivan et al,
1990). It is believed that oestrogen mediates its cardioprotective effects by providing
a favourable lipid profile (Kushawaha, 1992) and by enhancing the release and
activity of endothelium derived nitric oxide (EDNO) (Kauser and Rubanyi, 1997,
Hayashi et al, 1994). Despite the beneficial effects of oestrogen reported from
observational studies, recently, randomised clinical trials (Hulley et al, 1998) have
shown that hormone replacement therapy (HRT) had no overall benefit in coronary
heart disease. The HERS trial (Hulley et al, 1998) was stopped prematurely as during
the first year on HRT, there was a small but significant increase in the risk of acute
myocardial infarction. This increased risk occurred mostly, but not uniquely, in
women who already had established coronary heart disease. However, the early
termination of the trial was surprising as a trend was developing that cardiovascular
health was improving following long term treatment, as the risk was found to
decrease following 4-5 years treatment in the hormone replacement group. In 2002
the Women's Health Intiative (WHI) was published, this was a randomised
controlled study of asymptomatic healthy post-menopausal women, reporting that
combined oestrogen treatment was associated with a slight increase in the absolute
risk of stroke, heart attacks and breast cancer. However, this trial has been recently
met with criticism of a possible detection bias such as the unblinding of the study
due to the onset of symptoms associated with hormone replacement. Additionally,
following the publication of the results of the small increase in acute MI detected in
the HERS trial letters were sent to all participants of the WHI trial informing them of
the increase risk during the first study year which may have led to otherwise
clinically unrecognised Mis being diagnosed more often (Garbe and Suissa et al,
2004).
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1.4.2 Effects of oestrogen on the myocardium
Although the HERS trial, which indicated that oestrogen supplementation did not
provide any overall benefit in CHD, a subsequent study published by Hodis et al,
showed that healthy postmenopausal women treated with unopposed oestrogen, ie
not combined with progesterone, had a slower rate of coronary arteriosclerosis than
those treated with placebo (Hodis et al, 2001). The ESPRIT study which followed
shortly after the study by Hodis et al, was designed to assess whether unopposed
oestrogen provided protection against a second cardiac event or death in
postmenopausal women who had just suffered a first ischaemic event (Cherry et al,
2002). Although, a reduction in cardiac death was observed in women receiving
oestrogen supplementation it did not reach significance as the total death rate from
all causes of death was also reduced in this group. Therefore, despite the observation
that oestrogen had some beneficial effects on the rate of coronary arteriosclerosis, a
beneficial effect was not observed in those women who had previously suffered a
coronary event.
The myocardium relies on nutrients and oxygen being delivered by coronary arteries,
if these arteries become occluded, which may occur by the development of an
atherosclerotic plaque, blood flow would be obstructed. Therefore, the demands of
the myocardium are no longer being met and tissue may become ischaemic as a
result of hypoxia. If the ischaemic area of the myocardium is not reperfused it will
result in apoptosis and myocardial infarction (MI). However, the process of restoring
blood flow to the ischaemic area, can in itself result in tissue damage. The
reintroduction of oxygen during reperfusion to the ischaemic site can result in the
development of free radicals that can led to cellular damage and death. In a canine
model of ischemia reperfusion, chronic treatment with oestradiol attenuated
reperfusion arrhythmias, myocardial systolic dysfunction and the temporary
impairment of endothelial function (Kim et al, 1996). Although oestrogen has
beneficial effects on lipoprotein metabolism these account for only about 25- 40% of
its beneficial effects (Barrett-Connor and Bush, 1991) and in the study by Kim et al,
it was suggested that the protection provided by oestrogen was in part due to its
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antioxidant effects. Further studies also demonstrated a role for the anti¬
inflammatory effects of oestrogen in reducing leukocyte accumulation as a result of
myocardial ischemia reperfusion in the rat (Squadrito et al, 1997a). Squadrito et al,
demonstrated that chronic oestrogen treatment in the rat reduced expression of
TNF-a and attenuated the expression of ICAM-1 and leukocyte infiltration. This
resulted in a reduction in myocardial necrosis (Squadrito et al, 1997a, b). Although it
is clear from these studies that oestrogen is cardioprotective, the differences in the
effect on the cardiovascular system observed in clinical trials after one year
compared with those after a longer follow up period were also reported in a study by
Smith et al (2000). In this study, it was observed that during the acute period
following surgery to induce MI, a greater mortality was observed in female rats
treated with oestrogen and that these animals had an increased infarct size relative to
placebo. However, in those animals that survived, chronic oestrogen treatment
attenuated left ventricular dilation and normalised wall tension. It was suggested that
this benefit may be attributed to the effect of oestrogen in the vasculature to reduce
wall stress by reducing pre- and after- load. It was also suggested in this study that
oestrogen may act directly on the myocardium by inhibiting the hypertrophic action
of the endothelin system (Smith et al, 2000).
As a consequence of MI the heart may become hypertrophic. Initially this is a
compensatory mechanism for the reduction in cardiac function due to the infarcted
area. However, it eventually led to heart failure due to the reduction in left
ventricular systolic function as indicated by a reduction in cardiac output. Chronic
oestrogen treatment has been reported to reduce the development hypertrophy in a
pressure overload model (van Eickels et al, 2001). In this particular study, it was
reported that chronic supplementation of mice with oestrogen led to a reduction in
hypertrophy which was attributed to an increase in the expression of atrial natriuretic
peptide (ANP) and not to an inhibitory effect of oestrogen on the renin angiotensin
system as a result of a reduction in ATi receptor expression. ANP is suggested to
have anti-hypertrophic properties by attenuating protein synthesis via cGMP (Horio
et al, 2000). This was confirmed by the finding that oestrogen treatment of female
rats led to an increase expression of ANP (Jankowski et al, 2001). In addition to
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inducing the increase in ANP levels, oestradiol reportedly induced bradycardia, the
resulting reduction in oxygen consumption may have had an additional
cardioprotective effect to that of the antihypertrophic effects of oestrogen (Jankowski
et al, 2001). Interestingly, this study reported that ERa expression in the heart was
greater than that of ER8 and secondly, that the expression of ANP in the heart
reflected that of ERa. This suggests that ERa may mediate the oestrogen induced
increase in ANP.
1.4.3 Effects of oestrogen on the vasculature and the role of ERs
1.4.3.1 Effects of oestrogen on the vasculature
In addition to the effects of oestrogen on lipid metabolism, by which oestrogen may
provide protection against CE1D, other factors to be considered are the direct effects
of oestrogen on blood vessels. Oestrogen replacement therapy is reported to decrease
peripheral vascular tone in both healthy women and those with cardiovascular risk
factors (Lieberman et al, 1995), and the vessel wall is now well recognised as an
important target for oestrogen. Evidence is accumulating that oestrogen can act on
the vessel wall to inhibit vascular smooth muscle cell proliferation (Chen et al, 1996)
as well as influencing endothelial function (reviewed in Mendelsohn, 2002).
Oestrogen may influence endothelial function by modulating one, or all, of the three
main relaxing factors derived from the endothelium. These are NO, prostanoids and
endothelium derived hyperpolarising factor (EDHF). Animal studies have largely
concluded that chronic oestrogen treatment increases the basal release of NO from
the endothelium (Hayashi et al, 1992, Paredes- Carbajal et al, 1995, Wu et al, 2000,
Gonzales et al, 2001). However, multiple mechanisms may be involved in the
oestrogen upregulation of NO mediated responses. Possible mechanisms include an
increase in the amount of NOS protein, in the availability of substrate and/ or an
increase in the levels of bioactive NO. The findings by Huang et al and Mac Ritchie
et al, support an ability of oestrogen to upregulate transcription of the eNOS gene
and protein expression and increased eNOS activity (MacRitchie et al, 1997, Huang
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et al, 2000). Oestrogen may also stabilise eNOS mRNA and thereby increase eNOS
protein expression (Sumi et al, 2001) and also reduce the levels of the endogenous
nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA, Dai et al,
2004). Taken together these changes would result in an increase in the bioavailability
of NO. These effects are in addition to the antioxidant effects of oestrogen where
oestrogen has been reported to downregulate the expression of NADPH oxidase in
human endothelial cells and subsequently improve the NO/ O2" (superoxide) balance
(Wagner et al, 2001).
Interestingly, chronic oestrogen treatment was also reported to increase the release of
cyclooxygenase dependent vasocontricting metabolites of arachidonic acid (Paredes-
Carbajal, et al 1995 and Miller and Vanhoutte, 1990). However, the effects of
oestrogen on arachidonic acid metabolism are somewhat conflicting, as other studies
have reported that oestrogen enhances the release of prostacyclin and subsequently
vasodilation (Ospina et al, 2002, Ospina et al, 2003). It appears therefore, that the
effects of oestrogen on the vasculature can be both species dependent and also
dependent on the vascular bed studied.
In addition to NO and the prostanoids, a role for EDHF in mediating the endothelium
dependent response to oestrogen has been reported (Dalle Lucca et al, 2000 and Liu
et al, 2001). Liu et al reported that both normally cycling female rats in dioestrous
(short term oestrogen deprivation) and those which were ovariectomised (long term
deprivation), had a reduction in the endothelium-dependent relaxation response to
ACh. This was attributed to the reduction in the release of EDHL when compared to
rats which had elevated oestrogens (eg oestrous or supplemented with oestrogen
following ovariectomy).
However, oestrogen may also regulate vascular tone by acting directly on vascular
smooth muscle cells, independently of the endothelium. The enhanced contractile
responses following oestrogen deprivation in previous models have been attributed to
the reduction in endothelium-derived relaxing factors. However, whether the reduced
contractile response is agonist-dependent or not is unclear. Similar to the finding by
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Miller and Vanhoutte (1990), who studied rabbit aortas, Zhang and Davidge (1999),
found that oestrogen deprivation of female rats had no effect on the contractile
response of the mesenteric artery to the thromboxane analogue U46619. However,
they did report that chronic oestrogen treatment of female rats, did reduce the
response to PE and that this was attributed specifically to the reduction in the
expression of ai- adrenoceptors. This was the first study to show that oestrogen
attenuated the contractile response by altering the expression of a specific receptor.
Other studies have shown that the vasorelaxant effects of oestrogen on vascular
smooth muscle cells have been independent of the agonist used to stimulate
contraction.
In the rat aorta it was shown that oestrogen induced vasodilation that was blocked
not only by L-NAME, which supports the role of oestrogen to stimulate the synthesis
and subsequent release of NO from the endothelium, but also by tetraethyl
ammonium (TEA) which is a K+ channel blocker. Therefore, it was suggested that
the vasorelaxant effects of oestrogen can be endothelium independent due to the
modification of potassium (K+) channel function (Abou-Mohamed et al, 2003). The
calcium and voltage dependent K+ channel, known as the maxi K+ channel, is
composed of two units, a pore forming alpha-unit and an accessory subunit, the B1
subunit. The latter increases the channels sensitivity to both calcium and voltage and
the activity of the B1 subunit was enhanced by direct interaction with oestrogen
(Valverde et al, 1999). This effect of oestrogen was shown to be independent of
intracellular signals and was also induced by oestrogen which was conjugated to a
carrier protein which was therefore unable to cross the cell membrane. However,
later studies by Benkusky et al, demonstrated that oestrogen treatment increased the
sensitivity of the maxi K+ channel by increasing the transcription of the B1 subunit of
the maxi K+ channel and only in vessels from animals that had been chronically
treated with oestrogen (2002). Although there exists some discrepancy as to the
mechanism by which oestrogen enhances the sensitivity of the K+ channel, the
resultant effect is that oestrogen increases K+ efflux, repolarisation of the vascular
smooth muscle cell and closing of calcium channels and subsequent relaxation.
Oestrogen may also mediate relaxation in an endothelium-independent manner by
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blocking Ca2+ channels of vascular smooth muscle cells (Salom et al, 2002). Using
electrophysiological techniques on cultured, rat, aortic smooth muscle cells,
oestradiol was shown to inhibit the barium inward current through voltage-dependent
Ca2+ channels (Ogata et al, 1996) and to reduce the contractile response to
noradrenaline by reducing calcium entry (reviewed in Tostes et al, 2003). However,
the concentrations of oestrogen used in these studies were supraphysiological and
therefore a direct effect of oestrogen on calcium channels is difficult to interpret as
regards the effects of physiological concentrations of oestrogen.
1.4.3.2 The role of ERs
Two main areas of research on the effect of oestrogen on the vasculature have
emerged from the literature, namely; vascular injury and vascular tone.
The model used most consistently in studies designed to induce vascular injury was
balloon injury of the carotid artery. A study using female, ovariectomised rats
administered either oestrogen or placebo (Bakir et al, 2000) reported that oestrogen
attenuated the development of neointima formation following balloon injury of the
carotid artery. This study also showed that the protection provided by oestrogen was
receptor mediated as the antagonist blunted the effect of oestrogen in a dose-
dependent manner. Although the ER antagonist used in this study would block both
ERa and ERB a study published by Lindner et al (1998) suggested that ERB may
have a role in the direct vascular effects of oestrogen as regards protection following
vascular injury as the expression of ERB mRNA was found to have increased in
human male blood vessels following vascular injury.
Due to the high degree of homology between the ERa and B (reviewed in Nilsson et
al, 2001) and the lack of commercially available receptor selective agonists and
antagonists it has been difficult to study the individual effect of the receptors in
vascular function. However, the generation of ERa (ERKO, Lubhan et al, 1993) and
ERB (6ERKO, Krege et al, 1998) gene-modified mice have provided a useful tool for
such studies.
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It was believed that, by conducting studies with vascular injury models the role(s) of
the individual ERs in mediating the protective effect of oestrogen would be
elucidated. Iafrati et al reported, that oestrogen treated mice were protected against
the increase in vascular medial area and smooth muscle cell proliferation, which
developed following carotid arterial injury in placebo treated mice (1997). To
determine whether oestrogen mediated its effect via ERa the same study was carried
out in WT and ERKO mice and it was reported that both groups of mice were
protected to the same degree against injury, by the administration of oestrogen. This
suggested that oestrogen inhibited the increase in medial size and smooth muscle
proliferation by a mechanism independent of ERa, possibly via ER8. However,
subsequent studies of vascular injury in 8ERKO mice (Karas et al, 1999)
demonstrated that oestrogen treatment also protected against vascular injury in mice
lacking functional ER6. One possible explanation for the protection observed in both
the ERKO and 8ERKO mice is that oestrogen may be able to act through either of
the two ERs to provide the same degree of protection. It is also possible that in the
knock-outs the expression of the remaining ER subtype is increased to compensate
for the loss of the other receptor and therefore the expression of one ER is sufficient
to provide protection. The generation of oestrogen receptor selective agonists or
antagonists would be useful to either selectively stimulate or block the activity of one
receptor in a WT animal whose expression of ERa/ 6 has been unaltered.
Interestingly, studies in DERKO (ERKO/ 6ERKO double knock-out) mice found
that they were still partially protected from vascular injury (Karas et al, 2002). This
suggests that a component of protection provided by oestrogen to vascular injury is
not receptor dependent, that a third oestrogen receptor exists or, as recently reported,
that the ERKO mouse has a degree of residual activity (Couse et al, 1995) which is
sufficient to provide protection.
Oestrogen has also been shown to have a regulatory role in vascular tone (Paredes-
Carbajal et al, 1995, Hayashi et al, 1992, Wu et al, 2000) and chronic oestrogen
treatment increases release of endothelium derived relaxing factors, Section
1.4.1.2.2. However, the role of the individual receptors in regulating vascular tone
has only recently begun to be studied and the use of ERKO and 8ERKO mice has
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provided some interesting insights. Rubanyi et al reported that in male mice the basal
release of NO was reduced in aortas from ERKO mice when compared to those from
male WT controls (1997). It was shown that there was no difference in the stimulated
release of NO, suggesting that the significant increase in cytosolic free calcium level
and subsequent activation of NOS and release of NO may override the mechanism
for the basal release of NO and the differences which existed between these groups
of basal release. Although the role of individual ERs in producing the genomic
effects of oestrogen in the vasculature have been poorly investigated significant
attention has been spent on investigating the role of ERs on the rapid, nongenomic
effects. For example, in human endothelial cells, incubation with a cell impermeant
form of oestrogen was reported to rapidly increase NO production (Haynes et al,
2000a). As the rapid effect of oestrogen was blocked by either the non-specific ER
antagonist, ICI 182,780 or an inhibitor of PI3-kinase, it was suggested that the non¬
genomic increase in NO produced by oestrogen was mediated by the PI3- kinase
pathway and was ER dependent. Several studies have reported a role for ERa in
mediating the rapid effects of oestrogen on the NO pathway in cultured cells. ERa
has been shown to localise in signalling domains called caveolae, which are rich in
many signalling molecules and activate eNOS (Chambliss et al, 2000). The
activation of eNOS by oestrogen via the interaction of ERa with the PI3-kinase
pathway, was reported to be physiologically relevant in the protection provided by
oestrogen to ischaemia reperfusion injury in mice (Simoncini 2000). It was reported
that mice treated with oestrogen had an increase in eNOS expression and a reduction
vascular leukocyte accumulation that was attenuated by either inhibitors of PI3-
kinase or NOS. However, this group did not address the presence and possible role of
ER8 nor confirm that this effect in vivo was ER mediated.
It was not known at the time of the study by Rubanyi et al that two ER subtypes
existed and therefore they did not address the possibility that ER8 may influence
vascular tone (Rubanyi et al, 1997). It is only recently that characterisation of the
role of ER8 in the vasculature has begun. Nilsson et al (2000) reported that the
relaxant response seen in preconstricted mouse aortas following acute administration
of 178-oestradiol was greater in 8ERKO mice than WT controls. This suggested that
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ER6 negatively regulated the release of NO, the opposite effect to that proposed for
ERa. The difficulty in determining the role of ER6 in the vasculature is that
comparisons are being drawn between studies that are quite different. It is not
possible to determine the role of ERs when comparing observations where oestrogen
is being applied chronically within the physiological range to those in which it is
being applied acutely at pharmacological concentrations. Indeed, we know from
previous studies that physiological concentrations of oestrogen increase NO release
whereas supraphysiological doses inhibit NO release and increase the release of
constrictor prostanoids (Bolego et al, 1997). Therefore, it is conceivable that the
observations of Nilsson et al, that ER8 attenuates the release of basal NO, may be an
artefact due to the high concentrations of oestrogen used.
1.4.4 Influence of oestrogen on atherosclerosis and regulation of
blood pressure
1.4.4.1 Influence of oestrogen on atherosclerosis
Atherosclerosis is a complex inflammatory process which is characterised by the
accumulation of lipid, macrophages and smooth muscle cells in intimal plaques. The
endothelium is not only a physical barrier, protecting against blood clotting by
forming a protective layer between underlying vascular smooth muscle cells and
blood, but also mediates vascular tone. Endothelial dysfunction or injury is believed
to be an early trigger of atherosclerosis. Indeed impaired NO release in endothelial
dysfunction may contribute to the progression of the disease as NO, in addition to its
vasorelaxant effects is involved in endothelial regeneration, reduction in platelet
adhesion and inhibits leukocyte chemotaxis (Barbato et al, 2004). The pathogenesis
of endothelial dysfunction results in an overproduction of reactive oxygen species
(ROS) (reviewed in Yokoyama, 2004). In particular, the upregulation of NADPH
oxidase shifts the NO/ O2" balance in favour of O2" and is closely associated with
atherosclerotic progression. A strong relationship exists between
hypercholesterolaemia and initiation of atherosclerosis (Gould et al, 1998) as
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demonstrated by the clinical benefits of statins which reduce cholesterol. Due to the
increase in oxidative stress native LDL, which is unable to penetrate the
endothelium, is oxidised and can cross the endothelium by binding to scavenger
receptors. Once in the subendothelial layer oxLDL can be taken up into macrophages
to form foam cells which form the early stages of plaque development. Furthermore,
oxLDL acts as a chemotactic factor for inflammatory cells, thereby increasing the
inflammatory aspect of the process, which cause proliferation of vascular smooth
muscle cells by releasing cytokines and growth factors. Collagen is produced in
larger quantities by the smooth muscle and contributes to the development of a
fibrolipid plaque.
The beneficial effects of oestrogen on lipid metabolism in addition to the positive
influence on the NO pathway and the antioxidant effects of oestrogen as described in
Section 1.4.3, suggested that oestrogen may be protective against atherosclerotic
disease. Despite the described beneficial effects of oestrogen on lipid profile, the
atheroprotective effects of oestrogen were suggested to be mediated by direct effects
of oestrogen on the vascular wall as protection occurred at doses of oestrogen which
did not alter lipid profile (Chae et al, 1997).
The role of oestrogen receptors in mediating the protection provided by oestrogen
was suggested by the finding of Losordo et al, which reported that coronary arteries
from premenopausal women with atherosclerosis were less likely to stain positive for
ERs than vessels from women which lacked such lesions (Losordo et al, 1994).
Methylation of the ER gene promoter inhibits expression of ER (Ottaviano et al,
1994). At this time, a second ER had not as yet been identified and therefore no
distinction in ER subtype expression was made in these studies. However, a study by
Post et al (1999), that followed on from Losordo et aVs early observation suggested
a role for ERa. They reported that in the atherosclerotic region of a coronary artery
ERa was reduced in comparison to expression in a non- atherosclerotic region and
that the reduction in expression was due to methylation of the ERa gene promoter
(Post et al, 1999).
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Mice that do not express apolipoprotein E (Apo E-/-), which mediates the binding of
lipid particles to lipoprotein receptors for the utilisation and redistribution of lipids
(Pitas et al, 1987) suffer from premature atherosclerosis (Osada et al, 2000). These
mice provide a good model for studying the influence of oestrogen in a model of
hypercholesterolemia associated atherosclerosis. In such a model, oestrogen was
reported to reduce lesion size and complexity, as determined by the presence of foam
cells, formed/ developed fibrous cap and extent of calcification of the plaque, in
female ApoE-/- mice (Hodgin et al 2001). By crossing the ApoE-/- mouse with the
ERKO mouse, this group were able to demonstrate that the loss of ERa inhibited the
reduction in lesion size but complexity of plaque was unaffected. This suggests that
ERa mediates a component of the atheroprotective effect of oestrogen. However, a
role for ERp remains to be elucidated. As previously described in section 1.4.3.2,
oestrogen has been shown to inhibit vascular smooth muscie cell proliferation and
therefore this may be another mechanism by which oestrogen can protect against
atherosclerosis. However, the mechanism by which oestrogen inhibits smooth
muscle proliferation remains unclear.
1.4.4.2 Influence of oestrogen on blood pressure
A small cross over clinical trial revealed a small but significant decrease in both
systolic and diastolic blood pressure that was due to a fall in peripheral vascular
resistance (Luotola, 1983). However, clinical studies have provided confounding
evidence that HRT either had no effect on blood pressure (Stassen et al, 1989) or as
evident from a more recent study, that women receiving HRT had a smaller increase
in blood pressure than those which were not (Mohle- Boetani et al, 2001).
Furthermore, it cannot be ignored that the side effects of oral contraceptives is an
increase in blood pressure (Nichols et al, 1993, Qifang et al, 1994). This increase in
blood pressure observed with the use of oral contraceptives was attributed to
activation of the renin angiotensin system as plasma renin activity was reportedly
increased in users (Goldhaber et al, 1984).
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Following the initial observations of oestrogen on blood pressure, clinical trials have
tried to address the mechanisms by which oestrogen prevents the increase in blood
pressure following the menopause. Blood pressure is dependent on cardiac output
and peripheral resistance and can be regulated by the renin angiotensin system
(RAS), renal function and by vascular function. Therefore, investigation has begun to
characterise the effect of oestrogen on these systems.
1.4.4.2.1 Renin angiotensin system
Renin is secreted by the kidney and is the enzyme involved in the conversion of
angiotensinogen, which is released from the liver, to angiotensin I. Angiotensin I is
then converted to angiotensin II by angiotensin converting enzyme (ACE).
Angiotensin II is a potent vasoconstrictor but also stimulates the release of
aldosterone from the adrenal cortex. Aldosterone can increase blood pressure by
acting on the kidneys to increase sodium reabsorption.
Literature suggests that oestrogen acts on elements of the RAS which would result in
opposing outcomes. Studies have suggested that the anti-hypertensive effects of
oestrogen may be mediated by inhibiting the RAS. Plasma renin activity is reported
to be higher in postmenopausal women than premenopausal women and that
premenopausal women have lower renin activity than age- matched men (Schunkert
et at, 1997). Proudler et al and Gallagher et al, reported that oestrogen treatment
reduced the activity of ACE in both human and rat models (Proudler et al, 1995,
Gallagher et al, 1999). Following ERT, ACE activity was reduced by 20% in
comparison to baseline values in postmenopausal women (Proudler et al, 1995).
These findings suggest that the oestrogen induced reduction in blood pressure and
shift of the hypertensive effects of RAS, induced by angiotensin II, to the
vasodilatory actions of angiotensin I in both normotensive and transgenic
hypertensive rats (Brosnihan et al, 1996, Brosnihan et al, 1997) may be due to a
reduction in ACE activity. Oestrogen was also reported to act further downstream in
the RAS pathway whereby it attenuated angiotensin induced aldosterone secretion in
female rats (Roesch et al, 2000). However, contrary to these findings oestrogen
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could act through the RAS to increase blood pressure. The promoter region of the
angiotensinogen gene was reported to express an ERE (Feldmer et al, 1991) chronic
oestrogen treatment of female rats increased serum levels of angiotensinogen, with a
concomitant increase in expression of ERa in the liver, (Stavreus-Evers et al, 2001).
However, caution should be applied when considering the physiological implications
of such a finding as these effects were only observed with supraphysiological
concentrations of oestrogen.
1.4.4.2.2. Renal function
The importance of the kidney in the regulation of blood pressure and in particular in
hypertension is clearly demonstrated by the early findings of Curtis et al, who
reported that transplantation of a kidney from a normotensive donor to a
hypertensive recipient results in a reduction in blood pressure of the recipient to that
within the normal range (Curtis et al, 1983). The kidneys play a critical role in the
regulation of blood pressure by keeping constant the volume and composition of
body fluids despite fluctuations in water and solute intake. One defect that can occur
in hypertension is an alteration in the pressure natriuresis relationship, this refers to
an increase in sodium excretion in response to an increase in arterial pressure (Hall et
al, 1980).
At the time when this thesis was undertaken, few studies had been published
describing an influence of oestrogen on renal function. In a subpopulation of
postmenopausal Japanese women, oestrogen deprivation led to increased salt
sensitivity and hypertension (Tominaga et al, 1991). This suggests that the anti¬
hypertensive effects of oestrogen may in part be mediated by improved renal
function.
1.4.2.2.3 Vasculature
As described in Section 1.4.3, oestrogen has positive effects on the release of
endothelium derived relaxant factors and may also reduce contractile tone of
vascular smooth muscle cells in an ER dependent manner. However, whether the
effect of oestrogen on the vasculature can modulate blood pressure was not
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determined in those same studies and has been an area of oestrogen research in the
cardiovascular system that has been poorly studied to date.
Initial studies in the literature reported that the beneficial effects of oestrogen on the
bioavailability of NO may influence blood pressure. Doursout et al demonstrated that
oestrogen deprivation of female rats reduced the pressor response induced by
inhibition of NOS however, baseline blood pressure was unchanged (2002).
However, few reports have been published investigating the influence of oestrogen
on the vasculature and how this may affect blood pressure.
Clinical observations have suggested that ERP may mediate the anti-hypertensive
effects of oestrogen as a link was reported in Japanese women between ERP
polymorphisms and hypertension (Ogawa et al, 2000). However, further
investigations into the mechanisms by which oestrogen may affect blood pressure
and the ER involved have not as yet been published.
1.5 General aims of the study
Oestrogen was considered to have beneficial effects on the cardiovascular system as
initial clinical observations suggested that oestrogen lowered blood pressure
(Strassen et al, 1989, Seely et al, 1999) and reduced the incidence of coronary heart
disease (Sullivan et al, 1990). However, more recent controlled clinical trials have
reported no overall benefit of HRT in the prevention of CHD (Hulley et al, 1998,
Cherry et al, 2002) and therefore cast some doubt over the use of oestrogen in the
prevention of cardiovascular disease. Following from the initial observations of the
beneficial effects of oestrogen in the cardiovascular system, animal studies reported
that oestrogen may provide protection against MI due the antihypertrophic
properties of oestrogen in a rat model of MI (Jankowski et al, 2001). In the
vasculature oestrogen was reported to regulate vascular tone by enhancing the
release of endothelium-derived vasodilators such as NO (Hayashi et al, 1992, Wu et
al, 2000), prostacyclin (Ospina et al, 2002) and EDHF (Liu et al, 2001). However,
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only recently have the involvement of specific ERs in mediating these effects been
studied. The generation of ERKO mice demonstrated that OwStrogen acting through
ER may increase the bioavailability of NO and subsequently enhance vasodilation
(Rubanyi et al, 1997). However, literature has not yet fully characterised the
expression of ERs in the animal models studied, nor investigated whether the effects
of oestrogen on the vasculature may also be mediated by ERp. Furthermore, whether
the vascular effects of oestrogen mediated via ERs, contributes to the regulation of
blood pressure has currently not been determined.
The main aims of this thesis were to determine, using a mouse model whether
oestrogen acting through ERp modifies vascular function and contributes to the
regulation of blood pressure. This was investigated by firstly, determining the
distribution and cellular localisation of ERa and ER8 in the cardiovascular system
and whether this was altered under pathophysiological conditions such as myocardial
infarction and atherosclerosis. Once expression of ERs in the mouse cardiovascular
system had been determined, the effect of endogenous oestrogen, in male mice, on
the vascular system and the role of ER8 using the pERKO mouse. Finally, our aim
was to determine the effect of oestrogen status, and the role of ER8, on vascular
function and whether this contributed to the regulation of blood pressure in
mediating these effects. This was achieved by studying female mice of different
oestrogen status and through the use of the novel ER6 antagonist, Org 44488, in





All experiments involving animals were conducted in accordance with Home Office
guidelines as outlined in the Animals (Scientific Procedures) Act 1988 and under the
terms of Project Licence number 60/2813.
2.1 Animals
Animals were housed in a controlled environment on a 12hr light- dark cycle (lights
on 0700 - 1900hrs) and a set climate 21- 22°C with free access to water and standard
mouse chow containing 75.09% carbohydrate, 14.38% protein, 2.71% oil and 0.25%
salt (Special Diet Services (SDS), Witham, Essex, UK).
Animals used were, oestrogen receptor 6 knock-out (6ERKO), ApoE knock-out (-/-)
and C57B16 mice (Harlan Orlac, Bicester, Oxon, UK).
8ERKO mice generated by a targeted disruption of exon three of the ER8 gene as
previously described (Krege et al. 1998), were obtained from the Department of
Medical Nutrition, Karolinska Institute, Sweden. The colony was established in our
laboratory by breeding ER8 heterozygous mice to yield 8ERKO (-/-) and wild-type
(WT, +/+). Both WT and 8ERKO mice were on a mixed C57B16/SvJ129s genetic
background.
ApoE-/- mice on a C57B16 genetic background, were kindly made available by Dr I.
Megson who has a colony established at the University of Edinburgh.
Mice were allowed an acclimatisation period of a week in their new environment
prior to any surgical or experimental procedures.
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2.2 Genetic and Phenotypic analysis of I3ERKO mice
2.2.1 Genotyping of the (3ERK0 colony
The genotype of the mice was determined by polymerase chain reaction (PCR)
which was used to identify WT and ER6 targeted alleles.
2.2.1.1 DNA extraction from tail biopsies
Tail biopsies were taken from mice following weaning, aged 3-5 weeks under
halothane anaesthesia. Tail biopsies, 0.5cm in length from the tip of the tail, were
digested overnight at 55°C in tail buffer (1.0M Tris- HC1; pH8, 0.5M EDTA; pH8,
1.0M NaCl, 10% SDS, dtEO) containing lOmgmT1 Proteinase K (Promega,
Southampton, UK).
2.2.1.1.1 Method 1
Digested tails were incubated with 20|J of 20|ig|ir RNAse (Promega, Southampton,
UK) for lhr at 37°C following which 6^1 mercaptoethanol and 600(4 Tris washed
phenol (Fisher Scientific, Loughborough, UK) was added to each tube and placed on
a vertical rotator for 15mins. The samples were centrifuged at 13,000rpm for 2mins
and the aqueous phase and interphase were transferred to a fresh tube. 300|al of
phenol and 300|ul of 'chloroform' (chloroform: isoamyl alcohol 24: 1) were added to
each tube and rotated for 5mins prior to centrifugation as above. The aqueous phase
and interphase were transferred to a fresh tube, 600(4 'chloroform' and the sample
was rotated for 5mins.
Following centrifugation as above, the aqueous phase was transferred to a fresh tube,
600(4 isopropanol was added and the tube was inverted several times until DNA was
precipitated out. To pellet the DNA, the sample was centrifuged at 13,000rpm for
2mins and the supernatant was removed. 180(4 of 70% ethanol was added to the
DNA pellet to remove any isopropanol, centrifuged for 2mins and the supernatant
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removed. This step was repeated twice. Finally, the DNA pellet was dissolved in
200|J of TE buffer (IOjiM Tris, l|xM EDTA) and rotated for lhr at 37°C.
2.2.1.1.2 Method 2
Similar to the phenol extraction protocol, tail tips were digested overnight and treated
with RNase (Promega, Southampton, UK). However, following this the samples
were placed on ice for lOmins or until a precipitate formed. Samples were
centrifuged at 12,000 rpm for 2mins, placed on ice and the supernatant removed. An
equal volume of isopropanol was added to the supernatant and rotated to aid
precipitation of DNA before being centrifuged for 2mins at 12,000 rpm to pellet
DNA. The supernatant was removed and the pellet was washed with 70% ethanol.
Ethanol was removed and replaced by 200f.il TE buffer. The samples were then
placed at 94°C for 5mins to inactivate the Proteinase K (Promega, Southampton, UK)
and subsequently 37°C for 30mins to dissolve the DNA pellet.
2.2.1.2 Polymerase Chain Reaction
Each PCR reaction (25jul) contained 1U Taq DNA polymerase (Biothermstar,
Genecraft, Munster, Germany) 0.5mM dNTPs (Promega, Southampton, UK), 0.3|iM
specific primers (MWG Biotech) for gene of interest, Table 2.1, lOx PCR reaction
buffer containing 1.5mM MgCE (Biothermstar, Genecraft, Munster, Germany), and
l|d DNA. The samples were transferred directly from ice to the thermocycler where
the following reaction conditions were applied:-
An initial denaturing step of the DNA was carried out at 94°C for 15mins.
Amplification of DNA was as a result of 30 cycles of three defined stages. Firstly,
the DNA was denatured (92°C for 30s), which was followed secondly by the
annealing of primers to their complimentary DNA sequence (63°C for 30s) and
thirdly an elongation stage, the primers were enzymatically extended (68°C for
2mins). Once the cycles were completed an additional elongation step of 68°C for
lOmins was carried out.
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2.2.1.3 Agarose gel electrophoresis
PCR products were fractionated through a 1% agarose gel (LE, Agarose Seakem,
BMA, Rockland, USA) stained with ethidium bromide (0.04%, Sigma-Aldrich
Company Ltd., Dorset, UK) which enabled PCR products to be visualised under UV
fluorescence, Figure 2.1. 5pl of blue-orange 6x6 loading dye (Promega,
Southampton, UK) was added to 25pi of sample of which 12pl was loaded into the
gel well. A lOObp ladder (Promega, Southampton, UK) was run on all gels, the well
containing the DNA ladder was loaded with a 6gl mixture composed of 4pl DNA
ladder and 2pl loading dye.
The gel was run for lhr 30mins at 100V following which the PCR products were
visualised in an ultraviolet transilluminator, Figure 2.1 (Ultraviolet Products Ltd.,
Cambridge, UK) attached to a video display unit (SONY Coorporation, Japan).
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Figure2.1PCRfoERJ3alleles. GelelectrophoresisofPCRproductsfWT+/+,heterozyg us/-andfiERKO/- mice.Thearrowh adsindicat650bpproductw ichasspecififorthly e allelendth500bpproductfortargetinse tion.
2.2.2 Phenotypic analysis of the BERKO mouse
To confirm that the colony of 6ERKO mice established in our lab were
phenotypically identical to the colony described by Krege et al and housed in
Sweden, we analysed their ovarian phenotype (Krege et al, 1998).
2.2.2.1. Harvesting of ovaries.
Ovaries were harvested from female WT and 6ERKO littermates and processed as
outlined in section 2.4.1
2.2.2.2. Histological analysis of ovarian phenotype
To determine whether genetic background affected ovarian morphology serial
sections (6pm thick) were stained with hematoxylin and eosin. As sexually mature
females contain a heterogeneous population of follicles at different developmental
stages (Pederson and Peters, 1968, Butcher and Kirkpatric- Keller, 1984), an average
of 30 sections were cut from each ovary and every fifth section was examined to
obtain an overall view of the follicular populations. Briefly, sections of ovary were
immersed in Harris' hematoxylin for 5 mins, washed in tap water, differentiated with
acid alcohol for 5s and then washed in running tap water. Thereafter, the sections
were immersed in eosin for 30s before being rinsed in tap water. The sections were
rapidly dehydrated through increasing concentration of alcohol (70, 80, 95%) to
absolute alcohol (2 x lmin), histoclear for 5 mins and then to xylene (2x5 mins).
Finally, the slides were dried and coverslips mounted with DPX mounting medium
(BDH Laboratory Supplies, Dorset, UK).
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2.3 Surgical procedures
Prior to each surgical procedure animals were weighed. Anaesthesia was introduced
either by inhalation of either halothane or isoflurane (for bilateral ovariectomy), or
by i.p. injection of ketamine (76mgkg"1)/medetomidine (fmgkg1) (for recovery
radiotelemetry) or ketamine (lOOmgkg"1 )/xylazine (lOmgkg1) (for coronary artery
ligation, non-recovery blood pressure and echocardiography). Upon onset of
anaesthesia, analgesia was administered in the form of buprenorphine (0.05mgkg"',
s.c.).
Aseptic techniques were applied to all surgical proceedures. Hair was removed from
the surgical site by clippers. Depilatory cream (sensitive hair remover, Nair, Carter-
Wallace) was then applied to prevent hair from entering the incision site and
swabbed with Vetsept® (Genusxpress, Aberdeen, UK). Cling film was draped over
the animal leaving only the surgical site exposed. Lacrilube® (Genusxpress,
Aberdeen, UK) lubricating ointment was applied to the eyes to prevent desiccation
and the mouse was placed on a heating pad to maintain body temperature. The depth
of anaesthesia was determined prior to, and at regular intervals throughout, surgery
by pinching the foot of the mouse tightly and observing any changes in respiration.
Once surgery was completed, the anaesthetic effect of both ketamine mixtures was
reversed by the a,2-adrenoceptor anatgonist atipamezole (lmgkg"1, s.c.). Post¬
operatively, animals were monitored at least every lOmin until ambulatory, in a
recovery chamber set at an ambient temperature of 37°C containing mash and water.
Animals were weighed and closely observed on the days following surgery for any
signs of infection or poor health.
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2.3.1 Recovery surgical procedures
2.3.1.1 Regulation of and Staging of the oestrous cy^le
2.3.1.1.1 Bilateral ovariectomy
One variable in doing studies in female animals is the varying levels of oestrogen
during the oestrus cycle. This problem can be overcome by controlling the levels of
circulating oestrogen by performing ovariectomy (ovx). This procedure involves the
removal of the ovaries, which are the principal site of oestrogen production, and
implantation of pellets that release oestrogen, to achieve physiological concentrations
(0.05mg/pellet, 60 day release, 50-lOOpgml1, Innovative Research, Sarasota, USA),
or placebo (60 day release, Innovative Research, Sarasota, USA). Female WT mice
were randomised to receive either placebo pellets (-E) or oestrogen (E) containing
pellets (+E,) to re-establish circulating physiological levels of oestrogen.
Levels of oestrogen are elevated during both the pre- and post- ovulatory stage of the
oestrous cycle. Oestrogen stimulates the cells of the stratum basalis of the uterus to
undergo mitosis and promotes vascularisation and thickening of the endometrium.
When oestrogen levels are low, the endometrium is thin and atrophied as only the
stratum basalis of the endometrium remains. Therefore, due to the proliferative role
of oestrogen on the uterus, uterine weight can be used as an indication of the
circulating levels of oestrogen and to confirm oestrogen status following ovx, Figure
2.2 and Figure 2.3.
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Sham Placebo Estrogen
Figure 2.2 Effect ofoestrogen status on uterine weight
Uterine weight ofsham ovx mice (n=15) and ovx mice implanted
with either oestrogen 0.05mg/pellet (n=9) or placebo (n-8)
pellets. Values are expressed as mean± SEM and analysed using
a 1- way ANOVA followed by a Tukey post- hoc test, p<0.05
Figure 2.3 Uterifrom mice ofdifferent oestrogen status
Uteri were removed from mice that had undergone ovx and treated
with a) placebo b) sham ovx and c) ovx and supplemented with
oestrogen 0.05mg/pellet.
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Anaesthesia was induced by placing the mouse in a chamber containing 4%
halothane or isoflurane (Halothane-vet, Merial Animal Health Ltd., UK) vaporised in
a mixture of O2 (1.51 min"1) and N20 (0.51 min"1) for halothane and 02 alone for
isoflurane. Anaesthesia under halothane and isoflurane (1.7-2% in gas mixture) was
maintained via a nasal cone. The lumbar dorsum was shaved bilaterally and an
incision in the dorsal flank, of about 5mm in length, penetrating the abdominal cavity
was made. The parovarian fat pad was identified and retracted and the exposed ovary
and associated oviduct were severed and removed. A ligature (5/0 Mersilk, Ethicon
Ltd.) was secured around the severed ovarian vasculature to maintain haemostasis.
The uterine horn was returned to the abdominal cavity and the incision was closed,
firstly closing the abdominal wall (5/0 Mersilk, round bodied, Ethicon, UK) and then
closing the skin (5/0 Mersilk, cutting, slim blade, Ethicon, UK). A small,
subcutaneous incision was made inter scapular into which the pellet, either -E/ or +E
was placed and the incision subsequently closed.
Once the animal was ambulant it was returned to a cage containing a maximum of
three other animals, each of which had undergone the same surgical procedure. Food
and water were freely available. Mice were housed with animals within the same
oestrogen treatment as this prevents exposure to oestrogen via grooming of one
another.
Where mice were undergoing a second surgical procedure, a period of 7 days was
allowed for the animal to fully recover.
2.3.1.1.2 Staging the oestrous cycle
Vaginal smearing of experimental mice, in which the levels of oestrogen were not
controlled by ovariectomy and the implantation of oestrogen/ placebo releasing
pellets, was necessary to determine the ovarian cycle. The oestrous cycle was
monitored for 4 consecutive days, 1000-1030hrs, prior to surgery or towards the end
point of a study based on vaginal smear patterns and that ovulation occurs
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approximately every 4 days. This was done either prior to surgery or towards the end
point of a study.
The speculum was moistened by immersing in sterile saline prior to being introduced
in the mouse' vagina. Once inside the cervix the speculum was rotated to ensure
collection of cells and transferred to a glass slide and allowed to air dry. The slides
were taken to water prior to staining with toluene blue for 3mins to allow easy
visualisation of cell type, Figure 2.4. Smears were classified into one of 4 phases of
the oestrous cycle: proestrous was characterised by a smear of leukocytes and
elongated nucleated epithelial cells; large cornified epithelial cells were exclusively
found in oestrous; metoestrous was characterised by a smear composed of equal
numbers of nucleated epithelial cells and leukocytes; and a smear consisting almost
exclusively of leukocytes depicted dioestrous (Allen 1922, Fox 1970)
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Figure 2.4 Vaginal smears from female mice during the oestrous
cycle
The ovarian cycle of sham ovx female mice was determined by
vaginal smearing and smears were classified into 4 stages of the
oestrous cycle a) oestrous b) metoestrous c) dioestrous d) proestrous.
Black arrows indicate epithelial cells and red arrows indicate
leukocytes (x20 magnification).
2.3.1.2 Radiotelemetry
Implantable, miniaturised mouse blood pressure transmitters (Data Sciences
International, PA11-C20) were used to directly measure arterial pressure, activity
and heart rate digitally from within individual animals. These devices are currently
thought to provide the most sensitive and accurate method to monitor blood pressure
in conscious, free-moving mice (Mills et al, 2000). Radiofrequency signals from the
transmitters are converted to serial bit streams and data are collected and stored to
disk using the Dataquest A.R.T. data acquisition system (Data Sciences International,
St Paul, MN).
Surgery was carried out with the assistance and subsequent supervision of Mrs G.
Brooker. All animals were prepared for surgery as previously described and
anaesthetised using an anaesthetic mix of ketamine/medetomidine. A ventral midline
incision and a horizontal incision were made in the scapular region of the neck to
allow implantation of the body of the device. A tunnel was formed from this incision
across the left pectoral area and was enlarged using blunt scissors to form a pocket
along the left flank and lubricated by 1ml of warmed sterile saline.
Once the pocket had been made the carotid artery was isolated using sterile saline
soaked Q-tips to gently push the submandibular glands to the right and away from
site of access. Once the thorax was visualised an entry site was made to the left of the
thorax and between the sternohyoid and omohyoid muscles. The left common carotid
artery was isolated using fine tipped vessel dilation forceps with great care so as to
separate, whilst avoiding disturbing, the vagus nerve which runs parallel to the
artery. The artery was ligated at the bifurcation into the external and internal carotid
arteries and temporarily occluded at about 8-10mm lower with a second suture,
Figure 2.5a. Traction was applied to the most distal ligature which was then taped
into position putting tension on the artery. The most proximal ligature was elevated
using Spencer Wells, which were used as a weight to apply traction. This occludes
blood flow into the remaining middle portion of the artery which was then isolated so
that the blood vessel could be incised and the catheter introduced. Using a bent-
tipped 25G syringe needle as a catheter introducer. The carotid artery was punctured
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at the level of the bifurcation and the catheter was inserted and pushed caudally into
the vessel towards the occluding suture. The most proximal suture was then gently
released and the catheter was further advanced into the vessel to the point at which
the taper begins, about 13-14mm in length from tip, Figure 2.5b. At this point both
the proximal and distal sutures (5/0 Mersilk, Ethicon, UK) were tied around the
vessel and catheter and secured in place using Vetbond, Figure 2.5c.
Once the catheter had been secured in place, the body of the telemetry probe was
introduced into the pocket along the left flank. Prior to inserting the body of the
probe, the pocket was lubricated with 1ml warm sterile saline to allow easier
insertion of the device. The body of the device was then pushed into the pocket
between the front and rear limb and the incision site was closed (5/0 Mersilk, cutting,
slim blade, Ethicon, UK), Figure 2.5d.
Once ambulant, the animal was placed in a cage containing food and water.
Analgesia was made available as jelly (buprenorphine, 0.5mgkg-l), that was placed
inside the cage enabling the animal to self medicate during recovery. Body
temperature was maintained at 37°C by keeping the animal on a heating pad for a
further 48hrs or until it was fully conscious and active which ever was later. To
prevent dehydration, 1ml warm 0.9% sterile saline (s.c.) was administered at time of
surgery and repeated after 12hrs if the animal appeared dehydrated. This was
determined by checking the elasticity of the skin and extent of weight loss.
Animals were allowed a 10 day recovery period prior to commencing study, during
which time preliminary tests were carried out to confirm that blood pressure and
heart rate had stabilised. During the experimental period blood pressure, heart rate
and locomotor activity were sampled for a period of 10s every 15mins over the entire







Figure 2.5 Telemetry implantation.
A) Isolation of left common carotid artery B) Insertion of telemetry
catheter into the left common carotid artery and progressed into artery
until catheter notch is in line with the bifurcation C) Cathter is secured in
place. D) Animal which has been implanted with telemetry device, block
arrow indicates position of the body of the telemetry device on the left
flank ofthe recovered mouse.
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2.3.1.3 Coronary artery ligation
Dr I. Sharif performed the surgery for the induction of myocardial infarction by
coronary artery ligation (CAL), Figure 2.6. In brief, C57BL6 female mice
(14- 16wks) underwent a left intercostal thoracotomy to expose the heart. A ligature
(6/0 prolene suture, Ethicon, UK) was placed around the left main coronary artery
which was tied in CAL mice and pulled under the artery in sham-operated mice. The
thorax was then closed using a silk braided suture (5/0 mersilk, Ethicon, UK). Body
temperature was maintained at 37°C by being kept on a heating pad for a further
48hrs or until animal was fully conscious and active.
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Figure 2.6 Image of a female mouse heart which had
undergone CAL. Block arrow indicates area of infarct in the
left ventricle.
2.3.2 Non- recovery surgical procedures
2.3.2.1. Measurement of blood pressure
Dr I. Sharif kindly performed surgical implantation of the Millar catheter. All
animals were prepared for surgery as previously described. Once fully unconscious
the right carotid artery was isolated and cannulated with a 1.4 Fr (0.46mm) high
fidelity micromanometer catheter (Millar Instruments Inc., Houston, TX) connected
to a control unit (TCB-500, Millar Instruments Inc.). After a stabilisation period of
lOmins, measurements of arterial pressure and heart rate were obtained. All
measurements were recorded on a MAC computer using a Power Lab system. The
Miller control unit was connected to a data acquisition system which consisted of a
Powerlab (Powerlab/8sp, AD Instruments), which was connected to a MAC
computer with CHART v4.1 software (AD instruments).
2.3.2.2 Assesment of cardiac function
Echocardiography was kindly performed by Dr I. Sharif. To enable clear
visualisation of the heart the mouse was placed in left lateral decubitus position and
the chest area and probe head were covered with acoustic gel (Clear Image medical
ultrasound couplant, Diagnostic Sonan Ltd., Livingston, UK). Care was taken when
placing the probe on the left hemithorax in order to avoid excessive pressure which
could have induced bradycardia. Cardiac ultrasound imaging was performed using a
128-element probe (10-22MHz) with DIASUS P5.26 software (Dynamic Imaging),
the depth of which was set at 26mm with 1 focus line. Parasternal long- and short-
axis views were obtained. 2-dimensional echocardiographic loops of at least 20
cardiac cycles, b-mode tracings were stored on cd for offline analysis.
To assess cardiac function, left ventricular (LV) diameters during end-diastole
(LVEDD) and end-systole (LVESD) were measured to calculate percentage
fractional shortening (%FS = 100((LVEDD - LVESD)/LVEDD). LV areas during
end-diastole (LVED area) and end-systole (LVES area) were measured to calculate
percentage ejection fraction (%EF = 100((LVEDA - LVESA)/LVEDA). All
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measurements were calculated from images taken from the long axis view where
images were considered adequate for measurement when >75% of the epicardial and
endocardial contour could be adequately visualised.
2.4 Tissue collection for in- vitro purposes
2.4.1 Histology, immunocytochemistry and myography.
Organs were removed and then rinsed in ice-cold Krebs solution before undergoing a
rough dissection to remove excessive fat or connective tissue. Hearts were cut from
apex to base and all organs were blotted prior to being weighed
The thoracic aorta was removed and pinned out on a silicone-coated (Sylgard, Dow-
Corning, UK) dissecting dish containing ice-cold Krebs-Henseleit solution (Krebs).
The mesenteric bed was exteriorised and the intestine feeding the vascular bed was
removed to a sylgard plate containing ice-cold Krebs. Both the thoracic aorta and an
area of the first order mesenteric artery (the area distal to the first branch point of a
vessel leading on to the intestinal wall) were cleaned of connective tissue in
preparation for mounting onto a myograph.
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2.5 Pharmacological studies of isolated mouse blood vessels
2.5.1 Mounting of mouse blood vessels onto the myograph
2.5.1.1. Thoracic aorta
Following dissection, the aorta was cut into two transverse rings 4mm in length and
mounted on a small vessel myograph (Model 700MO, Danish Myotech, Denmark)
containing 10ml of oxygenated (95% O2, 5% CO2) Krebs at 37°C. Mouse aortic rings
were placed under an optimum resting tension of 0.75g and allowed to equilibrate for
60 minutes, during which time the tissue was washed periodically with Krebs and the
tension adjusted when necessary to 0.75g, equivalent to 7.36mN.
2.5.1.2 First order mesenteric artery
The vessel was prepared as previously described for mounting onto a wire myograph
containing 10ml of oxygenated Krebs solution warmed to 37°C. Two isolated rings
of first order mesenteric artery were cut to a length of 4mm of which 2mm
constituted the area of the artery to be studied and the remaining 2mm of tissue used
to feed the artery onto the wires which was removed once the vessel was mounted.
Two tungsten wires (4pM diameter) were inserted through the lumen of the isolated
artery (2mm in length). A force transducer connected to one of the two wires
recorded mechanical activity, isometrically. The second wire was attached to a
support carried by a micromanipulator. First order mouse mesenteric arteries were
placed under an optimum resting tension of 0.2g, equivalent to 1.96mN. In a manner
similar to the aorta set-up, mesenteric arteries were allowed to equilibrate for 60mins
with tension being adjusted as necessary.
Isometric tension from the vessels was measured by a DSC6 strain gauge transducer,
processed by a MacLab/4e analogue digital converter and displayed through Chart™
software.
56
All vascular studies performed on mouse mesenteric arteries were carried out by
Dr P. Medina
2.5.2 Standard start protocol
After 60mins, the following protocol was carried out before commencing the
experimental protocol in order to normalise contractile data:-
The maximum contractility of the tissue was determined using Kreb's containing
60mM KC1 (equimolar replacement of NaCl by KC1) and the integrity of the
endothelium assessed by measuring endothelium dependent relaxation to
acetylcholine (ACh) of noradrenaline (NA) induced tone. Aortic rings were subjected
to two exposures of 60mM KC1, followed by 60mM KC1 combined with NA 1CT7M
and a final exposure to 60mM KC1 until the response had plateaued, separated by
subsequent wash-out and a resting period of lOmins. Thereafter, the tissue was
exposed twice to the adrenergic receptor agonist NA (10"7M) and on the second
exposure instead of wash-out the presence of endothelium was confirmed by
examining the relaxant response to the endothelium dependent agonist ACh (10"6M),
Figure 2.7. Aortic rings with relaxations to ACh greater than 70% were considered
as having an intact endothelium and used in the experiments. The pharmacological
protocols which were applied following the stabilisation period and the above






















Figure 2.7 Schematic diagram of the responses of
aorta and first order mesenteric vessels from mice to
the standard start protocol, KCl; 60mM, NA; 10~7M,
ACh; 10'6Mand * indicates wash out.
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2.6 Histology and immunocytochemistry
2.6.1 Processing of tissue
Following harvesting, section 2.4.1, tissues were fixed for 16hrs in 10% neutral
buffered formalin. This noncoagulant fixative was chosen as it allows good
histological detail of the tissues to be preserved because it does not drastically
change the fine network of tissue proteins. In addition, for immunohistological
analysis of interest for this thesis, the type of chemical reaction between formalin and
protein enhances nuclear staining opposed to cytoplasmic staining. The tissues were
transferred to 70% alcohol to remove formalin and subsequently stored in 70%
alcohol until processing. During processing the tissues were put through a series of
increasing concentrations of ethyl alcohol to remove water which was within the
spaces of the protein network. The tissues were then immersed in xylene which
removes ethyl alcohol from the tissues, as this is immiscible with paraffin and then
infiltrated with paraffin which provided a supporting matrix for the tissue. The
resulting blocks were cut into either 5 or 6pm sections using a microtome. Creases
were removed from the sections by floating out onto a water bath (40°C) which also
aided the transfer of sections to Superfrost plus™ microscope slides (BDH
Laboratory Supplies, Dorset, UK). Sections were allowed to air dry and incubated at
37°C overnight in an incubator. Sections were treated with xylene (2 x 5mins) to
remove the wax and rehydrated through decreasing concentrations of alcohol (100,
95, 70%, 2mins each) to water to rehydrate the sections.
2.6.2 Histological analysis
2.6.2.1 Van Geison Stain
As a result of coronary artery ligation (section 2.3.1.3), cardiomyocytes become
terminally damaged and are replaced histologically by collagen and fiborous scar
tissue. The deposition of scar tissue formed in the infracted zone of the left ventricle
from CAL mice was confirmed using van Geison's stain for collagen.
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Briefly, 5 pm sections of hearts were immersed in celestin blue for 5mins, rinsed in
tap water and subsequently stained in Mayer's Haemalum for 5mins before being
rinsed again in water. Staining was differentiated by a brief immersion in 1%
hydrochloric acid/ 70% alcohol mix and then rinsed in water. Thereafter, sections
were immersed in van Geison for 3mins, rinsed very briefly in water and dehydrated
in absolute alcohol (2 x 5mins) before being transferred to xylene (2 x 5mins).
Finally, the slides were dried and coverslips were mounted with DPX mounting
medium.
2.6.3 Immunohistochemistry
Sections were pressure cooked for 20mins in citrate buffer (0.1M, pH6), washed in
water and then treated with 3% H2O2 at room temperature for 30mins to dampen any
endogenous peroxidase activity in the tissue. The tissue was washed twice in Tris-
buffered saline for 5mins and then treated to block endogenous biotin activity by
incubating with blocking serum (rabbit serum (1 part)/Tris-buffered saline (TBS) (4
part)/5% BSA) containing avidin at room temperature for 30mins. Sections were
washed and incubated under the same conditions for 15mins with TBS containing
biotin. Following washing with TBS, sections were incubated overnight at 4°C, with
primary antibody, Table 2.2, all antibodies were diluted in blocking serum. On the
second day, the first of every two TBS washes was done using 0.05% Tween/TBS.
The addition of the Tween detergent helps to eliminate background. The primary
antibody was washed off before the sections were incubated for 30mins at room
temperature with the biotinylated secondary antibody, Table 2.2, and then washed to
remove any excess unbound secondary antibody. Sections were incubated for 30mins
with ABC-HRP, which binds to the biotinylated secondary antibody. Sections were
then washed and bound secondary antibody visualised using 3-3'-diaminobenzidine
(DAB) a substrate which reacts with HRP to generate a brown stain and the colour
change was monitored microscopically. DAB is active for 5min and can be
inactivated in samples in which staining becomes apparent during that time by
washing with water. The reaction can be repeated for a second time in samples in
which no colour change was observed once the initial application of DAB has been
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washed off. If no staining appears following a second exposure, it is unlikely that
subsequent exposures to DAB will result in a colour change. The tissues were then
counterstained with nuclear stain, Harris' haemotoxylin. The sections were placed in
haemotoxylin for 3mins before being washed in water and rinsed in acid/alcohol for
5s to remove any excess haemotoxylin. Tissues were rinsed in water and dehydrated
by placing in increasing concentrations of alcohol, (70, 95, 100% up to 100%) and
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2.7 Calculations and statistical analysis
2.7.1 Calculations
The dose ratio (DR) is the ratio by which the agonist concentration has to be increased in
the presence of a second drug to restore a given level of response. Dose ratio (DR=
D1/D2) was calculated for the contractile response to PE in the presence of indomethacin
by dividing the concentration of PE that produced a given contractile response (Di) by
the concentration of PE in the presence of indomethacin that produced the same
contractile response (D2).
2.7.2 Statistical analysis
Statistical analysis was carried out using GraphPad 'Prism' software (CA, USA).
Statistical significance was calculated by two-way ANOVA followed by a Bonferroni
post hoc test. Unpaired t-test was also used where appropriate. Significance level was
taken at P< 0.05.
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2.8 Solutions, drugs and chemicals.
Salts were purchased from Sigma- Aldrich Company, Ltd., Dorset, UK, unless otherwise
stated.
Solutions for molecular biology
Tail Buffer
1.0M Tris- HC1 adjusted to pH 8, 0.5M EDTA adjusted to pH 8, 1.0M NaCl, 10% SDS
TE Buffer
lOpM Tris, lpM EDTA, adjusted to pH 8 with concentrated hydrochloric acid
DEPC H20
5 drops of diethyl pyrocarbonate (DEPC) were added to 500mls of distilled H20. The
bottle was then shaken vigorously for 30 seconds and left to stand for 20 minutes. The
solution was then shaken again and left for 1 hour before being autoclaved.
TBE
TBE contained 0.45M Tris base, 0.445M Boric Acid and 0.5M EDTA (pH 8.0) made up




0.9w/v sodium chloride solution
Physiological salt solution
118mM NaCl, 4.7mM KC1, 25mM NaHC03, 1.17mM KH2P04, 1.2mM MgS04 in
distilled water, pH 7.4.
A xlO stock solution was made up and stored at 4°C. On experiment day, the stock was
diluted and supplemented with 5.5mM glucose, 0.03mM EDTA and either 1.6mM CaCl2
for the male vascular study, Chapter 4, and 2.5mM for the female vascular study,
Chapter 5.
60mM Potassium Chloride salt solution
62.7NaCl, 60mM KC1, 25mM NaHC03, 1.17mM KH2P04, 1.2mM MgS04 in distilled
water, pH 7.4.
A x5 stock solution was made up and stored at 4°C. On an experiment day, the stock
solution was diluted and supplemented with 5.5mM glucose, 0.03mM EDTA and either
1.6mM CaCl2for the male vascular study, Chapter 4, and 2.5mM for the female vascular
study, Chapter 5.
Drugs
All stock concentrations of drugs used were made up in deionised water and stored at
-20°C unless otherwise stated. On experiment day, drugs were diluted to required
concentration using physiological salt solution.
Indomethacin




Stock solution of NAdr (10"2M) also contained ascorbic acid (10-1M). The stock solution
was stored at -20°C until required.
Org 44488
Dr Darcey Black (Organon, Newhouse, Scotland) generously supplied Org 44488
Histological stains
Van Geison
100ml saturated aqueous picric acid and 10ml 1% Acid Fuschin
Celestin Blue




Immunolocalisation of ERs in the mouse
cardiovascular system
3.11ntroduction
Oestrogen induces cellular responses in target tissues by binding to specific oestrogen
receptors. The first of the two receptors to be cloned, from a human breast cancer cell
line was, ER, later designated ERa, (Green et al, 1986). Shortly afterwards, ERa cDNA
clone was isolated from the mouse uterus which shared 97% and 88% homology with
ERa protein sequences isolated from human and rat respectively (White et al, 1987). It
was believed for many years that this receptor was the sole mediator of oestrogen action
on target cells until a second ER was discovered in the rat prostate (Kuiper et al 1996)
and mouse ovary (Tremblay et al, 1997). This second ER was designated ER6 to
distinguish it from ERa.
Following the identification of ERs, immunohistochemical and molecular biological
techniques were employed to determine their distribution and cellular localisation.
Initially, this was predominantly in the reproductive system but was also extended to
other tissues including those of the cardiovascular system (Orimo et al, 1993, Leiberman
et al, 1990, Karas et al, 1994, Iafrati et al, 1997) as research in that area increased.
In the vasculature, ERa was shown to be expressed in rat aortic smooth muscle cells
(Orimo et al, 1993) and also human vascular smooth muscle cells (Bausero et al, 2000).
However, in contrast to this, ERa was not expressed in either the aorta or carotid artery
of the guinea- pig (Leiberman et al, 1990). This suggested that there was a degree of
species variation in the expression of ERa in the vasculature. In addition to the
expression in vascular smooth muscle cells, ERa was also localised to the nuclei of
endothelial cells (Diano et al, 1999, Critchley et al, 2001) and in the heart, localised to
nuclei of cardiomyocytes and coronary arteries of both rat and rabbit (Lou et al, 1998,
Saunders et al, 1997, Neudling et al, 2001).
Immunohistochemical and RT-PCR analysis of female rat vascular beds demonstrated
the expression of ERG protein in the nuclei of vascular smooth muscle and endothelial
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cells of the aorta, tail and uterine arteries (Andersson et al, 2001, Lindner et al, 1998)
and ER6 mRNA in the rat carotid artery (Makela et al, 1999). Similar to ERa, ERB was
expressed in the nuclei of cardiomyocytes and coronary arteries of both rat and rabbit
(Lou et al, 1998, Saunders et al, 1997, Neudling et al, 2001).
At the time of this study, little work had been published on the expression of ERs in the
cardiovascular system of the mouse. Karas et al had demonstrated that ERa and ERB
were detectable by RT-PCR in mouse aorta (1999). However, as mRNA was extracted
from whole tissue this does not provide information as to the cellular localisation of
these receptors. As the literature suggests that expression of ERs in the cardiovascular
system may be species dependent, we felt it necessary firstly, to determine the tissue
distribution and cellular localisation of ERs in the mouse cardiovascular system.
Secondly, as we were using the 6ERKO mouse to determine the effects of oestrogen on
the cardiovascular system mediated through ERB, we wished to confirm that these
animals did not express immunoreactive ERB.
Oestrogen has been shown to be protective against the development of atherosclerosis
(Adams et al, 2002, Potier et a,I 2003) and myocardial infarction (Smith et al, 2000)
Mice that do not express apolipoprotein E (Apo E-/-), which mediates the binding of
lipid particles to lipoprotein receptors for the utilisation and redistribution of lipids,
(Pitas et al, 1987), suffer from premature atherosclerosis as a result of a severe lipid
disorder (Osada et al, 2000). Several studies have reported that oestrogen has an
atheroprotective effect in Apo E-/- mice such that it dramatically inhibited lesion
initiation, and progression (Bourassa et al, 1996, Elhage et al, 1997, Tse et al, 1998).
The atheroprotective effect observed in these studies was not associated with a reduction
in plasma cholesterol, thus suggesting that the protective effect of oestrogen was not due
to an effect on plasma lipids but rather by a direct effect on the vessel wall. Furthermore,
literature suggests that the atheroprotective effects of oestrogen are receptor mediated
and can in part be to ERa, as lesion size following chronic oestrogen supplementation of
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female mice, is significantly greater in mice lacking ERa compared to WT littermates
(Hodgin et al, 2001).
In mice, coronary artery ligation leads to myocardial infarction and a reduction in left
ventricular systolic function (Booth et al, 2002) and provides an animal model for
studying MI. In this model, chronic oestrogen supplementation was reported to reduce
infarct size and cardiomyocyte apoptosis in mouse models of MI (van Eickels et al,
2003). The cadioprotective effect of oestrogen to reduce infarct size was shown to ER
mediated as the observed reduction in myocardial injury was abrogated by ICI 182, 780,
a non-specific ER antagonist (Booth et al, 2003).
Although literature suggests that the protective effects of oestrogen in the
aforementioned mouse models of atherosclerosis and myocardial infarction was ER
mediated, ER expression in either the vasculature or myocardium has not been reported.
We hypothesis that ERs are expressed in the vasculature and cardiomyocytes of
Apo E-/- and CAL mice respectively. The third aim of this study was a preliminary
study to determine whether the technique of immunohistochemisty for the detection of
ERp in the mouse cardiovascular system could be applied for the detection of ERp in the
mouse pathophysiological models of atherosclerosis and myocardial infarction. A
second arm to this part of the study included a preliminary in-Testigation as to whether
chronic oestrogen supplementation improved cardiac function following MI.
3.2 Methods
3.2.1 Animals
Animals used for this study were as outlined in Section 2.1. Briefly, to determine the
distribution and cellular localisation of oestrogen receptors (ERs) in the mouse
cardiovascular system, wild type (WT, 14- 18wks) male and female littermates of the
BERKO mouse, of a mixed genetic background C57B16/ SvJ129, were used.
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Immunohistochemical analysis of ER expression in the cardiovascular system of the
6ERKO (14- 18wks) was characterised in both male and female mice also.
Immunoexpression of ERs in animal models of pathophysiological conditions were
studied. C57B16 female mice purchased from Harlan, underwent bilateral ovariectomy
as outlined in Section 2.3.1.1.1 (13- 15 wks) or were allowed to continue cycling, one
week prior to CAL surgery to induce myocardial infarction or sham, as outlined in
Section 2.3.1.3. Cardiac function was assessed by echocardiography as outlined in
Section 2.3.2.2. Tissues were harvested from animals two weeks post- surgery (16-
18wks).
Apolipoprotein E knock- out female mice (Apo E-/-, 32- 36wks) which are an
established model of atherosclerosis (reviewed in, Smith and Breslow, 1997, Van Dijk et
al, 2000, Fazio and Linton, 2001), were kindly made available to us by Dr I Megson
who has a colony established at Edinburgh University.
3.2.2 Tissue collection and processing
Animals were euthanased and tissue obtained and processed for immunohistochemistry
as outlined in Section 2.4.1 and 2.6.1.
Tissues used for immunohistochemical analysis of the mouse cardiovascular system
were heart, aorta and mesenteric artery. The positive controls for ERa expression were
mouse ovary and mouse uterus (Horigome et al, 1988, Korach et al, 1988, Hiroi et al,
1999) and mouse ovary for ERB (Krege et al, 1998, Dupont et al, 2000). Positive
controls were included in each run. In addition to the positive control for ERB, female
WT sections of heart and aorta which had previously stained positive for ERB were
included in the runs for the detection of ERB in i) hearts from mice which had undergone
coronary artery ligation and ii) aorta from Apo E-/- mice.
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3.2.3. Histological analysis
3.2.3.1. Haemotoxylin and Eosin
Ovaries from both WT and 6ERKO female mice were stained with haemotoxylin and
eosin as outlined in Section 2.2.2.2. Dr Norah Spears (University of Edinburgh) kindly
analysed the ovarian phenotype.
3.2.3.2. Van Geison
Myocardial infarction was induced in female mice as outlined in Section 2.3.1.3 by Dr
Isam Sharif. The deposition of collagen rich scar tissue formed in the infarcted zone of
the left ventricle from CAL mice was confirmed using van Geison's stain for collagen
deposition, as outlined in Section 2.6.2.
3.2.3.3 Oil Red
Dr Saibal Biswas performed the histology for the detection of aortic fatty streak lesions
in female Apo E-/- mice (40wks) using oil red O. Briefly, thoracic aortas were isolated,
stripped of adipose tissue and immediately stained in 0.75% Oil red O (Sudan IV) in
isopropanol for 15- 20mins. Excess stain was removed in 70% ethanol. Aortas were
opened longitudinally and the surface of the lumen examined for visible plaque areas.
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3.2.4. Immunohistochemical analysis
3.2.4.1 Immunoexpression of ERa
For the detection of ERa in the mouse CVS, sections of heart, aorta and mesenteric
artery from WT, C57B16/ SvJ129 female mice were treated as outlined in Section 2.6.3.
Two different mouse anti-human ERa antibodies, as outlined in Table 2.2 of Section
2.6.3, were used over a range of dilutions, 1:100- l:20diln. Negative controls, sections
which had not been incubated with primary antibody, were also included for each tissue
type in each run.
3.2.4.2 Immunoexpression of ERB
Immunoexpression of ERB in the mouse CVS was studied using two anti-ERB
antibodies which were directed against different regions of the ERB protein, namely the
hinge region and the c-terminus, as outlined in Table 2.2 of Section 2.6.3. Antigen
retrieval and treatment for endogenous peroxidase activity in sections from the tissues
studied was performed as outlined Section 2.6.3. The antibody directed against the hinge
region of ERB was used at 1:1000- 1:750 dilution and the antibody directed against the
c- terminus was used at 1:100. Negative controls were sections which had not been
incubated with primary antibody and were included for each tissue type in each run.
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3.3 Results
3.3.1 Immunolocalisation of oestrogen receptors in the mouse
cardiovascular system
3.3.1.1 Localisation and cellular distribution of ERa
Immunoreactive ERa protein was not detected in the cardiovascular system of female
WT mice, using either of the anti ERa antibodies tested, Figure 3.1.
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Figure 3.1 Immunoexpression ofERa in the female mouse cardiovascular system.
Immunohistochemistry for ERa in the cardiovascular system of normally cycling female
WT mice (14- 18wks, n=3). Haemotoxylin stained sections of tissues which were not
incubated with anti- ERa antibody a) heart c) aorta and e) mesenteric artery.
Immunohistochemistry of b) heart d) aorta and f) mesenteric artery with an anti- ERa





Both antibodies to ERa used in this study were raised against human ERa and therefore
to demonstrate that they detected immunoreactive ERa, we tested our conditions in
human endometrium. ERa protein was detected in the nuclei of human endometrium
using both antibodies, as shown with NCL-ER-6F11 Figure 3.2. Secondly, to determine
whether both antibodies could cross- react with mouse ERa we repeated the conditions
using mouse ovary and found that both antibodies were able to cross- react with mouse
ERa. Immunoreactive ERa was detected in the germinal epithelium and ovarian cortex
but not found to be expressed in the theca cells, as shown by with NCL-ER-6F11 Figure
3.2.
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Figure 3.2 Immunoexpression ofERain the mouse ovary and human endometrium
Immunohistochemistry for ERa in the ovaries of normally cycling female WT mice (14-
18wks, n= 3) and human endometrium, a) Haemotoxylin stained section of ovary which
was not incubated with anti- ERa antibody, -ve control. Immunohistochemistry of b)
mouse ovary and c) human endometrium. Sections a)- c) x20 magnification.
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3.3.1.2 Localisation and cellular distribution of ERR
To confirm that the antibody directed against the c-terminus of human ER6 was able to
detect immunoreactive ER6 in mouse tissues, ovaries from female WT mice were
immunostained under the conditions used. Immunoreactive ER6 protein was detected in
the nuclei of granulosa cells of follicles as well as in the ovarian cortex, Figure 3.3
which is consistent with previously published reports (Krege et al, 1998, Schomberg et
al, 1999, reviewed Saunders et al, 1998).
These conditions were then applied for the detection of ER6 in the cardiovascular
system of both male and female wild-type (C57B16/ SvJ129 genetic background) mice.
Immunoreactive ERB was detected in the heart of WT female mice. Expression was
localised specifically to the nuclei of cardiomyocytes in the myocardium, Figure 3.3, but
also to cells of the endocardium and epicardium. Therefore, ERB was expressed
diffusely throughout the heart in the majority of cardiomyocytes, although some
cardiomyocytes did not stain positive for ERB. Not shown in this figure, ERB was also
expressed in coronary arteries, where it was localised to both the endothelium and
smooth muscle. No immunoreactive ERB was detected in the cell cytoplasm.
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Figure 3.3 Immunoexpression ofER/3 in the female mouse
Immunohistochemistry for ER/3 in the tissue of normally cycling female WT mice (14-
18wks, n- 5). Haemotoxylin stained sections of tissues which were not incubated with
anti- ER/3 antibody a) ovary and c) heart. Immunocytochemistry ofb) ovary and d) heart
with the anti- ER/3 antibody raised against the c-terminus of the ER/3 protein. Images a)
and b) are x20 magnification and images c) and d) x40 magnification. (GC) granulosa




ER8 was detected in the aorta, a conduit vessel and the mesenteric artery, a resistance
vessel using anti-ERB antibodies directed to the c-terminus of the protein, Figure 3.4. The
nuclei of endothelial cells, from both vessels studied, expressed immunoreactive ER8.
Nuclei of vascular smooth muscle cells also expressed immunoreactive ERB, Figure 3.4.
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Figure 3.4 Immunoexpression ofER/3 in the vasculature of the female mouse
Immunohistochemistry for ERJ3 in tissue of normally cycling female WT mice (14- 18wks,
n- 5). Haemotoxylin stained sections of tissues which were not incubated with anti- ER/3
antibody a) aorta and c) mesenteric artery. Immunocytochemistry of b) aorta and d)
mesenteric artery with the anti- ER(3 antibody directed against the c-terminus of the ER/3




Similar to the expression of ERB in the cardiovascular system of the female mouse,
immunoreactive ERB was detected in the nuclei of cardiomyocytes and endothelial and
vascular smooth muscle cells of coronary arteries in male mice, Figure 3.5.
ERB was also detected in endothelial cells and vascular smooth muscle cells of both the
aorta and mesenteric artery, Figure 3.5 which was comparable with that observed in
female WT mice.
No immunopositive reaction was detected in negative controls of tissues, where sections
had not been incubated with the primary ERB antibody, Figure 3.4- 3.5.
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Figure 3.5 Immunoexpression of ERJ3 in the male mouse
Immunohistochemistry for ERJ3 in tissue of male WT (14- 18wks, n= 5). Haemotoxylin
stained sections of tissues which were not incubated with anti- ERJ3 antibody a) heart, c)
aorta and e) mesenteric artery. Immunocytochemistry of b) heart, d) aorta and f)
mesenteric artery with an anti- ERJ3 antibody directed against the c-terminus of the ERJ3
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3.3.1.3 Immunoexpression of ERG in the BERKO mouse
Surprisingly, we were able to detect immunoreactive ERB protein in male and female
BERKO mice (Krege et al, 1998) using the anti-ERB antibody directed against the
c-terminus of the protein, with the same distribution pattern and cellular localisation to
that of male and female WT mice. To confirm the expression of ERB protein in the
BERKO mouse we repeated immunohistochemical analysis using a second antibody to
ERB, which was directed against a different region of the protein, the hinge region.
Figures 3.6 and 3.7, show that immunoreactive ERB protein was detected in the nuclei
of cardiomyocytes, endothelial and vascular smooth muscle cells of the female BERKO
mouse which was independent of the epitope of the antibody used to raise the anti-ERB
antibody.
95
Figure 3.6 Immunoexpression ofERfi in the femalefiERKO mouse
Immunohistochemistry for ERfi in tissue of normally cycling female fiERKO mice (14-
18wks, n= 5). a) and c) Haemotoxylin stained sections of heart tissue which were not
incubated with the anti-ERfi antibody directed against the hinge region and c-terminus
of the ERW protein respectively. Immunocytochemistry for the detection ofERfi in section
b) antibody directed against the hinge region of ERfi and in section d) using the
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Figure 3.7 Immunoexpression ofERfi in the vasculature of the femaleflERKO mouse
Immunohistochemistry for ERfi in the vasculature of normally cycling female fiERKO
mice (14- 18wks, n= 5). a) and d) Haemotoxylin stained sections ofaorta which were not
incubated with anti- ERfi antibody under the conditions used for immunocytochemistry
for the antibodies to the c- terminus and hinge region respectively. Immunocytochemistry
for the detection of ERfi in sections b) and c) used the antibody directed against the
c-terminus of ERfi and sections e) and f) used the antibody directed against the hinge




A similar pattern of distribution and cellular localisation was detected in the male
GERKO mouse, Figure 3.8.
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Figure 3.8 Immunoexpression ofERJi in the maleJIERKO mouse
Immunohistochemistry for ERfi in the vasculature of male fiERKO mice (14-18wks,
n= 5). Immunoreactive ERfi protein as detected by the antibody directed against the c-
terminus region of ERfi a), b) and c) and the antibody directed against the hinge region




The PERKO mice generated and described by Krege et al were shown not to express
immunoreactive ERB protein in their ovaries and to present with an ovarian phenotype
(1998). As it was from these mice that our own colony was generated we therefore
wanted to confirm whether these mice had the same ovarian phenotype as previously
described (Krege et al, 1998).
The BERKO ovaries did exhibit a clear ovarian phenotype when compared to WT
littermates, Figure 3.9a and b. For example the ovaries of BERKO mice were found to
contain more apoptotic cells and to have atresia in the ovarian medulla in comparison to
ovaries from WT, Figure 3.9a and b and SvJ129 (not shown). There was a reduction in
the number of corpora lutea in the BERKO ovaries and those that were present had rough
or jagged edges, which indicated that they were degenerating. In addition, the ovaries
did not contain any normal corpora lutea which was consistent with a reduction in the
number of ovulations. Furthermore, there was an increase in the number of atretic
follicles in which the oocyte had either become less spherical in shape or begun to
breakdown or pull away from the zona pellusida even before the atrium had developed
in the follicle, Figure 3.9.
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Figure 3.9 Morphology ofovariesfromfemale WT and J3ERK0 mice
Haemotoxylin and eosin stained sections of ovary from normally cycling
female mice (14- 18wks, n= 5) a) WT and b) J3ERKO mice, x5
magnification. (CL) corpus luteurn, (OM) ovarian medulla and (F) follicle
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Consistent with the results obtained using cardiac tissue, Figure 3.3, we also detected
immunoreactive ER6 in the ovaries from our colony of female BERKO mice using the
antibodies directed against two different regions of the ERB protein, Figure 3.10. The cell
specific pattern of expression was similar to that of WT mice with similar distribution to
that of the WT mouse.
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Figure 3.10 Immunoexpression ofERfi in the ovary ofthe female fiERKO mouse
Immunohistochemistry for ERfi in the ovary ofnormally cycling female fiERKO mice (14-
18wks, n= 5). Haemotoxylin stained sections of ovary which were not incubated with
anti- ERfi antibody formed the negative control for the anti- ERfi antibody directed
against a) the c-terminus and c) the hinge region of the ERfi protein respectively.
Immunocytochemistry usedfor the detection of ERfi using an antibody directed against b)
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3.3.1.4 Oestrogen and oestrogen receptors in pathophysiological
models.
3.3.1.4.11mmunoexpression of ERB in a mouse model of atherosclerosis
Specimens containing root, arch and thoracic aorta were stained for neutral lipids and
fatty acids using oil red O, Figure 3.11. Fatty lesions were deposited in the aortic arch of
female Apo E-/- mice aged 40wks.
Aorta from normally cycling female Apo E-/- mice expressed immunoreactive ERB in
both endothelial and vascular smooth muscle cells of the aortic arch and thoracic aorta
Figure 3.12. Immunoreactive ERB was also localised to the nuclei of endothelial cells of
the atherosclerotic plaque, Figure 3.12b.
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Arch
Figure3.11Detectionoffattyles onsinthea r afApoE-/-mous . Aortafr mano mallycyclingfemaleApE-/-(40wks)stainedwithoiredO.Arr sindic e sitesoffa tystreakdepo itioninth icrch.
Figure 3.12 Immunoexpression ofERfi in the aorta of thefemale Apo E-/- mouse
Immunohistochemistry for ERfi in tissue of normally cycling female Apo E-/- mice (20-
22wks, n= 5). Haemotoxylin stained sections of a) aortic arch and c) thoracic aorta
which were not incubated with the anti-ERfi antibody. Immunocytochemistry for the
detection ofERfi in sections using an antibody directed against the hinge region ofERfi,
b) aortic arch, d) thoracic aorta. The aortic arch is the site of the atherosclerotic lesion.
All images were x40 magnification.
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3.3.1.4.2 Echocardiography and immunodetection of ERR in a mouse
model of myocardial infarction
3.3.1.4.2.1 Effect of CAL and oestrogen status on body and tissue weights
Body weight of mice in each of the three oestrogen treatment groups was not
significantly different in either CAL or sham operated animals, 2-way ANOVA (surgery
x oestrogen status) p<0.05, Table 3.1.
The uterine weight of female mice which had undergone ovx and received chronic
oestrogen supplementation, was significantly greater than that of normally cycling mice
and those which had been ovx and administered placebo, Table 3.1.
Heart weight had not increased as a result of CAL, despite scar formation, compared to
sham operated controls and neither was there a difference in heart weight between
animals of different oestrogen status, Table 3.1.
3.3.1.4.2.2 Effect of CAL and oestrogen status on cardiac function
In-vivo echocardiography, two weeks post-surgery, demonstrated that CAL led to a
reduction in ejection fraction which was not different between female mice of different
oestrogen status, Figure 3.13.
Fractional shortening was also decreased following CAL and was not different between
the three treatment groups. However, the Bonferroni post-hoc test revealed that
fractional shortening was significantly reduced following CAL in normally cycling
female animals and those which were ovariectomised and supplemented with oestrogen.
Although a trend was developing in both the placebo and oestrogen treated animals such









































Table3.1BodyntissuweightsforemachichhundergoneCALu ry FemaleWTic ,ofdifferentestrogenstatuswh hhadundergoneCALrmu ry,eigh d
attimeofbeingeuthanisedndtissuharvestedwighxpresp rce tagey weight.Valuesareexpressedmean±SEMndnalysusing2-ayANOVAfollow db Bonferronipost-h cte t,*p<0.05comparedy u gh rtfanimals(Shamycli g,= ;CAL cycling,n=9;Shamovx+pl ebo3,CALl ,4estrogen=3and ovxestrogen,n=6).
* * *
cycling placebo oestrogen
Figure 3.13 Assessment of ejection fraction andfractional shortening
in female mice which had undergone CAL or sham.
Ejectionfraction andfractional shortening were assessed in female WT
mice (16-18wks) which had undergone either sham surgery, □ or CAL,
■. Female mice, which had undergone surgery, were of different
oestrogen treatment; normally cycling or ovx and supplemented with
either placebo or oestrogen pellets. Data are expressed as mean± SEM
and analysed using a 2-way ANOVA (treatment x surgery) followed by
a Bonferroni post- hoc test. *p<0.05 Sham operated animals; cycling
n=5, Ovx+ placebo n= 3, Ovx+ oestrogen n— 3, CAL animals; cycling
n— 8, Ovx+ placebo n= 4, Ovx+ oestrogen n=6.
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3.3.1.4.2.3 Immunoexpression of ERU following CAL In female mice
Female WT mice that had undergone CAL, in each of the oestrogen treatment groups
studied, developed a collagen rich scar in the infarcted region of the left ventricle when
compared to sham operated animals, Figure 3.14 (not shown for female supplemented
with oestrogen or those treated with placebo)
Immunoreactive ER6 was localised to the nuclei of cardiomyocytes of sham operated
animals and to the nuclei of surviving cardiomyocytes in the area of infarction, Figure
3.14.. Although not all of the cardiomyocytes of sham operated animals were positively
stained for ER6, it appeared that surviving cardiomyocytes in the area of infarction all
expressed immunoreactive ER6, Figure 3.14. The localisation of ERB to the nuclei of
cardiomyocytes was not different in female animals that had undergone ovariectomy and
administered placebo or supplemented with oestrogen (not shown).
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Figure 3.14 Immunoexpression ofERfi in the infarcted heart offemale mice which are
normally cycling
Immunohistochemistry for ERfi in the heart ofnormally cyclingfemale mice (16- 18wks)
which were either sham operated (n= 5) a) and b) or had undergone coronary artery
ligation (CAL, n=8) c) and d) to induce myocardial infarction. Van Geison staining of
sections of the heart indicates that a) sham operated animals did not develop an infarct
whilst c) myocardial infarction occurred in mice which underwent CAL, xlO
magnification. Immunoreactive ERfi was detected in b) cardiomyocytes ofsham operated
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At the time of this study the cellular localisation and distribution of ERs in the mouse
cardiovascular system was unknown. We have shown in this study that ER8 was
localised to the nuclei of cardiomyocytes and endothelial and vascular smooth muscle
cells of aorta, mesenteric arteries and coronary arteries in both male and female WT
mice. However, immunoreactive ERa was not detected in these tissues suggesting that
ER8 is the predominant ER isoform expressed in the mouse cardiovascular system.
We also demonstrated that immunoreactive ERG was detected in ETC and VSMC in the
aorta of female atherosclerotic susceptible mice and in the region of atherosclerotic
plaques that had developed in the aortic arch. This study also showed that in female WT
mice, in which myocardial infarction was induced by CAL surgery, immunoreactive
ERG was localised to the nuclei of cardiomyocytes in the infarcted area and also in the
nuclei of cardiomyocytes in the non- infarcted region of the myocardium.
ER expression in the cardiovascular system of humans and animal models; rats, rabbits
and guinea pigs (Orimo et al, 1993, Leiberman et al, 1990, Karas et al, 1994) has been
reported to vary with the vascular bed and also species studied. In human and non-
human primate, the endometrium expressed ERG but not ERa (Critchley et al, 2001).
Although ERa was expressed in VSMC and ETC in the rat, ERa was not detected in the
aorta of the guinea- pig (Orimo et al, 1993, Leiberman et al, 1990). Therefore, it was of
interest to determine whether and which ERs were expressed in the cardiovascular
system of the mouse and particularly those tissues in which we wanted to study the
effect of oestrogen.
Our finding that ERG was expressed in the mouse heart is supported by the expression of
ERG in both human and rat hearts (reviewed in Taylor and Al- Azzawi, 2000, Jankowski
et al, 2001, Grohe et al, 1998). ERG expression was localised to the nuclei of
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cardiomyocytes in the mouse myocardium which was similar fo the expression of ER6
in rat cardiomyocytes. However, a recent study by Yang et al, reported that expression
of ER8 was immunolocalised to the mitochondria of primary cultured rat
cardiomyocytes (2004). This is in contrast to previous reports of ERB expression in rat
cardiomyocytes and indeed our own study of expression in the mouse myocardium. It is
possible that the differences between our own study and Yang et al (2004), is due to
differences in the species studied or due to the differences in techniques used. Whereas
we studied whole tissues from adult mice, in which cellular proteins were immediately
fixed following tissue harvesting, they studied cultured neonate' rat cardiomyocytes and
it is possible that culturing technique may alter protein expression and explain the
differences between the two studies.
Interestingly, a study by Forster et al, reported that ER6 protein was not detected in
either the nuclear or mitochondrial fraction of mouse heart (2004). Although they
detected several bands for ERB in the mitochondrial fraction none was specific for ERB.
Attempts to establish the technique of Western blotting for the detection and
quantification of ERB protein in mouse tissue in our own lab have not proven successful.
However, we have clearly demonstrated in this study, through the use of two antibodies
directed against different epitopes that ERB is expressed in the nuclei of cells in the
myocardium in the mouse heart.
Although ERa was shown to be expressed in the rat heart (Grohe et al, 1998) we were
unable to detect immunoreactive ERa in the mouse. It is possible that either the levels of
ERa protein are below those which we are able to detect or that it is not expressed in the
mouse heart. The recent study by Forster et al, reported that they did not detect
immunoreactive ERa in the myocardium of mouse hearts however, they did not show
this in their paper (2004). Further investigation is required therefore to confirm whether
ERa expression in the mouse heart is either not expressed or below the level of
detection, as may be suggested by expression of ERa mRNA.
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Our study showed for the first time that ERB and not ERa was immunolocalised to the
nuclei of VSMC and ETC of both mesenteric and coronary arteries of the mouse.
Rodrigo et al, reported that both ERa and ER8 protein could be detected by western
blotting in rat mesenteric arteries (2002). Due to the differences in the expression of ERs
in the vasculature between species previously reported, (Leiberman et al, 1990) this is
not sufficient evidence to suggest that the levels are lower than the detection threshold.
Although early vascular studies of oestrogen and ERs by Rubanyi et al reported that
mRNA for ERa was detected in mouse aorta (1997), it does not necessarily follow that
the message would be translated to protein. Indeed, Liang et al supported our finding,
by reporting that ERS and not ERa was localised to the nuclei of ETCs and VSMCs in
mouse aorta (2001). Therefore, the difference observed in expression of ERa between
the cardiovascular system of the mice in our studies and those of rats in other studies
may be attributed to differences between the species, such that ERa is not expressed in
the mouse cardiovascular system. This did seem a likely explanation until later studies
by Liang et al, reported that although they were unable to detect ERa in the mouse aorta
by immunohistochemistry (2001) they were now able to detect ERa protein by Western
blotting (Liang et al, 2003). This may be because the antibodies which are currently
available for the detection of ERa are better able to detect protein which has been
isolated and denatured, as with Western blotting, than those for immunohistochemistry.
Therefore, it is not possible for us to conclude from our study that ERa is not expressed
in the mouse cardiovascular system but rather that the levels of expression may have
been undetectable by our methods, at least in the cardiovascular system as was
detectable in the mouse reproductive system with the same antibody.
Subsequent chapters of this thesis studied the influence of oestrogen and the role of ER8
in mediating the effects of oestrogen on the mouse cardiovascular system. As oestrogen
is known to regulate the expression of its own receptors (Zou and Ing, 1998), future
studies to quantify the level of expression of ERs in the mouse cardiovascular system
would provide insight into the mechanisms by which oestrogen may produce its effects
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on the cardiovascular system. In the vasculature, high and low concentrations of
oestrogen can produce opposing effects. Interestingly a study by Rodrigo et al, reported
that rats supplemented with oestrogen for 4 days have an almost 3 fold increase in
expression of ERB protein in mesenteric artery in comparison to ovx and vehicle treated
animals, whereas expression of ERa protein remained unchanged (2002). Initial stages
in the development of real- time RT- PCR to quantify ER expression have been
undertaken in our lab but are not yet complete. In addition to this, establishing the
technique of Western blotting for ERs would allow us to relate the level of ER mRNA to
the quantification of protein expressed for each receptor.
One of the aims of this thesis was to determine the role of ERB in the cardiovascular
system using the 6ERKO mouse as our experimental model. However, we wanted to
confirm that ERB was not expressed in the tissues to be studied in these animals. As
clearly shown in this chapter, ERB was immunolocalised to the heart, aorta and
mesenteric arteries of 6ERKO (as determined by genotyping), with a similar distribution
to that of WT mice. This was confirmed using two different antibodies that were
directed against different regions of the ERB protein. In order to replicate the data in the
paper by Krege et al (1998), we used an antibody directed against the c- terminus of
ERB. The 8ERKO mice were prepared by insertion of a neo cassette into exon 3 which
codes for the DNA binding domain of the receptor. This \,as reported to alter the
reading frame of the protein resulting in a premature stop codon and therefore should not
contain any of the protein coded by the exons 5- 8 (ligand binding domain). However, in
our hands ERB protein was detected using the antibody directed against the c-terminus
not only in tissues of the cardiovascular system but also in the ovaries from BERKO
mice in a similar expression pattern to that of the WT mouse. The second antibody used
was directed against the hinge region of the protein which is immediately downstream of
the DNA binding domain. ERB was localised in an identical manner to that detected
using the c-terminus antibody by the antibody directed against the hinge region.
Although immunoreactive ERB was detected in the BERKO mouse we confirmed that it
was unable to function as native WT protein in the ovarian follicles as BERKO mice
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presented with a similar ovarian phenotype to that described by Krege et al (1998).
Although WT littermates were on the same mixed genetic background (C57B16/
SvJ129), to exclude the possibility that the phenotype observed could be explained by
the genetic background of the animals, ovarian morphology of SvJ129 mice was also
analysed. As the morphology of SvJ129 ovaries was similar to that of WT mice used in
this study, we concluded that the phenotype observed in the 6ERKO mouse could solely
be attributed to the disruption of the ER8 gene and subsequently the function of ER6
protein expressed in these mice.
The occurrence of transcriptional read through in the generation of knock out animals,
using a comparable targeting strategy, has been reported with the ERKO mouse (Couse
et al, 1995). Indeed, it was shown in the original targeting paper of the BERKO mouse
(Krege et al, 1998) that alternate splicing of the ER8 gene could also occur in the
targeted gene, resulting in ER8 mRNA variants. Two of the variants result in clones that
lack exon 3 and generate stop codons in exon 4. As the antibodies used in this study
were downstream of the region coded for by exon 4, it is unlikely that our colony of
mice were of these variants. However, a third clone was produced from the targeting
strategy which lacked the exons coding for the DNA binding domain but preserves the
reading frame, such that protein downstream of the DNA binding domain would be
translated. Expression of ER8 isoforms lacking either exon 4 or exon 5 have been
reported in both rats and humans where their function has yet to be defined but it has
been suggested that they may function as dominant negative receptors (Price et al, 2000,
Inoue et al, 2000). Further studies in our animals are required to determine whether the
form of ER8 expressed in these animals has any residual activity whilst also determining
the regions of protein which are expressed in this animal following gene disruption.
Western blotting of protein samples from these mice for ER8 are currently ongoing to
determine whether our colony of BERKO mice express a truncated form of the ER8
protein and which regions of the native WT ER8 protein are missing.
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This chapter also included a preliminary study to determine whether
immunohistochemistry, applied to study the localisation of ER6 in the mouse
cardiovascular system, could be used to study the expression of ER6 in mouse models of
atherosclerosis and myocardial infarction. To determine the expression and localisation
of ER6 in atherosclerotic vessels, we used Apo E-/- mice which are a well established
animal model of atherosclerosis. The literature reports that advanced atherosclerotic
plaques containing extracellular lipids and fibrous connective tissue had developed in
Apo E-/- by 24 weeks of age (Bentzon et al, 2003). The female mice used in this study
were aged between 32- 36 weeks and confirmed as a suitable model for determining the
expression of ERs in atherosclerosis as vessels from female mice, aged 40 weeks, were
shown to contain fatty lesions in the aortic arch.
Several studies have reported that oestrogen has an atheroprotective effect in Apo E-/-
mice in that it dramatically inhibited lesion initiation, and progression such that it rarely
progressed beyond small uncomplicated fatty streaks consisting of macrophage foam
cells (Bourassa et al, 1996, Elhage R et al, 1997, Tse et al, 1998). Although oestrogen
has beneficial effects on lipid profile, the atheroprotective effects of oestrogen were
suggested to be mediated by direct effects on the vascular wall as protection occurred at
doses of oestrogen which did not alter lipid profile (Chae et al, 1997). Surprisingly, the
localisation of ERs in the mouse model of atherosclerosis has not been characterised
despite several studies using ER knock-out mice as a tool to elucidate the mechanisms
by which oestrogen may mediate the apparent atheroprotection. Our initial studies
demonstrated, using immunohistochemistry, that ERI3 was Lnmunolocalised to both
vascular smooth muscle and endothelial cells of normally cycling female Apo E-/- mice
in both the aortic arch, the site of atherosclerotic lesions and in the thoracic aorta.
Although there are no reports in literature to support our finding in Apo E-/- mice,
Nakumura et al reported that ER6 was expressed in human aorta containing
atherosclerotic lesions (Nakumura et al, 2004). The study by Nakumura et al, also
reported the expression of ERa in such lesions however we were unable to detect levels
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of ERa protein by immunohistochemistry in female WT mice which thereby prevented
optimisation of the conditions.
A role for both ERs in mediating the protective effects of oestrogen in atherosclerosis
has been demonstrated in both human and mouse. In human vessels, ERa and ER8
expression, as measured by immunohistochemistry and real- time PCR, in the neointima
decreased in intensity and number in proportion to the development of atherosclerosis
(Nakamura et al, 2004). This suggests that the reduction in the expression of ERs in the
neointima may suppress the anti- atherogenic effects of oestrogen. However, whether the
reduction of ERs in the atherosclerotic vessel was cause or effect remains to be
elucidated. Although the expression of ERa protein has not as yet been studied in the
vasculature of Apo E-/- mice, studies by Hodgin et al, demonstrated a role for ERa in
mediating the protective effects of oestrogen through the generation of a double ERa/
Apo E-/- knock out mouse (2001). They demonstrated that oestrogen reduced lesion size
by more than 80% in Apo E-/- mice which expressed ERa compared to less than 35% in
mice lacking ERa. This was supported by Adams et al, who reported that dietary soy
isoflavones reduced the levels of esterified cholesterol in the aorta of Apo E-/- mice and
that the reduction in esterified cholesterol levels was lost with the loss of expression of
ERa (2002). When the cholesterol efflux pathway becomes saturated, as a protective
response to the increase in free circulating cholesterol levels, cholesterol is esterified
(Fazio et al, 2001). Therefore the study by Adams et al, by measuring the levels of
esterified cholesterol, demonstrated that ERa mediated the atheroprotective effect of
oestrogen by reducing cholesterol levels (2002). However, an additional arm of the
study also addressed the role of ERp by crossing the pERKO mouse with the Apo E-/-.
In contrast to the ERKO/Apo E-/-, the loss of ERp did not inhibit the reduction in
esterified cholesterol by isoflavones in dietary soy. Taken together these studies
implicate a role for ERa but not ERp in mediating the atheroprotective effects of
oestrogen on plaque development. However, Hodgin et al suggested that ERp may also
mediate the protective role of oestrogen in plaque development as the lesions which did
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develop in ERKO mice were essentially fatty streaks of lipid laden foam cells and had
few advanced characteristics (2001). Therefore, following from our initial observation
that ERp is expressed in the aorta of Apo E-/- mice, we would like to investigate the
effect of oestrogen on plaque development and the level of expression of ERs during
plaque development. Although we were unable to optimise the technique of
immunohistochemistry for ERa in the mouse cardiovascular system and subsequently
unable to determine whether ERa is expressed in the vasculature of Apo E-/- mice, an
alternative will be to use real- time RT-PCR. This will show whether mRNA for both
ERa and ERp is expressed in vessels from these mice and secondly, enable
quantification of receptor expression. Also of interest would be the use selective ER
agonists or antagonists as pharmacological tools to determine the role of each individual
receptor on mediating the effects of oestrogen during plaque development.
In this preliminary study of the expression of ERp in the mouse models of
cardiovascular pathophysiology, we also examined the effect of CAL and subsequently
MI on the expression of ER6 in the mouse myocardium and cardiac function. We
demonstrated that immunoreactive ER6 was detected in the nuclei of cardiomyocytes in
the infarcted region and also in the nuclei of cardiomyocytes in the non- infarcted
region. However, for the reasons explained previously, we were unable to confirm
whether ERa was expressed under pathophysiological conditions in the mouse heart as it
appeared from our own studies that ERa expression in the mouse heart. Following
myocardial infarction we demonstrated that cardiac function was impaired as assessed
by ejection fraction and fractional shortening as a measure of left ventricular systolic
function but that this was not different between animals of different oestrogen status. It
was demonstrated that CAL led to a reduction in ejection fraction which was unaffected
by oestrogen status. CAL also resulted in a reduction in fractional shortening which was
not different between the three treatment groups. However, the difference in fractional
shortening of placebo treated animals was not found to be significantly lower following
CAL than those which were sham operated or ovariectomised and supplemented with
oestrogen. However, the trend for CAL to reduce fractional shortening in placebo treated
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animals may have reached significance if the number of animals studied in this group
was increased, as ejection fraction was shown to be decreased in placebo treated animals
and both ejection fraction and fractional shortening are measures of left ventricular
systolic function. A recent study by van Eickels et al supported our finding that the
oestrogen status of mice had no affect on impaired cardiac function post- MI (2003).
However these authors did demonstrate that chronic oestrogen treatment reduced infarct
size and reduced cardiomyocyte apoptosis. Several studies have suggested that the
reduction in infarct size by oestrogen is receptor mediated. A possible mechanism for
the reduction in infarct size due to inhibition of apoptosis following oestrogen treatment,
was the finding that cardiomyocytes transfected with either ERa or ER6 can inhibit
p65/p50 NF-kB DNA binding complexes which would otherwise lead to the activation
of genes which would lead to programmed cell death (Pelzer et al, 2001). Furthermore, a
study in female rats which had undergone CAL and as a result developed cardiac
hypertrophy reported that oestrogen treatment elevated levels of ANP (Jankowski et al,
2001). ANP is suggested to have anti-hypertrophic properties by attenuating protein
synthesis via cGMP (Horio et al, 2000) and interestingly the study by Jankowski et al,
demonstrated that ERa expression in the heart was greater than that of ERG and
secondly, that the expression of ANP in the heart reflected that of ERa. This suggests
that ERa may mediate the oestrogen induced increase in ANP. In further support of a
role for ERa, an ERa selective agonist was recently reported to reduce hypertrophy and
improve cardiac contractility in female SHR rats (Pelzer et al, 2004). Interestingly, the
antihypertrophic effects of this drug were not blocked by an ER antagonist. However,
the study did not place too much of an emphasis on this finding as they considered the
cardioprotective effects mediated by the ERa agonist could be attributed to the
concomitant increase in cardiac contractility as concluded from the increase in cardiac
output and expression of a-myosin heavy chain. We have not as yet measured infarct
size in the hearts of mice from each of the oestrogen treatment groups studied and
indeed it will be interesting to determine whether, as expected from the literature,
oestrogen reduced infarct size in our model also.
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In mice, it was suggested that oestrogen acting through ERa in the myocardium,
although it is yet not known whether ERa protein is expressed in mouse myocardium, is
protective against ischaemia reperfusion injury as ERKO mice have fewer viable
myocytes following such an insult than WT controls (Zhai et al, 2000). A more recent
study by Pelzer et al, reported that following MI, female PERKO mice had increased
mortality and biochemical markers of heart failure when compared to WT littermates
(2005). Therefore from these studies it would be interesting to extend our own study
from which we demonstrated that ERp was expressed in the myocardium of infarcted
hearts, to study the effects of oestrogen in our mouse model of MI and the effects of
oestrogen on the expression of ERs under these pathophysiological conditions. Although
we were unable to apply immunohistochemical techniques to determine the expression
of ERa in the mouse heart, using real- time RT-PCR we would hope to study the
expression of both ERa and that of ERp.
In summary, this study suggests that ERG is expressed in the nuclei of cardiomyocytes,
vascular smooth muscle and endothelial cells in both aortic and mesenteric vascular beds
in male and female mice. Expression of ER6 in the cardiovascular system was found to
be unaltered under pathophysiological conditions as was detected in the nuclei of
infarcted hearts and atherosclerotic vessels.
However, we were unable to detect ERa in the mouse cardiovascular system although
the method was suitable for the detection of ERa as demonstrated by the expression of
immunoreactive ERa in the mouse ovary. This suggests therefore, that either ERa is not
expressed in the mouse cardiovascular system or that protein expression is below the
levels able to be detected by immunohistochemistry.
The detection of immunoreactive ERG in GERKO mice despite female GERKO mice
presenting with a similar ovarian phenotype to that described in the original targeting
paper (Krege et al, 1998) suggests that the expression of residual ERG protein does not
function as native WT ERG.
133
Chapter 4
Role of ER(3 in the cardiovascular system of male mice
and the effect of ageing
4.11ntroduction
In the male, oestrogen is produced by local tissue aromatisation of androgenic
precursors from the testes and adrenal glands by the enzyme aromatase. Aromatase is
expressed in the vasculature suggesting that there may be a local paracrine role for
oestrogen in blood vessels (Simpson et al, 2002).
Several clinical observations and animal models report that endogenous oestrogen in
males modulates endothelial function and support a role for endogenous oestrogen in
the male cardiovascular system. Sudhir et al (Sudhir et al, 1997a, Sudhir et al,
1997b) reported that, in a young man, a deletion mutation in the ER gene lead to
oestrogen insensitivity which was manifested in part, by premature coronary artery
disease and endothelial dysfunction. Furthermore, studies in healthy young men, in
which the enzyme aromatase was inhibited, demonstrated a reduction in flow-
mediated dilation (Lew et al, 2003), suggesting that endogenous estrogens are
involved in regulation of endothelial function in healthy males. Complimentary to
this study, an animal model of male mice lacking endogenous oestrogen due to the
lack of functional aromatase, had a reduced response to ACh in aortic rings
supporting the view that in male mice, oestrogen facilitates vasorelaxation (Kimura
et al, 2003).
The generation of ERa (ERKO, Lubahn et al, 1993) and ERB (BERKO, Krege et al,
1998) knock-out mice have provided a useful tool by which to study the receptors
involved in mediating the effect of oestrogen. Studies by Rubanyi et al reported that
aortic rings isolated from male ERKO mice had a significant reduction in response to
the NO synthase inhibitor, L-NAME indicating a reduction in basal release of NO
relative to WT controls (1997). These results suggest that ERa in the vasculature of
the male mouse has a predominant role in modulating endothelial NO production
(Rubanyi et al, 1997).
ERB has also been implicated in mediating the effects of oestrogen in the vasculature
but its role remains to be fully elucidated. Blood vessels isolated from male BERKO
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mice were found to have an enhanced relaxant response to acute administration of
pharmacological concentrations of 1713- oestradiol (Nilsson et al, 2000). Nilsson et al
suggested, therefore, that ERB may modulate vascular relaxation directly or
indirectly by inhibiting the activity of ERa.
The aims of this study were to further characterise the role of ERB in regulating
endothelial and vascular smooth muscle cell function using the 8ERKO mouse
obtained through collaboration with Prof Gustafsson. At the time of planning this
study, Zhu et al (2002) reported that BERKO mice developed hypertension with age.
Therefore, we decided to study vascular function in both young and aged animals
whilst also including studies of cardiac function.
4.2 Methods
4.2.1. Animals
WT and BERKO male mice were maintained, bred and genotyped as outlined in
Section 2.2. To study the effect of both genotype and age, animals were assigned to
one of two age groups for the study. The group of young animals were aged 14-18
weeks, WT (n= 5) and BERKO (n= 5), and the aged group were 52- 54 weeks, WT
(n= 5) and BERKO (n= 6) upon commencing the study.
4.2.2 Analysis of cardiac function
Animals were anaesthetised and cardiac dimensions were measured by
echocardiography as outlined in Section 2.3.2.2., enabling cardiac function to be
assessed between mice lacking functional ERB compared to age- matched WT
controls. In addition, the effect of age on animals of the same genetic background
could also be analysed.
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4.2.3. Millar catheter blood pressure measurement
Blood pressure was measured in unconscious animals over a period of 5min once the
animal had stabilised as outlined in Section 2.3.2.1. An average of MABP, over 5
separate time points, was calculated for each animal.
The mean arterial blood pressure was analysed to determine whether ERB influenced
blood pressure in young and aged mice, by comparing WT and BERKO mice within
these age groups and also whether any influence of ERB on MABP altered with age
by comparing MABP of both genetic backgrounds between age groups.
At the end of in-vivo analysis, tissues were harvested as outlined in Section 2.4.1 to
measure tissue weight and obtain thoracic aorta for functional analysis of the
vasculature.
4.2.4. Assessment of vascular function
Thoracic aorta was removed from each animal following exsanguination, two rings
of endothelium intact aorta was obtained from each animal. Aortic rings were
mounted on separate chambers of the myograph and prepared for functional analysis
as outlined in Section 2.5.1.1 and Section 2.5.2.
4.2.4.1. Response to agonist induced contraction
To determine whether ERB was involved in regulating the contractile function of
vascular smooth muscle cells and whether this altered with age, a cumulative
concentration response curve (CRC) to the ai- adrenoceptor agonist, phenylephrine
(PE, 10"9- 10"6M) was carried out on aortic rings from male WT and BERKO mice.
Once the CRC was complete, PE was washed out and rings were allowed to re-
equilibrate for 15 minutes before continuing with the experimental protocol.
137
4.2.4.2 Endothelium -dependent and -independent vasodilation
To investigate the response to vasodilating agents, both aortic rings were pre-
constricted by a submaximal concentration of PE (~ ECso) obtained from the PE
CRC. In the first of the two rings, to assess endothelium- dependent relaxation and
the stimulated release of nitric oxide from endothelial cells, a CRC to the muscarinic
receptor agonist acetylcholine (ACh, 1CT10- 10"5M) was carried out on aortic rings
from each experimental group. To determine the ability of vascular smooth muscle
cells to respond to NO, a CRC to the nitric oxide donor, sodium nitroprusside (SNP,
10*11- 10"6M) was performed on the second of the 2 aortic rings obtained from each
animal. Once the CRC was complete, ACh or SNP, depending on the ring of aorta,
was washed out and allowed to re- equilibrate for 15mins before continuing with the
protocol.
4.2.4.3 Basal release of NO and constrictor prostanoids
The potentiation of the response to PE in vessels pre- incuba.ed with the nitric oxide
synthase inhibitor L-NAME (10"4M, for 40min), which blocked the synthesis of NO
and subsequently its release, when compared to the response to PE when L-NAME
was not present, was an indication of the levels of basal NO activity in the
vasculature. One of the aortic rings obtained from each animal was incubated with L-
NAME and a concentration of PE that produced 80% of the maximum response to
PE was used to contract the vessel.
The second aortic ring obtained from the same animal was incubated with
indomethacin (10~5M, for 40min) which inhibits the release of prostanoids by
inhibiting the enzyme cyclooxygenase (COX). Preliminary experiments in our lab
demonstrated that in this strain of mouse, which was on a mixed C57B16/SvJ129
background, incubation with indomethacin inhibited the synthesis and release of
constrictor prostanoids from the endothelium. The response to PE (-ECgo) was
therefore decreased by the presence of indomethacin when compared to that
produced in the vessels which had not been incubated with indomethacin. It was the
decrease in the response to PE by indomethacin that provided an indication of the
basal levels of constrictor prostanoids.
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4.3 Results
4.3.1 The effect of age and loss of functional ERR on body and
tissue weight
Body weight in both WT and 6ERKO mice was found to increase with age.
However, there was no significant difference between genotypes, 2-way ANOVA
(genotype x age) p<0.05, Table 4-1. Tissue harvested from both young and aged
male WT and BERKO mice was weighed. There were no significant difference in the
weight of the heart, spleen or liver between genotype, WT and BERKO, of young and
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4.3.2. Role of ERR on blood pressure and the effect of age
MABP was measured in both WT and 8ERKO, young and aged male mice, Figure
4-1. There was no significant difference in mean arterial Mood pressure (MABP)
between age- matched WT and 8ERKO animals in either the young or aged cohort of
animals studied. There was a significant increase in MABP with age in both WT and
BERKO animals, Figure 4-1.
4.3.3 Effect of loss of functional ERR and age on cardiac function
Cardiac dimensions were measured in both WT and BERKO male mice which
subsequently enabled analysis of cardiac function. As shown in Figure 4-2 the
ejection fraction of young BERKO male mice was significantly greater than that of
age-matched WT littermates. However, this difference in ejection fraction was no
longer found to be significant between aged WT and BERKO animals.
Although ejection fraction increased in mice lacking functional ERB when compared
to WT littermates, there was no difference in fractional shortening observed either
with genotype or age, young; WT 0.31+ 0.02, BERKO 0.33± 0.01, aged; WT 0.38±
0.01, BERKO 0.32± 0.04, 2- way ANOVA (genotype x age).
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WT BERKO
Figure 4-1 MABP in both young and aged WT andJJERKO mice
MABP of anaesthetised young (14- 18wks) and aged (52- 54wks)
WT and fiERKO mice measured by carotid cannulation. Data are
expressed as mean± SEM Data was analysed using a 2 way-
ANOVA followed by a Bonferroni post- hoc test, *p<0.05 (n= 5 in
each group exceptfor agedfiERKO, n= 6).
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Figure 4-2 Assessment ofejection fraction in male mice
Ejection fraction measured in both young (14- 18wks) and aged (52-
54wks) WT and J3ERK0 male mice. Data are expressed as mean±
SEM and analysed using a 2-way ANOVA (genotype x age) followed
by a Bonferroni post- hoc test. *p<0.05 (n—5 in each group, except
for aged J3ERKO, n= 6)
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4.3.4 Analysis of vascular function
4.3.4.1 Influence of ERP on agonist induced contraction of vascular
smooth muscle cells.
Cumulative addition of PE to aorta isolated from both young WT and 6ERKO mice
lead to contraction of the vascular smooth muscle, Figure 4-3. The response to PE
was expressed as a percentage of the response to 60mM KCl which was similar
between all groups, young; WT 1.73± 0.13g, PERKO 1.35± 0.2g, aged; WT 1.46±
0.1 lg, pERKO 1.31±0.18g, 2- way ANOVA (genotype x age).
The vasculature of mice lacking functional ERP had increased sensitivity and higher
Emax to PE than their age- matched WT controls Figure 4-3a and Table 4-2. The
response to PE was not different between young and aged WT mice, Table 4-2, in
that neither the EC50 nor Emax were significantly different. Although the sensitivity to
PE in vessels from aged PERKO mice was greater than that of age matched WT




















Figure 4-3 Response to PE in the vasculature of male mice
Cumulative concentration response to PE (10~9- 10'6M) in aortic rings
with intact endothelium isolated from a) young (14- 18wks) WT (B,
n=5) and J3ERKO (n, n= 5) and b) aged (52- 54wks) WT (R, n=5) and
(3ERKO (n, n= 6) . Values expressed as mean± SEM and analysed
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4.3.4.2 Influence of ER(3 on the basal release of NO and constrictor
prostanoids from the vascular endothelium
In young animals, the increased response to PE in the presence of L-NAME was less
in the vasculature of the 8ERKO mouse relative to their age- matched WT controls
Figure 4-4, 2-way ANOVA (genotype x age) followed by a Bonferroni post hoc test.
However, there was no significant difference between aged WT and 8ERKO in the
contractile response to PE in the presence of L-NAME. As there was no difference
within genotype with age, it is difficult to determine whether the levels of basal NO
in WT were reduced with age or that they were increased in the aged BERKO,
Figure 4-4.
In addition to the activation of second messenger pathways in vascular smooth
muscle cells, the contractile response to PE in the mouse vasculature is also
attributed to the release of constrictor prostanoids from the endothelium The
reduction in the response to PE in the presence of indomethacin, an inhibitor of
COX, was indicative of the levels of constrictor prostanoids released from the
vascular endothelium. The response to PE in the presence of indomethacin was
reduced by an equal extent in both WT and BERKO in both age groups studied, 2-






























Figure 4-4 Basal release ofNO in the vasculature of WT and
pERKO mice
Enhancement of the contractile response to PE (~EC80) in the
presence of the NOS inhibitor, L-NAME (10~4 M). Data expressed as
mean± SEM, n=5, except for aged fERKO, n— 6, and analysed
using a 2-way ANOVA *p<0.05
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young aged
Figure 4-5 Basal release of constrictor prostanoids in the
vasculature of WT and J3ERKO mice
Reduced contractile response to PE (~EC80) in the presence of the
COX inhibitor, indomethacin (10~5M). Data expressed as mean±
SEM, n—5, except for aged (4ERKO, n= 6, and analysed using a 2-
way ANOVA
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4.3,4.3 Influence of ERR on endothelium- dependent and -independent
vasodilation
4.3.4.3.1 Influence of ERfl on endothelium- dependent vasodilation
Aortas from both young WT and 8ERKO mice were preconstricted with PE (~ECso)
before constructing a CRC to either ACh or SNP.
Endothelium intact vessels from young 8ERKO mice were less sensitive to
relaxation induced by ACh and there was also a reduction in the maximum relaxation
relative to that of age matched WT controls, Figure 4-6a. Age did not alter the
relaxation response to ACh in WT animals, Table 4-3. In contrast, in the 8ERKO, the
Emax of ACh was slightly greater in aged animals relative to young, Table 4-3.
However, similar to that observed in the young cohort of animals, vessels from mice
lacking functional ER6 were less sensitive to ACh and had a lower maximal
relaxation response relative to age matched WT controls, Figure 4-6b.
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Figure 4-6 Relaxation response to ACh in the male vasculature
Cumulative concentration response to ACh in uortic rings with
intact endothelium isolated from a) young (14- 18wks) WT (M, n=
5) and J3ERKO (n, n= 5) and b) aged (52- 54wks) WT (M, n- 5)
and (3ERKO (n, n= 5) . Values expressed as mean± SEM and
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4.3.4.3.2 Influence of ERR on endothelium -independent vasodilation
The ability of VSMCs to relax in response to NO was assessed by the relaxation
response to the nitric oxide donor drug, SNP, in the mouse vasculature. In young
animals, the response to SNP was not found to be significantly different between
6ERKO mice and age- matched WT controls, Figure 4-7 and Table 4-4. The relaxant
response to SNP was not affected by age in the vasculature of either WT or 8ERKO
mice and nor was there any difference between the vasculature of the 8ERKO mice
and age-matched WT controls, Table 4-4, 2-way ANOVA (genotype x age) followed
by a Bonferroni post- hoc test.
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Figure 4-7 Relaxation response to SNP in the vasculature of
male mice
Cumulative concentration response to SNP in aortic rings with
intact endothelium in vessels, preconstricted with PE (~EC80),
isolated from WT (B, n=5) and /3ERKO (n, n= 5). Values
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4.4 Discussion
The main findings of this study were that in- vitro analysis of vascular function
demonstrated that isolated aorta from BERKO mice had an increased sensitivity to
PE compared to age- matched WT controls. In the presence of L-NAME the increase
in contractile response to PE was less in young 6ERKO mice than that of age-
matched WT controls. This suggests that the basal release of NO from the
endothelium was reduced in animals that did not express ERB. However, in aged
animals there was no difference in the basal release of NO between WT and 8ERKO
mice. Similar to the reduction in basal release of NO in young 6ERKO mice, the
stimulated release of NO, and other EDRFs, by ACh was reduced in 6ERKO animals
relative to WT controls. In contrast however, the difference in the response to ACh
between these groups was also observed in aged animals. Although the basal and
stimulated release of NO was impaired in the 6ERKO mouse, the ability of vascular
smooth muscle cells to relax in response to NO was the same as that of age- matched
WT controls.
Despite the observed vascular phenotype in both young and aged 6ERKO mice and
the contribution of the vasculature to the regulation of blood pressure, there was no
difference in MABP between 8ERKO mice and their age- matched WT controls. In
addition to assessing vascular function and blood pressure in the 8ERKO mouse we
also assessed cardiac function. We found that in the young cohort of animals studied
the loss of functional ER8 was associated with an increase in ejection fraction but not
fractional shortening.
A role for ER8 in the vasculature was demonstrated by our study as the sensitivity
and maximum response to PE was greater in 8ERKO mice than that of their WT
controls. In addition, basal and stimulated release of NO was also reduced in the
8ERKO. Therefore, due to the observed differences in the NO pathway in the
6ERKO mouse relative to WT, it seems that the reduction in NO levels and or
activity might explain the potentiation of the contractile response in the 8ERKO
mouse.
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Chronic oestrogen treatment has been shown to increase basal release of NO in rat
and rabbit aorta and as well as stimulated release of NO in rat vasculature (Paredes-
Carbajal et al, 1995, Hayashi et al, 1992, Wu et al, 2000). The suggested mechanism
by which oestrogen increases NO is by altering the activity of the enzyme which
produces NO, eNOS (Gonzales et al 2001). However, the role of the individual
receptors in regulating vascular tone has only recently begun to be studied through
the use of ERKO and 6ERKO mice and more recently selective ER agonists and
antagonists. The contractile response to PE in the presence of L-NAME was reduced
in aorta from male and female ERKO mice when compared to WT control, which
suggests that the basal release of NO was reduced (Rubanyi et al, 1997) in mice
lacking ERa. A suggested mechanism for ERa activation of NO is that eNOS is
activated following the localisation of ERa to caveloae and activation of the
MAPkinase pathway (Chen et al, 1999, Garcia-Cardena et al, 1998). Further studies
involving ERKO and 6ERKO mice lead the authors to suggest that oestrogen acting
through ERa, but not ER6, increased the basal release of NO (Darblade et al, 2002).
However, there does lie some controversy in the literature as more recent studies
have demonstrated that ER6 also influences the relaxation induced by NO in blood
vessels. Through the recent development of ER specific agonists, Montgomery et al
reported that although the magnitude of relaxation to ERa agonists in rat mesenteric
arteries was greater than that of the ER6 agonist, ERB was still clearly able to induce
relaxation (Montgomery et al, 2003). The mechanisms by which oestrogen may
increase NO through ER8 are poorly understood at the moment. However, ERp,
similar to ERa, was shown to localise to functional signalling domains, caveolae,
where it mediated non- genomic activation of eNOS that was independent of ERa
(Chambliss et al, 2002). In addition, Zhu et al reported that loss of ER6 inhibited the
ability of oestrogen to attenuate constriction in mouse aorta ir> which the endothelium
had been removed (Zhu et al, 2002). The authors suggested that this was due to the
reduction in oestrogen induced iNOS expression in the 6ERKO mouse reported in
this study.
Oestrogen, which because it has a hydroxyl group on its phenolic A- ring, is shown
to possess natural antioxidant effects similar to vitamin E by suppressing free radical
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induced peroxidation chain reactions (Sugioka et al, 1987, Green et al, 1997). These
antioxidant effects are achieved by improving NO/ O2 balance at a genomic level by
inhibiting a subunit of NADPH oxidase, gp91phox, which is an important source of
O2 and thereby reduce the cells capacity to generate O2 (Wagner et al, 2001). More
recent studies have implicated a specific role for ER6 in mediating the antioxidant
effects of oestrogen. Tamir et al reported that the generation of reactive oxygen
species within physiological concentrations was sufficient to increase ER8
expression whilst ERa remained unchanged in several cell types (2002).
Furthermore, Montano et al, demonstrated that ER6 mediated regulation of the
enzymes involved in the generation of glutathione, which detoxifies electrophiles
(Montano et al, 2004). Therefore, it seems possible that the impaired endothelial
function of 6ERKO mice in our study, may also, in part, be due to the loss of the
antioxidant effects of oestrogen via ER6. Therefore, in mice lacking functional ER6,
oxidation and subsequent inactivation of NO would be enhanced.
Preliminary experiments in our lab showed that the vasculature of the mice studied
released predominantly constrictor prostanoids from the endothelium as the
contractile response to PE was significantly reduced in the presence of indomethacin.
There was no difference in the contractile response to PE in the presence of
indomethacin between the experimental groups therefore it is unlikely that the
potentiated PE response was due to an effect mediated by ERp on the
cyclooxygenase pathway. This is despite reports that oestradiol decreases
cerebrovascular tone in rats by shifting the products of the endothelial
cyclooxygenase pathway from constricting prosanoids, such as PGH2 to the
vasodilator prostacyclin, PGI2 (Ospina et al, 2003). Other possible mechanisms for
the enhanced response to PE in the 6ERKO mouse could be due to a direct effect of
ER8 on vascular smooth muscle cells to alter ion flux, expression and or activity of
receptors, or reduce the sensitivity of contractile proteins.
Literature does support a role for oestrogen in regulating ion flux as it was reported
that oestrogen can enhance potassium efflux by binding to the 81 subunit of the
Maxi- K channel (Valverde et al, 1999, Benkusky et al, 2002). Subsequently these
channels become more sensitive to voltage and calcium and enhance potassium
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efflux. Zhu et al reported that the loss of functional ER6 prevented the outward flux
of potassium from BKca channels or Kv potassium (Zhu et al, 2002). Therefore, it is
possible that the enhanced contractile response to PE in our colony of 6ERKO mice,
in addition to a reduction in NO release, can also be explained by the impaired
function of K+ channels such that K+ efflux would be impaired and vascular tone
increased.
Another possibility is that oestrogen acting through ER6 alters adrenoceptor ativity
and/ or expression. Chronic oestrogen treatment reduced ai/6- adrenoceptor- induced
stimulation of melatonin synthesis and release by inhibiting 6- adrenoceptor induced
accumulation of cAMP and ai- adrenoceptor induced phosphoinositide hydrolysis
(Hernandez- Diaz et al, 2001) Therefore, the enhanced contractile response to PE in
the vasculature of animals lacking functional ER8 could be explained by oestrogen
acting through ER6 to inhibit the hydrolysis of phosphoinositide to inositol
triphosphate, thereby attenuating the release of stored calcium and subsequently, the
contraction of vascular smooth muscle cells. Further vascular analysis studying the
contractile response to different contractile agents, such as 5-HT or U46619,
thromboxane analogue, may provide some useful insight into whether the enhanced
contractile response is unique to the modification of contraction induced by aj-
adrenoceptors.
We demonstrated that MABP was not different between WT and 6ERKO mice and
that, as expected MABP increased with age (reviewed in Luscher et al, 1995 and
Marin et al, 1995), which was found to be similar in both groups. This suggests that
either ER8 is not involved in the regulation of blood pressure or that ERa may
compensate for the loss of functional ER6. Several studies have indicated that when
both ERs are present they may have opposite effects on gene transcription but in the
absence of the other, they can partially replace the transcriptional effects (Lindberg et
al, 2003, Weihua et al, 2000). Indeed studies looking at the role of ERs in vascular
injury observed that oestrogen provided a degree of protection in both ERKO and
8ERKO mice suggesting that oestrogen may be able to act through either of the two
ERs to provide the same degree of protection (Iafrati et al 1997, Karas et al, 1999). It
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is possible that in the knock-out, the remaining ER expression and function is
increased to compensate for the loss of the other and therefore the expression of one
ER is sufficient to provide protection. However, ERp was thought to influence blood
pressure as a clinical study of post- menopausal Japanese women reported that a
repeat polymorphism in the ER6 gene was associated with hypertension (Ogawa et
al, 2000). Our finding that there was no difference in MABP between aged WT and
8ERKO animals was in contrast to a recently published study (Zhu et al, 2002)
which reported that although WT and 6ERKO mice both developed an increase in
blood pressure with age, the increase was significantly greater in year old BERKO
mice when compared to age- matched WT mice. Possible explanations for this
discrepancy was firstly, that the 6ERKO mice established in our lab expressed
immunoreactive ERB, refer to Section 3.3.1.3. Therefore the BERKO mouse that we
studied may be a variant of the BERKO mouse generated in the original targeting
paper (Krege et al, 1998) and indeed the BERKO mouse used by Zhu et al, (2002).
Further evidence to support this was from personal communication with J- A
Gustafsson, he reported that the spleen and hearts of aged BERKO mice were grossly
enlarged when compared to age-matched WT controls. However, the spleen from the
strain of BERKO mice established in our lab from those generated by Krege et al,
(1998) did not become enlarged with age when compared to WT littermate controls.
Although we detected an increase in blood pressure in both aged WT and BERKO
mice when compared to young animals there were no differences in heart weight
indicating that the increase in blood pressure had not led to hypertrophy of the heart,
or indeed that there were any differences in heart weight between WT and BERKO
mice. Secondly, the method used for the measurement of blood pressure also
differed. In this study we measured blood pressure acutely in anaesthetised animals,
whereas Zhu et al, implanted radiotelemetry probes and measured blood pressure
over an eight day period. As telemetry blood pressure stuaies allow the animal to
recover from surgery before measurements are taken, therefore the effect of
anaesthetic is removed and without the stress of handling the animal, small changes
in blood pressure are more reliably detected. In the study by Zhu et al, year old
BERKO mice had a significant increase in blood pressure of only lOmmHg relative
to age- matched WT controls. MABP in our study of aged WT and BERKO mice was
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of a similar magnitude, WT; 132.8± 10.3mmHg and 6ERK0; 144.6± 1.8mmHg.
Therefore, it is possible that as we measured blood pressure acutely by carotid
cannulation where blood pressure will be influenced by anaesthesia and surgery to an
extent, that any small differences in blood pressure between BERKO and WT
animals in our study would not reach significance due to the variability within the
group.
As clearly shown in Section 3.5 ERB was expressed in cardiomyocytes of the mouse
heart. Although literature supports a role for oestrogen on the myocardium, the
specific role of ERs has not been elucidated to date. Clinical studies clearly
demonstrate a role for oestrogen on the heart, as they report that healthy women have
higher ejection phase indices than age- matched men. In addition premenopausal
women have a higher pressure- volume ratio, ejection fraction and ejection rates
when compared to post- menopausal women (Buonanno et al, 1982, Pines et al,
1992). Animal studies support the clinical observations in that papillary muscles
from female rats had higher rates of shortening than those of males (Capasso et al,
1983)
From our own studies, it appears that endogenous oestrogen in male mice may
decrease left ventricular systolic function via ERB in young animals as ejection
fraction was higher in 6ERKO animals than age- matched WT controls and that this
effect was lost with age. Interesting, however, was that the ejection fraction had
increased and yet fractional shortening, another indicator of left ventricular systolic
function remained unchanged and therefore it is difficult to conclude that the loss of
functional ER6 in the 8ERKO mouse lead to an increase in systolic function. In
addition, clinical studies have reported that although chronic oestrogen treatment
may lead to a reduction in left ventricular wall mass in hypertensive postmenopausal
women, systolic function, as measured by left ventricular fractional shortening was
not modified (Modena et al, 1999). However, acute infusion of 176- oestradiol in
both male and female rats increased cardiac output and the ejection fraction (Beyer et
al, 2001). It is difficult to extrapolate a mechanism for the effect of oestrogen on the
myocardium as systolic function measured by echocardiography, expressed as
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ejection fraction and fractional shortening are not independent of pre- and after- load.
Young 6ERKO male mice had an increased response to PE and a reduction in the
basal and stimulated release of NO, both of which would contribute to increase
afterload. Therefore, it is more likely that the increased ejection fraction is due to a
direct effect on the myocardium as increased afterload would act to reduce the
ejection fraction.
One possible explanation for the increase in ejection fraction could have been cardiac
hypertrophy with or without cardiac chamber dilatation. However, analysis of heart
weight in our colony of animals clearly showed that there was no difference between
WT and 6ERKO mice suggesting that the hearts from 8ERKO mice were not
hypertrophic. It may also have been of benefit to increase the sample size in each of
our experimental groups due to the limitations of echocardiography as a means to
access systolic function. Mainly because the measurements taken are not necessarily
of the same sample section of the heart between animals and that it assumes that the
heart is cylindrical in shape.
In conclusion it has been shown that ER6 mediates the effects of oestrogen on the
male vasculature as the loss of functional ER8 lead to enhanced contractility and
impaired endothelial function. However, the increase in vascular tone and impaired
endothelial vasodilatation were not implicated in the regulation of MABP, as this
was not different between age-matched WT and 6ERKO mice. Finally, the loss of
functional ER6 increased ejection fraction independently of fractional shortening and
cardiac chamber dilation or hypertrophy.
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Chapter 5
The influence of oestrogen and the effect of the
proprietary, Organon oestrogen receptor B selective
antagonist on blood pressure and vascular function of
the female mouse.
5.1 Introduction
Oestrogen was suggested to have a protective role in the cardiovascular system as
women suffered less from cardiovascular disease during their reproductive life than
age-matched men (Benetos et al, 1999). Furthermore, this apparent protection
gradually declined after the menopause.
One such observation of the beneficial effect of oestrogen in the cardiovascular
system was that it may be involved in the regulation of blood pressure. It was
suggested that oestrogen lowered blood pressure as premenopausal women had a
lower systolic and diastolic blood pressure than postmenopausal women (Stassen et
al, 1989, Seely et al 1999, Cagnacci et al 1999), or women who had undergone
surgical hysterectomy and ovariectomy. In addition young women have lower
systolic blood pressure than age-matched men (Pearson et al 1997, Anastos et al
1991). Following the menopause not only does blood pressure increase in women but
it is also typically higher than that of age-matched men (Pearson et al, 1997). From
such observations, it was thought that HRT may have beneficial effects on blood
pressure. However, clinical studies have been contradictory, Staessen et al (1989)
reported that treatment of postmenopausal women had no effect on blood pressure,
whereas, in contrast, a similar study by Scuteri et al (1999) reported that women
taking HRT had lower blood pressure than those who were not. The PEPI trial, in
which normotensive postmenopausal women were administered HRT with a 3 year
follow up, showed no benefit in comparison to placebo treated women regarding
blood pressure. However, a more recent study by Mohle-Boetani et al which had a
longer follow up period than that of the PEPI trial, almost double, showed that there
was a smaller increase in blood pressure in post-menopausal women on HRT than
those who were not (2001). The main difference between these studies was that the
age group studied were older, suggesting that the effect of the therapy on blood
pressure was intensified with age.
To date the underlying mechanism(s) by which oestrogen may modulate blood
pressure are not yet fully understood. Oestrogen has been reported to influence many
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of the factors that are involved in the regulation of blood pressure such as autonomic
tone and baroreceptor reflex. In the central nervous system, oestrogen was reported
to enhance parasympathetic tone, attenuate sympathetic tone and enhance
baroreceptor reflex activity (Saleh et al 2000, Saleh et al, 1998, 1999 and 2000).
Oestrogen also has effects on the renin angiotensin system, where it has reportedly
reduced circulating levels of renin, angiotensin converting enzyme and
downregulated the expression of the ATi receptor (Harrison- Bernard et al, 2003,
Roesch et al, 2000, Nickenig et al, 1998).
Oestrogen may also influence blood pressure by modulating vascular reactivity and
endothelial function. Chronic oestrogen treatment increased basal release of NO in
rat and rabbit aorta, as well as stimulated release of NO in rat vasculature (Paredes-
Carbajal et al, 1995, Hayashi et al, 1992, Wu et al, 2000). Although the exact
mechanism by which oestrogen increases NO is as yet unclear, a suggested
mechanism was that oestrogen alters the activity of the enzyme, eNOS, which is
involved in the production of NO (Gonzales et al, 2001).
The role of individual ERs in regulating blood pressure ana vascular tone has only
recently begun to be studied through the generation of ERKO and 6ERKO mice.
Studies by Rubanyi et al (1997) suggested a role for ERa in regulating the basal
release of NO. However, neither this study nor others have been designed to assess a
role for ERa in the regulation of blood pressure in mice. In contrast, the
characterisation of ER8 in the cardiovascular system includes studies by Zhu et al
who, using male mice, reported that 8ERKO mice developed hypertension with age
and that the loss of ER6 lead to increased vascular tone (2002). In the previous
chapter, Chapter 4, it was demonstrated that the loss of functional ER6 in male mice
led to enhanced contractility, similar to that reported by Zhu et al, and impaired
endothelial function, as was concluded from the increase in sensitivity to the
contractile agonist, PE. Impaired endothelial function was demonstrated as the basal
release of NO, the stimulated release of NO and other endothelium- derived relaxant
factors were reduced. However, the ability of vascular smooth muscle cells to relax
in response to vasodilators was similar to that of WT mice. In our colony of animals,
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altered vascular function due to loss of ERp was not associated with alterations in
blood pressure in male mice.
In Chapter 3, we demonstrated that ERP was expressed in the mouse cardiovascular
system. However, immunoreactive ERp protein was also detected in the tissues of
PERKO mice. Further investigation of the colony of PERKO mice established in our
lab demonstrated that the ERp protein expressed in our colony was unable to
function as native WT ERp protein. This was concluded from the observation that
female PERKO mice presented with an ovarian phenotype similar to that described
in the original targeting paper (Krege et al, 1998). The recent development of ERP
selective agonists and antagonists has allowed us to employ a different approach to
studying the individual role of ERs as an alternative to ER knock out mice. Due to
the detection of ERp in our colony of pERKO mice we decided to take a more
traditional approach to studying the role of ERp in the female cardiovascular system
and use the Organon ERp selective antagonist.
Therefore, the aim of this study was to determine the effect of oestrogen status and





Female C57B16 mice were purchased from Harlan UK and maintained as outlined in
Section 2.2. To study the effect of oestrogen status and the role of ERp on blood
pressure and vascular function, animals aged 17-19 weeks were assigned to one of
three groups. The age of mice used in this study was selected due to the report by
Zhu et al (2002) that differences in blood pressure between WT and PERKO mice
were detected in male and female mice which were aged between 5- 6 months of age.
In the first group, animals were allowed to continue their oestrous cycle, the stage of
which was determine by vaginal smearing, as outlined in Section 2.3.1.1.2.
Alternatively, animals underwent surgical bilateral ovariectomy and were
supplemented with either oestrogen or placebo releasing pellets as outlined in
Section 2.3.1.1.1. Animals were allowed a minimum recovery period of 7 days by
which point body weight had returned that measured pre-operatively.
Study A
Animals were sacrificed 3 weeks post- surgery (20 -23weeks) and tissues harvested
for in- vitro studies.
5.2.2 Radiotelemetric blood pressure measurement
Study B
Radiotelemetric devices were implanted in animals aged 18- 20 weeks, from each of
the above experimental groups as outlined in Section 2.3.1.2, (sham ovx n= 5, ovx-E
n = 5 and ovx+E n= 4). This enabled blood pressure (systolic, diastolic and mean
pressure), heart rate and activity to be measured in conscious animals.
Following a 7 day recovery period, blood pressure, heart rate and activity were
acquired continuously, rate of sampling was 10s every 15mins, Figure 5.1. To
determine whether oestrogen influenced blood pressure, heart rate and activity, data
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was acquired for animals in each of the groups; normally cycling females and those
which had undergone ovx and administered placebo or supplemented with oestrogen.
To determine the role of ERp in mediating the effects of oestrogen on the parameters
measured, the said ERp selective antagonist (lmgkg -1, s.c.) was administered as
instructed by Organon. A one hour window was scheduled between 10:30 and 11:30
to allow daily administration of the ERP selective antagonist and to check the health
status of each animal. As the vehicle for the ERP selective antagonist was saline
(Dulbecco's phosphate buffered saline, filter sterilised, Sigma- Aldrich, UK) vehicle
controls were administered (~0.08ml, s.c.) for 3 consecutive days leading up to
administration of ERp selective antagonist. Upon completion of the vehicle controls,
animals were treated with ERp selective antagonist for 7 days prior to being
euthanised and harvesting of tissues for in- vitro purposes, Figure 5.1.
At the onset of study B the appropriate vehicle control was unknown and therefore
not every animal in each group was able to be administered vehicle. Once we were
informed of the vehicle for ERP selective antagonist without first doing a vehicle
control. However, in those animals which had been administered vehicle, we found
that the vehicle had an effect on blood pressure and therefore we had to compare
ERp selective antagonist within each oestrogen status group to that of the vehicle
control. This meant that animals had to be excluded from each of these groups which
had not received vehicle control. This reduced the number of animals in the
experimental groups from 5 to 3 for those female mice which were normally cycling
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5.2.3 Assessment of vascular function
Mesenteric arteries were harvested from animals from both Study A and Study B.
Therefore, the purpose and groups for the vascular study were; Study A: to assess the
effect of oestrogen status on vascular function; normally cycling; n= 8, Ovx treated
with placebo; n= 6 and Ovx supplemented with oestrogen; n= 7 and Study B: to
determine the role of ERB in mediating the effects of oestrogen on vascular function;
normally cycling; n= 8, normally cycling + ERp selective antagonist; n= 7, Ovx
treated with placebo; n= 6, ovx treated with placebo + ERP selective antagonist; n=
6, Ovx and supplemented with oestrogen; n= 7 and Ovx supplemented with
oestrogen + ERp selective antagonist; n= 7.
Two rings of first order mesenteric arteries were obtained from the mesenteric
vascular bed which was removed from each animal following exsanguination,
mounted on the myograph and prepared for functional analysis as outlined in Section
2.5.
All of the vascular studies for this chapter were performed by Dr Pascual Medina.
5.2.3.1 Response to agonist induced contraction
Once the vessels were mounted and had undergone an equilibration period, the
standard start protocol was carried out. The aim of the standard start protocol was not
only to sensitise vessels to agonists but also to test the integrity of the vessel prior to
the experimental protocol. Exclusion parameters were established such that vessels
were only accepted for the study that had a contractile response to KC1 greater than
500mg. In addition, to confirm the presence of endothelium, a relaxation response to
ACh greater than 70% had to be obtained. Whilst establishing the technique in our
lab, certain vessels obtained from mice in Study A and Study B did not meet the
exclusion criteria of the protocol and therefore were not included in the analysis.
To determine whether oestrogen status was involved in regulating the contractile
function of vascular smooth muscle cells, and the role of ERB in mediating these
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effects, cumulative concentration response curves (CRC) to the ai-adrenoceptor
agonist, phenylephrine (PE, 10~9- 10"6M) was carried out on endothelium intact rings
of first order mesenteric artery. Once the CRC was complete, PE was washed out and
rings were allowed to re-equilibrate for 15 minutes before continuing with the
experimental protocol.
5.2.3.2 Endothelium -dependent and -independent vasodilation
To investigate the response to vasodilating agents, the mesenteric artery, was pre-
constricted by a submaximal concentration of PE (~ECgo). To assess endothelium-
dependent relaxation and the stimulated release of nitric oxide from endothelial cells,
a CRC to the cholinoceptor agonist acetylcholine (ACh, 10"'°- 10"5M) was carried
out on one of the two mesenteric rings obtained from each animal within each
experimental group. To determine the ability of vascular smooth muscle cells to
respond to NO, a CRC to the nitric oxide donor, sodium nitroprusside (SNP, 10"-
10"6M) was performed on the second of the 2 rings obtained from each animal. Once
the CRC was complete, ACh or SNP, depending on the ring of mesenteric artery,
was washed out and allowed to re- equilibrate for 15mins before continuing with the
protocol.
5.2.3.3 Basal release of NO and prostanoids
One of the rings of mesenteric artery obtained from each animal was then incubated
with the nitric oxide synthase inhibitor L-NAME (10"4M, for 40min) which blocks
the synthesis of NO. A CRC to PE was then constructed and the increased contractile
response to PE, as compared to the CRC to PE in the absence of L-NAME, due to
the block of NO synthesis by L-NAME was an indication of the basal level of NO
activity.
The second ring of mesenteric artery obtained from the same animal as above, was
incubated with indomethacin (1CT5M, for 40min) which inhibits the production of
vasoactive prostanoids pathway by inhibiting the enzyme cyclooxygenase (COX).
The CRC to PE was now constructed in the presence of indomethacin and the
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response compared to that produced to PE in the absence of indomethacin. A
variation in the extent of the decrease in the contractile response to PE by




5.3.1.The effect of oestrogen status and the ERR selective
antagonist on body and tissue weight.
Study A
The body weights of mice which had undergone sham ovx, and were normally
cycling, or bilateral ovx with subsequent administration of placebo or oestrogen
supplementation, were not found to be significantly different, Table 5.1. Tissues
harvested from these animals were weighed and corrected for body weight. Female
mice which had been supplemented with oestrogen following ovx had a significant
increase in uterine weight when compared to both sham ovx and ovx mice
administered placebo. Uterine weight of animals administered placebo was lower
than that of normally cycling female mice, Table 5.1. As one of the parameters that
the study was designed to assess was the effect of oestrogen on blood pressure, we
also measured heart weight, in the event that any changes in blood pressure would
have lead to hypertrophy of the heart. We found, however, that there was no
difference in heart weight.
Study B
The body weight of animals which had been administered the ERP antagonist was
not found to be different to those animals which had not, nor was there any
difference between animals of different oestrogen status receiving the ER|3
antagonist, Table 5.1. Similar to that observed in animals which had not received the
ERP antagonist, placebo treated ovx animals which had received the ERP antagonist,
had a reduction in uterine weight compared to normally cycling female mice and
those which had undergone ovx and supplemented with oestrogen. Similar to the
increase in uterine weight observed in Study A between normally cycling females and
those supplemented with oestrogen, in Study B, ovx mice supplemented with
oestrogen and administered the ERP antagonist had a higher uterine weight than
normally cycling females administered the ERP antagonist, Table 5.1. Treatment
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with the ERP antagonist did not affect uterine weight between animals of the same
oestrogen status which had not received the ERP antagonist. Once again we found
that there was no significant difference in heart weight with oestrogen status in
animals treated with or without the ERP antagonist, or indeed between animals of the
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5.3.2. Regulation of blood pressure and haemodynamic
parameters.
5.3.2.1. Influence of oestrogen on blood pressure, heart rate and
activity
Study B
MABP was acquired by radiotelemetry in female mice of different oestrogen status;
normally cycling, ovx administered placebo or ovx supplemented with oestrogen,
Figure 5.1. MABP, over the course of the final 24hrs of the study period, was found
to be significantly greater in mice ovx and supplemented with oestrogen than sham
ovx female mice. MABP of those mice which had undergone ovx and received
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Figure 5.2 Mean arterial blood pressure acquired in female mice of
different oestrogen status.
Mean arterial bloodpressure (MABP) in sham ovariectomised ( ,n= 5)
or ovariectomised with either a) oestrogen (n= 4) or b) placebo (n= 5)
supplementation (—). Data are expressed as the mean of data acquired
every 15mins over the final 24hrs of each treatment group. Values are
mean± SEM and analysed using a 2- way ANOVA (time x oestrogen




Circadian variations in heart rate (HR), SBP, DBP, MABP and activity were determined
by constructing 12hr rolling averages for animals in each of the oestrogen treatment
groups studied. The 12hr periods were related to the 12hr light and dark cycles in the
animal unit. The light period, termed "day" was from 0700 to 1900 and the dark cycle
"night" from 1900 to 0700.
Heart rate
There was no significant difference in HR between sham ovx, ovx mice treated with
placebo or oestrogen during either day or night, Table 5.2. However, HR was shown to
increase in each of the three oestrogen treatments groups at night during which time the
animals were also shown to be most active.
Blood pressure
SBP, DBP and MABP increased at night in each of the three oestrogen treatment groups.
However, differences in blood pressure between mice of different oestrogen status
during both day and night were also observed, Table 5.2.
MABP of placebo treated ovx animals was found to be lower than that of normally
cycling female mice, Figure 5.2. Further analysis of blood pressure between these two
groups demonstrated that MABP of placebo treated animals was less than that of sham
ovx animals during the day but that there was no difference between these two groups at
night, Table 5.2. As DBP was not found to be different between sham ovx and placebo
treated mice the lower MABP in placebo treated mice may be associated with the
reduction observed in SBP in this group. During the day, when MABP was lower than
sham ovx, SBP was found to be reduced in placebo treated animals when compared to
sham ovx mice, Table 5.2.
From Figure 5.2, it was observed that chronic oestrogen treatment of ovx female mice
lead to an increase in MABP when compared to normally cycling female mice. MABP
178
was found to be greater than placebo treated animals during the day and both sham ovx
and placebo treated animals at night, Table 5.2. This was not reflected in SBP during the
time periods studied and therefore, the increase in MABP may be attributed to the
differences in DBP following chronic oestrogen treatment, Table 5.2. DBP of ovx mice
which received oestrogen was shown to be greater than that of sham ovx and placebo
treated ovx mice during both day and night periods, Table 5.2.
Activity
The activity of mice in each of the three oestrogen groups studied was shown to increase
at night when compared to the levels of activity during the day which is the animals
natural inactive period, Table 5.2. However, oestrogen status appeared to affect the level
of activity during both the inactive and active periods. Although the levels of activity
were much less during the day than at night for each of the groups of mice, mice which
had undergone ovx and administered either oestrogen or placebo were found to be less
active than that of sham ovx animals. This reduction in activity in the oestrogen and








HR (bpm) 574.1± 557.4+ 564.8± 628.0± 600.11 603.51
6.7 5.1 10.2 5.9* 5.2* 9.8*
SBP 118.7+ 112.6+ 116.6+ 132.8+ 129.21 131.51
(mmHg) 0.9 0.9$ 1.7 0.9* 0.9* 1.6*
DBP 90.0± 87.0± 96.3+ 101.41 101.51 107.91
(mmHg) 1.0 0.8 1.3$Y 0.9* 0.8* 1.6*$Y
MABP 99.6+ 95.5± 102.4+ 111.81 110.71 115.81
(mmHg) 0.9 O 00 ■eo 1.5Y 0.8* 0.7* 1.6*$y
Activity 8.8± 4.0± 4.6+ 23.21 15.1+ 12.91
0.9 0.4$ 0.5$ 1.5* 0.9*$ 1.4*$
Table 5.2 Comparison ofhaemodynamic parameters and activity during
day and night in female mice ofdifferent oestrogen status
Following radiotelemetry implantation, heart rate (FIR), systolic (SBP),
diastolic blood pressure (DBP), mean arterial blood pressure (MABP)
and activity from the final 24hrs of each study period in female mice
which had undergone sham ovariectomy (n=5), ovariectomy
administered placebo (n=5) or supplemented with oestrogen (n—4) were
analysed. Data were expressed as 12hr rolling averages from 0700 to
1900, for day measurements, and 1900 to 0700, for night measurements.
Values were expressed as mean± SEM and analysed using a 2-way
ANOVA (oestrogen status x time) followed by a Bonferroni post- hoc test.
*p<0.05 relative to day measurements of animals of the same oestrogen
status, $p<0.05 relative to sham ovx mice at the same time point and
rp<0.05 relative to ovx mice administered placebo 'within the same time
point.
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5.3.2.2. Influence of ERp on the effects of oestrogen on blood pressure
Study B
To determine the influence of ER6 on the observed effects of oestrogen on MABP, we
analysed MABP following the administration of the ERp selective antagonist (lmgkg1)
over a 7 day period. The ERp selective antagonist, was found to increase MABP
recorded in normally cycling female mice relative to vehicle control during the final
24hr period of the last day of treatment, Figure 5.3. In contrast the ERp selective
antagonist, reduced MABP from vehicle in mice which had undergone ovx and been
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Figure 5.3 MABP in female mice following administration of the
ERfiselective antagonist (lmgkg'1).
Mean arterial blood pressure (MABP) recorded in female mice in the
final 24hr period following 7day administration of the ERfJ
antagonist. Female mice which were either a) sham ovariectomised
or b) ovariectomised and supplemented with oestrogen, were
administered vehicle (—) prior to treatment with the ERf antagonist
(—). Data are expressed as the mean ofdata acquired every 15mins
over the final 24hrs ofeach treatment period. Values are mean± SEM
and analysed using a 2- way ANOVA (time x ERfi antagonist)
*p<0.05 when compared to vehicle control gro^p (n=3 in each
group).
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5.3.2.2.1. Influence of ERJ3 on haemodynamic parameters In normally cycling
female mice
Circadian variations in HR, SBP, DBP, MABP and activity, such that all of these
parameters increased at night, were observed in normally cycling female mice whether
during the administration period of vehicle or the ERp antagonist in each animal.
Heart rate
Although HR increased at night compared with that measured during the day, HR in mice
administered the ERp antagonist was less than that during the vehicle treatment period of
the same animals during both night and day, Table 5.3.
Blood pressure
SBP, DBP and MABP increased at night in normally cycling female mice during the
periods of administration of vehicle or the ERp antagonist, Table 5.3.
Administration of the ERP antagonist to normally cycling female mice resulted in an
increase in MABP when compared to vehicle control, Figure 5.3. The increase in MABP
was shown to be elevated by the ERp antagonist during both day and night relative to
vehicle controls, Table 5.3. The increase in MABP during these periods may be attributed
to the concurrent increase in DBP by ERp antagonist but not to an effect on SBP as this
was found to be unaffected by treatment with the antagonist in normally cycling female
mice, Table 5.3.
Activity
The activity of normally cycling female mice was shown to increase at night when
compared to the levels of activity during the day which is the animal's natural inactive
period, Table 5.3. The level of activity in these mice was shown not to differ between the
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5.3.2.2.2. Influence of ER/3 on haemodynamic parameters in ovx female mice
treated with oestrogen
In contrast to the presence of circadian variations in ovx female mice treated with oestrogen,
Table 5.2, during the period of vehicle and following that the administration of the ERp
antagonist, these animals showed no diurnal variation in HR, SBP, DBP or MABP Table 5.4.
Heart rate
HR was not different between day and night in female mice treated with oestrogen during the
period of either vehicle or that of administration of the ERp antagonist, Table 5.4.
Blood pressure
MABP, SBP and DBP were not different between day or night in female mice treated with
oestrogen during the periods of administration of vehicle or the ERP antagonist antagonist, Table
5.4.
Administration of the ERp antagonist to oestrogen treated female mice resulted in a decrease in
MABP when compared to vehicle control, Figure 5.3b. MABP was shown to be decreased by
the antagonist during the night relative to the administration period of the vehicle control, Table
5.4. The decrease in MABP during this period may be attributed to the concurrent decrease in
DBP by the ERp antagonist but not to an effect on SBP as this was found to be unaffected by
treatment with the antagonist in female mice treated with oestrogen, Table 5.4.
Activity
The activity of oestrogen treated female mice during the period of vehicle control administration
was shown to increase at night when compared to the levels of activity during the day, Table 5.4.
However, this pattern was not observed in the same animals during the period of administration
of ERp antagonist, as there was no difference in activity between night and day during this
period, Table 5.4. This may be due to the increase in day time activity of mice treated with the
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5.3.3 Analysis of vascular function




Cumulative addition of PE to first order mesenteric arteries from sham ovx, ovx
supplemented with oestrogen and ovx treated with placebo female mice, led to
contraction of the vascular smooth muscle, Figure 5.4. The response to 125mM KCl was
similar between all groups (Sham ovx; 0.69± 0.05g, Ovx - E; 0.68± 0.08g, Ovx + E;
0.8±3 0.03g, 2- way ANOVA, (ER(3 antagonist x oestrogen status) followed by a
Bonferroni post- hoc test. Therefore the response to PE was expressed as a percentage of
125mM KCl. From Figure 5.4a, oestrogen supplemented female mice have an increased
sensitivity to PE when compared to sham ovx mice as indicated by the leftward shift of
the concentration response curve in oestrogen treated mice, Table 5.5. There was no
difference in the contractile response to PE between sham ovx mice and those that were














Figure 5.4 Response to PE in the vasculature offemale mice
Cumulative concentration responses to PE in first order
mesenteric artery rings with intact endothelium isolated from
female, a) sham ovx (U) and ovx supplemented with oestrogen (n)
and b) sham ovx and ovx mice treated with placebo (Values
expressed as mean± SEM and analysed using a 2- way ANOVA













































Table5.5ContractileresponsestPEiheva culaturffem i TheEC50andmaxwerecalculat dfot ontractileeffectfPEi bs npres cith r L-NAME(10~4M)orindomethacin5ns lated,endot eliumt ctfirstrd re ent r cv s ls.Ves wereisolatedfr memalicth tshamvxhadundergonendsupplem nt dthoestrogen. Datareexpressedmean±SEMndanaly edusing2-w yANOVA(oestrogst tusERJ3t onist), followedbyaBonferronipost-h cte t.<0.05*whencompareshamvx,swhqui le t oestrogenstatusinStudyA.
L-NAME
Cumulative addition of PE in the presence of L-NAME (10"4M) to first order
mesenteric arteries from sham ovx, ovx supplemented with oestrogen and ovx treated
with placebo female mice did not alter the contractile response to PE suggesting that
in the vascular bed studied, NO is not the main mediator of basal tone. The increased
sensitivity to PE and the similarity in the shape of the curve to PE between vessels
from mice supplemented with oestrogen compared to sham ovx mice was still
observed, Figure 5.5a and Table 5.5. This suggests that the increased sensitivity to
PE in mice that were supplemented with oestrogen was not due to changes in NO
availability.
The contractile response to PE in the presence of L-NAME was not shown to be





Figure 5.5 Response to PE in the presence ofL-NAME in the vasculature
offemale mice
Cumulative concentration responses to PE in the presence of
L-NAME (10~4M), in first order mesenteric artery rings with intact
endothelium. Vessels were isolatedfrom female, a) sham ovx (M) and ovx
supplemented with oestrogen (n) and b) sham ovx and ovx mice treated
with placebo (0). Values expressed as mean± SEM and analysed using a
2- way ANOVA followed by a Bonferronipost hoc test, *p<0.05
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Indomethacin
Cumulative addition of PE in the presence of indomethacin (10"5M) did not alter the
contractile response to PE in first order mesenteric vessels from sham ovx, Figure
5.6a, or ovx mice which were administered placebo. However, vessels from ovx
mice supplemented with oestrogen incubated with indomethacin resulted in a
leftward shift of the PE CRC, Figure 5.6b. Although the EC50 and the Emax for the
response to PE in the presence of indomethacin were not different to that of PE
alone, Table 5.5, Figure 5.6b suggests that chronic oestrogen treatment increased the
release of vasodilatory prostanoids.
The increased sensitivity to PE in ovx mice supplemented with oestrogen when
compared to sham ovx mice, Figure 5.4a, remained in the presence of indomethacin,
Figure 5.7a. Although indomethacin resulted in a slight leftward shift of the
contractile response to PE in ovx mice supplemented with oestrogen, Figure 5*6b, it
was not found to further enhance the difference in contractile response between sham
and oestrogen supplemented mice (dose ratio: sham ovx; 1.93± 0.41, ovx + E; 0.9±
0.25, unpaired t-test). This suggests that despite an increase in vasodilatory
prostanoids from the endothelium, chronic oestrogen supplementation still resulted in
increased contraction to PE.
There was no significant difference in the contractile response to PE in the presence





Figure 5.6 Response to PE in the presence of Indomethacin in the
vasculature offemale mice
Cumulative concentration responses to PE in the presence of
indomethacin (10~5M) in first order mesenteric artery rings with intact
endothelium. Vessels were isolatedfrom female a)sham ovx and b) ovx
mice supplemented with oestrogen. Values expressed as mean± SEM





Figure 5.7 Response to PE in the presence of Indomethacin in the
vasculature offemale mice
Cumulative concentration responses to PE in the presence of
indomethacin (10~5M) in first order mesenteric artery rings with intact
endothelium. Vessels were isolatedfrom female a)sham ovx (M) and ovx
supplemented with oestrogen (n) and b) sham ovx and ovx mice treated
with placebo (0). Values expressed as mean± SEM and analysed using
a 2- way ANOVA followed by a Bonferronipost hoc test, *p<0.05
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ACh and SNP
To assess endothelium- dependent and -independent relaxation in vessels from sham ovx
and mice ovx and supplemented with oestrogen, mesenteric arteries were preconstricted
with PE (~ECgo) prior to constructing a CRC to ACh in one of the rings and SNP in the
second of the rings obtained from the animal. The response to PE, to preconstrict the
vessels, was similar between each of the groups (sham ovx; 0.63± O.lg, ovx treated with
placebo; 0.78± 0.02g and ovx supplemented with oestrogen; 0.65± 0.08g, 2-way
ANOVA, (ERp antagonist x oestrogen status)) and therefore relaxation was expressed as
a percentage of the contraction produced in response to PE. Mesenteric arteries from ovx
mice supplemented with oestrogen had a decreased sensitivity to ACh, Figure 5.8a and
SNP, Figure 5.8b when compared to the relaxation response of vessels from sham ovx
mice. The relaxation response to ACh and SNP was not different between sham ovx and
ovx mice administered placebo, Figure 5.9a and Figure 5.9b.
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Figure 5.8 Response to ACh and SNP in the vasculature offemale
mice
Cumulative concentration response to a) ACh and b) SNP in first
order mesenteric artery rings with intact endothelium in vessels,
preconstricted with PE (~EC80), isolated from sham ovx (M) and ovx
+ oestrogen supplementation (n). Values expressed as mean± SEM
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Figure 5.9 Response to ACh and SNP in the vasculature offemale
mice
Cumulative concentration response to a) ACh and b) SNP in first
order mesenteric artery rings with intact endothelium in vessels,
preconstricted with PE (~EC80), isolatedfrom sham ovx (0) and sham
ovx and ovx mice treated with placebo (0). Values expressed as
mean± SEM and analysed using a 2- way ANOVA.
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5.3.3.2 Influence of ERR in mediating the effects of oestrogen on the
female mouse vasculature
The influence of ERB in mediating the effects of oestrogen on the female mouse
vasculature, was determined by studying vessels from animals treated with the ERP
selective antagonist for a period of 7 days, Study B. Vessels were harvested from
female mice that were normally cycling or ovx and supplemented with either
oestrogen or placebo. Data was compared with the vessels used in Study A that did
not receive the ERB antagonist.
5.3.3.2.1 Normally cycling female mice
PECRC
The contractile response to PE in first order mesenteric arteries from sham ovx
female mice following treatment with the ERp antagonist was not found to be
different when compared to sham ovx mice which had not been treated with the
antagonist, Figure 5.10 and Table 5.5.
PE CRC + L-NAME
The contractile response to PE in vessels incubated with L-NAME was not different
between vessels from sham ovx mice treated with the ERp antagonist and those
which were not, Figure 5.11a, and Table 5.5. This indicates that treatment of mice
with the ERp antagonist, did not alter NO bioavailability in mice whose oestrogen
levels were normally cycling.
PE CRC + Indomethacin
The contractile response to PE in the presence of indomethacin was not different
between sham ovx mice that had been treated with the ERp antagonist and those
which were not Figure 5.11b and Table 5.5. This suggests that the antagonist did not
alter the release of prostanoids in normally cycling female mice.
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Figure 5.10 Response to PE in the presence of the ERp selective
antagonist in sham ovxfemale mice
Cumulative concentration response to PE in first order mesenteric
artery rings with intact endothelium isolated from sham ovx (M) and
sham ovx + ERfi selective antagonist (EJ). Values expressed as mean±
SEMand analysed using a 2- way ANOVA (cone x ERp antagonist).
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Figure 5.11 Response to PE in the presence of L-NAME and
Indomethacin in the vasculature of female mice treated with ER/3
antagonist
Cumulative concentration responses to PE in the presence of a) L-NAME
(10~4M) and b) Indomethacin (10~5M) in first order mesenteric artery rings
with intact endothelium. Vessels were isolated from female, sham ovx (M)
and female sham ovx + ERJ3 antagonist (f~J. Values expressed as mean±
SEM and analysed using a 2- way ANOVA (concentration x ER/3
antagonist)
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Endothelial -dependent and -independent relaxation
The sensitivity to endothelium dependent relaxation in response to ACh in
mesenteric arteries preconstricted with PE (ECgo) significantly increased in vessels
from sham ovx animals treated with the ERp antagonist when compared to vessels
from sham ovx, Figure 5.12a. However, treatment with the antagonist did not alter
the ability of vascular smooth muscle cells to relax as the relaxation response to the
endothelium independent vasodilator SNP was not found to be different to that of
sham ovx animals, Figure 5.12b.
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Figure 5.12 Response to ACh and SNP in the vasculature ofnormally
cyclingfemale mice treated with the ERJ3selective antagonist
Cumulative concentration response to a) ACh and b) SNP in first order
mesenteric artery rings with intact endothelium in vessels, preconstricted
with PE (~EC80), isolatedfrom sham ovx (M) and sham ovx treated with the
ERfselective antagonist ([J). Values expressed as mean ± SEMand analysed
using a 2-way ANOVA (concentration x ERJ3 antagonist) followed by a
Bonferronipost hoc-test *p<0.05
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5.3.3.2.2 Ovariectomised female mice supplemented with oestrogen
PE CRC
The CRC to PE in mesenteric arteries from female mice that were ovariectomised
and supplemented with oestrogen, was shifted to the right in animals treated with the
ER(3 antagonist when compared to those which were not, Figure 5.13a and Table
5.5. This suggests that, in animals supplemented with oestrogen, the ER(3 antagonist
inhibits the effect of oestrogen on enhancing vessel sensitivity to PE.
PE CRC in the presence of L-NAME
The contractile response to PE in the presence of L-NAME was shifted to the right in
vessels obtained from mice that had been treated with the ER(3 antagonist, Figure
5.13b and Table 5.5. The sensitivity of vessels from mice supplemented with
oestrogen to PE in both the absence and in the presence of L-NAME was reduced in
vessels obtained from animals which had been treated with the ER(3 antagonist.
Therefore, this suggests that the inhibitory effect of the ERp antagonist on the
increased sensitivity to PE as a result of chronic oestrogen treatment cannot be
attributed to differences in the bioavailability of basal NO.
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Figure 5.13 Response to PE in the absence and presence ofL-NAME in
the vasculature of ovariectomised female mice supplemented with
oestrogen and treated with the ER/3 selective anatgonist
Cumulative concentration responses to PE in a) the absence and b) the
presence of L-NAME (10~4M) in mesenteric artery rings with intact
endothelium. Vessels were isolatedfrom female mice which had undergone
ovx and supplemented with oestrogen (n) and those which were also
treated with the ER/3 selective anatgonist (A,). Values expressed as mean±
SEM and analysed using a 2- way ANOVA followed by a Bonferroni post
hoc test, *p<0.05 (concentration x ERJ3 antagonist).
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PE CRC in the presence of Indomethacin
Vessels obtained from mice which had received chronic oestrogen supplementation
caused a slight shift to the left of the PE CRC in the presence of indomethacin, Figure
5.6. In contrast, in vessels from mice supplemented with oestrogen which had been
treated with the ER(3 selective antagonist, the contractile response to PE was unaltered by
indomethacin, Figure 5.14a. Therefore, this suggests that the ER(3 antagonist blocks the
release of vasodilating prostanoids from the endothelium induced by chronic oestrogen
supplementation.
In the presence of indomethacin, the ERp antagonist reduced the sensitivity to PE in mice
supplemented with oestrogen when compared to vessels from mice which were not
treated with the antagonist, Figure 5.14b. However, the dose ratio to PE was found to be
greater in the presence of indomethacin of oestrogen supplemented mice treated with the
antagonist when compared to those which were not (dose ratio: ovx + E; 0.9± 0.25, Ovx
+ E + ERp antagonist; 1.37± 0.23, unpaired t- test).
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Figure 5.14 Response to PE in the presence ofIndomethacin in the
vasculature of ovariectomised female mice supplemented with oestrogen
and treated with the ERfselective antagonist
Cumulative concentration responses to PE in first order mesenteric artery
rings with intact endothelium obtainedfrom ovx female mice supplemented
with oestrogen. Vessels were isolated from a) mice treated with the ER/3
selective antagonist and response to PE in the absence (k) orpresence (p) of
indomethacin and b) response to PE in the presence of indomethacin in
vessels from mice treated with vehicle (n) or the ER{3 selective antagonist
(p). Values were expressed as mean SEM and analysed using a 2- way
ANOVA followed by a Bonferroni post hoc test, * p<0.05 (concentration x
ER(3 antagonist).
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Endothelium -dependent and -independent vasorelaxation
The endothelium -dependent and -independent relaxation to ACh and SNP
respectively was different between ovariectomised mice supplemented with
oestrogen and those which had also received the ERfl selective antagonist, Figure
5.15. Treatment with the ERp antagonist, increased the sensitivity of vessels from
female mice which were supplemented with oestrogen to the endothelial dependent
relaxation response to ACh as indicated by a leftward shift of the concentration
response curve, Figure 5.15a. The increase in sensitivity to the NO donor drug, SNP
following treatment with the ERp selective antagonist implies that the antagonist, in
mice supplemented with oestrogen enhances vascular smooth muscle cell relaxation,
Figure 5.15b. This suggests that the increase vasorelaxation produced in vessels
from mice supplemented with oestrogen and treated with the ERP antagonist is due
to enhanced sensitivity of vascular smooth muscle cells to NO.
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Figure 5.15 Relaxation response to ACh and SNP in the vasculature of
ovariectomised female mice supplemented with oestrogen and treated
with the ERfrselective antagonist
Cumulative concentration response to a) ACh and b) SNP in first order
mesenteric artery rings with intact endothelium in vessels preconstricted
with PE (~EC80), isolated from ovx female mice supplemented with
oestrogen (n) and those which were treated with the ER(3 selective
antagonist (A). Values are expressed as mean± SEM and analysed using
a 2- way ANOVA (concentration x ERfd antagonist), followed by a
Bonferronipost hoc test *p<0.05.
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5.3.3.2.3 Ovariectomised female mice treated with placebo
PECRC
The contractile response to PE in first order mesenteric arteries from sham ovx
female mice following treatment with the ER(3 selective antagonist was not found to
be different when compared to ovx mice administered placebo which had not been
treated with the ERp antagonist, Figure 5.16.
PE CRC + L-NAME
The contractile response to PE in the presence of L-NAME was not different
between mice which had undergone ovx, administered placebo and treated with the
ERp antagonist and those which were not Figure 5.17a. This indicates that treatment
with the antagonist did not alter NO bioavailability in ovariectomised mice which
had been treated with placebo
PE CRC + Indomethacin
The contractile response to PE in the presence of indomethacin was not different
between mice which had undergone ovx and treated with placebo and treated with
the ERp antagonist and those which were not Figure 5.17b. This suggests that the
antagonist did not alter the release of prostanoids in ovx female mice treated with
placebo.
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Figure 5.16 Response to PE in the presence of the ER/3 selective
antagonist in Ovxfemale mice treated with placebo
Cumulative concentration response to PE in first order mesenteric
artery rings with intact endothelium isolatedfrom ovx mice treated with
placebo (0) and ovx treated with placebo and administered the ERJ3
selective antagonist (O). Values expressed as mean± SEM and analysed
using a 2- way ANOVA (cone x ERJ3antagonist)
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Figure 5.17 Response to PE in the presence of L-NAME and
Indomethacin in the vasculature of ovariectomised female mice
administeredplacebo and treated with the ER(5selective antagonist
Cumulative concentration responses to PE in the presence ofa) L-NAME
(10~4M) and b) Indomethacin (10~5M), in first order mesenteric artery rings
with intact endothelium. Vessels were isolated from female, ovx and
treated with placebo (0) and ovx treated with placebo + ER/3 antagonist
(O). Values expressed as mean± SEM and analysed using a 2- way ANOVA
(concentration x ER/3 antagonist)
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Endothelial -dependent and -independent relaxation
The sensitivity to endothelium dependent relaxation produced to ACh in mesenteric
arteries preconstricted with PE (EC8o) was not different between vessels from ovx
animals administered placebo and treated with the ERp selective antagonist when
compared to vessels from those which were not, Figure 5.18a. In addition, treatment
with the antagonist did not alter the relaxant ability of vascular smooth muscle cells
as the relaxation response to the endothelium independent vasodilator SNP was not
found to be different to that of placebo treated mice, Figure 5.18b.
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Figure 5.18 Response to ACh and SNP in the vasculature of female
ovariectomised mice administered placebo and treated with the ERJ3
selective antagonist
Cumulative concentration response to a) ACh and b) SNP in first order
mesenteric artery rings with intact endothelium in vessels, preconstricted
with PE (~EC80), isolatedfrom ovx female mice treated with placebo (0)
and those treated with the selective ERj3 antagonist (O). Values expressed




The novelty of this study was, that for the first time an ERG selective antagonist, a
proprietary Organon compound, was used as an alternative method to that of knock¬
out animals to study the role of ER6. This study was designed to determine the effect
of oestrogen, and the role of ER8 in mediating those effects, on blood pressure and
vascular function.
To study the effect of oestrogen on blood pressure and the vasculature, C57B16 mice
were assigned to one of three groups; sham ovx, ovx treated with placebo or
supplemented with oestrogen. During the oestrous cycle oestrogen concentration
fluctuates and reaches its peak during proestrous. In this study, the individual cycle
of each animal was known for the days leading up to and including the experiment
end point. To control for the cycling levels of oestrogen in female mice, the ovaries,
the main site of oestrogen synthesis, were surgically removed and animals either
treated with placebo or supplemented with oestrogen. In this study we demonstrated
that placebo treated animals were an appropriate model of oestrogen deprivation as
there was a marked decrease in uterine weight due to atrophy of the uterus. The
concentration of oestrogen, 50pgmr', that was chosen to supplement animals that
had been ovx was within physiological levels and equal to the concentration of
oestrogen in the mouse during proestrous (Jabonlea- Shariff et al, 1999).
Administration of either placebo or oestrogen to ovariectomised animals was via
implantation of subcutaneous pellets as described in section 2.3.1.1.1. Proestrous is
the stage during which ovarian follicular development occurs and is prior to oestrous,
the period of ovulation. The animals in this study which were normally cycling were
known to be either dioestrous, i.e. entering into proestrous, or met- oestrous i.e.
coming out of oestrous. Therefore, it is likely that their average circulating oestrogen
levels were lower when compared to those which were ovx and supplemented with
oestrogen, although the concentration of oestrogen was not measured. The limitation
of this study was the low number of animals in each group studied using telemetry,
particularly sham ovx mice. By increasing the sample size, we would better observe
the overall effect of endogenous oestrogen in each stage of the oestrous cycle.
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Blood pressure was measured in animals from each group following implantation of
radiotelemetry devices. Recently, the development of such devices for implantation
in small rodents has enabled physiological measurements to be taken from conscious
and free moving mice without introducing stress artefacts, it also provided a more
favourable alternative to techniques such as the tail- cuff method and exteriorised
catheters, which are limited as although the tail cuff method is non- invasive, it is
known to be affected by environmental and physiological factors (Bunag, 1983,
Krege et al, 1995). The use of exteriorised catheters introduces stress artefacts in the
measurements taken as animals have to be tethered (Mattson, 1998). Much research
has been committed to the development for implantation into small rodents such that
devices can be implanted into mice as small as 17g (Butz and Davisson, 2001). In
our study we inserted the catheter into the left carotid artery and placed the
transmitter subcutaneously on the left flank. This was chosen as not only was
catheterisation of the carotid a less invasive operation procedure, it was also reported
in literature to have a greater degree of success than catheterisation of the aorta, >
90% and < 20% respectively which can result in the occlusion of blood flow to the
hindlimbs (Carlson and Wyss, 2000). In addition, collateral flow from the right
carotid artery is sufficient to perfuse the left side of the head and face, due to the
Circle of Willis. Catheterisation of the left carotid artery was chosen to avoid aortic
disruption which may have occurred if the right carotid was selected.
In this study we demonstrated that female mice which had undergone ovx and been
supplemented with oestrogen had a small but significant increase in MABP when
compared to that of sham ovx animals or those which were ovx and administered
placebo. SBP was not found to be elevated in oestrogen treated animals and therefore
the increase in MABP was attributed to the concomitant increase in DBP. During the
day, oestrogen treatment lead to an increase of 6.3mmHg -md 9.3mmHg in DBP,
compared to sham ovx and placebo treated animals respectively. Similar to that
observed during the day, at night DBP was elevated in animals treated with
oestrogen when compared to sham ovx and placebo treated animals (an increase of
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7.5mmHg and 6.4mmHg compared to sham ovx and placebo treated animals
respectively).
This study also suggests that the presence of both endogenous and exogenous
oestrogen increased blood pressure as mice administered oestrogen and those which
were sham ovx had a higher mean arterial blood pressure, as measured over a 24hr
period, than those which were ovx and administered placebo. The lower MABP of
placebo treated mice was shown to occur during the day and can be attributed to the
reduction in SBP in the placebo treated group (reduction of 6.1mmHg compared to
normally cycling females). A decrease in systolic blood pressure such as that
observed in placebo treated animals may be attributed to an increase in aortic
distensibility. A study by Tatchum-Talom et al, would support such a finding as they
demonstrated in rats that oestrogen deprivation lead to a reduction in aortic stiffness
when compared to oestrogen treated ovx rats, which were found to have increased
aortic stiffness associated with increase pulse pressure and left ventricular
hypertrophy (2002). However, whether oestrogen deprivation would lead to a
reduction in aortic stiffness in mice would require further investigation by pulse
wave velocity and determining the elastimcollagen ratio.
The finding in this study that exogenous oestrogen resulted in a small but significant
increase in MABP when compared to that of mice which were normally cycling may
be surprising. Early clinical observations and animal studies report that oestrogen
either had no effect on blood pressure, as with longitudinal clinical studies (Pearson
et al 1997), or that blood pressure was lowered following oestrogen supplementation,
in cross over clinical studies (Anastos et al 1991) and in a knockout mouse model of
menopause associated hypertension (Javeshghani et al, 2003). However, it has been
known for some time that one of the harmful effects of combined oral contraceptives
(COCs) was an increase in blood pressure (Nichols et al, 1993, Qifang et al, 1994).
The long- term use of COCs can increase a woman's risk two- fold of developing
hypertension (Chasan- Taber et al 1996).
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The mechanisms by which oestrogen may increase blood pressure are poorly
understood. It is possible that the increase in blood pressure observed following
oestrogen treatment is mediated by direct effects of oestrogen on the vasculature, or
indirectly by modulating the renin angiotensin system (RAS), renal function or
sympathetic nervous system.
Contradictory findings have been reported regarding the effects of oestrogen on the
RAS as some studies have shown that oestrogen attenuates the RAS and reduces
blood pressure (Nickenig et al, 1998, Roesch et al, 2000). In contrast, an oestrogen
response element has been described in the angiotensinogen gene promoter (Feldmer
et al, 1991) and oestrogen administration has been reported to stimulate the hepatic
synthesis of angiotensinogen as observed in post-menopausal women receiving ERT
(Schunkert et al, 1997). This has also been shown in animal models, where both
physiological and pharmacological concentrations of oestrogen increased circulating
levels of angiotensinogen in female rats (Stavreus- Evers et al, 2001) and that it was
directly proportional to oestrogen concentration as angiotensinogen levels were high
during oestrous and low during metoestrous in the rat brain (Greenland & Semia,
2004).
In addition to activation of the renin- angiotensinogen, oestrogen may also increase
blood pressure by altering renal function. A study of acute sodium loading in young
pre-menopausal women reported that following suppression of endogenous
oestrogen and progesterone, administration of exogenous oestrogen and progesterone
increased distal tubule sodium reabsorption and reduced sodium excretion
(Stachenfeld et al, 2004). As progesterone could not produce these effects
independently, they were attributed to oestrogen. A reduction in sodium excretion
and an increase in water retention contribute to an increase in blood pressure (Hall et
al, 1980). However, studies have reported that oestrogen is not associated with an
increased blood pressure response to salt. A study by Pechere- Bertschi et al, in
which young women using oral contraceptives, who were salt resistant, responded to
low salt intake by increasing sodium reabsorption and decreasing reabsorption in
response to sodium loading (2003). This was similar to non- oral contraceptive users
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who were salt resistant regardless of the stage of the menstrual cycle (Pechere-
Bertschi et al, 2000). However, this group reported that although systemic blood
pressure was not affected, oestrogen influenced the renal haemodynamic response to
salt (Pechere- Bertschi et al, 2003). Women taking oral contraceptives had an
increased glomerular filtration rate and an increase in proximal reabsorption of
sodium which they suggested may be due to an increase in RAS. Therefore human
models suggest that the increase of blood pressure in response to oestrogen observed
in our study is more likely to involve increased activity of the RAS than an altered
pressure-natriuresis response. Further studies in our own lab for RAS activation are
currently ongoing and should provide some insight as to whether the observed effect
of oestrogen on blood pressure may in part be explained by an effect on the RAS in
this particular experimental model.
Oestrogen may also alter blood pressure by influencing sympathetic or
parasympathetic activity. In the clinical setting it has been reported that pre¬
menopausal women have higher baroreflex sensitivity than age-matched men
(Huikuri et al, 1996) and that this difference was attributed to the female sex
hormone. Animal studies demonstrated that female rats that were chronically treated
with oestrogen, at a dose equivalent to that during proestrous and additionally treated
with an acute administration of oestrogen, had increased parasympathetic tone and an
enhanced ability to resist increases in sympathetic output relative to male rats (Saleh
and Connell, 1999). Although the dose of oestrogen used to supplement rats in this
study was equivalent to that used in our study, the comparisons were drawn between
distinct experimental groups and therefore it is difficult to apply the observations by
Saleh et al. They compared male to female rats which were supplemented with
oestrogen whilst we compared the effect of exogenous to endogenous oestrogen and
also to oestrogen deprivation in female mice. It is not possible to exclude a role for
oestrogen to increase blood pressure by exerting effects on the central nervous
system in our model as the literature also reports that treatment of female rats with
oestrogen decreased 0,2- receptor expression in brain tissue by increasing G protein
coupled receptor kinase (Ansonoff and Etgen, 2001). Therefore, it may be that
relative to placebo-treated mice and sham ovx mice in our study, chronic oestrogen
218
treatment increased MABP by attenuating the reduction of sympathetic nervous
system discharge that would otherwise be mediated via the -receptor. Furthermore,
the enzyme catechol-O-methyl transferase (COMT, reviewed in Mannisto and
Kaakkola 1999) that metabolises endogenous (and exogenous) catecholamines, is
also involved in the metabolism of estradiol (reviewed in Mannisto and Kaakkola,
1999). Therefore, in our mouse model, where exogenous oestrogen treatment
increased blood pressure relative to endogenous oestrogen and placebo treated
animals, competition between oestrogen and catecholamine for COMT may have
resulted in an increase in the circulating levels of catecholamine. It is possible that
the elevated levels of catecholamine result in a reduction in the sensitivity of central
a,2- receptors and therefore attenuate the 0,2- mediated reduction in sympathetic
stimulation. This hypothesis is very speculative and deserves further investigation
with more direct measurements.
We also found in this study that oestrogen deprivation lead to a reduction in MABP
when compared to mice with either endogenous or exogenous oestrogen treatment.
This finding may be surprising as a study by Javeshghani et al, reported that chronic
oestrogen deprivation in mice, due to ablation of the gene for the follicle stimulating
hormone receptor (FORKO mice) and therefore low levels of oestrogen, lead to an
increase in MABP (2003). However, it is supported by the more recent study of Head
et al, who demonstrated that female mice which were aromatase deficient, therefore
unable to synthesis oestrogen, had a lower blood pressure than that of WT mice
(2004). They reported a reduction in MABP of 4.5mmHg in ARKO mice relative to
WT controls. Similarly, we found that MABP was reduced by 4.1mmHg in ovx
placebo treated females when compared to female mice which were normally
cycling. Although Head et al were unable to determine a mechanism for the
reduction in MABP they suggested that it may be due to a role of oestrogen in
maintaining normal vasoconstrictor activity (2004).
An additional feature of this study was the assessment of diurnal variation. We
demonstrated that HR, blood pressure and activity increased at night, the natural
active period, in each of the oestrogen treatment groups studied. Reports in the
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literature show that fluctuations in levels of oestrogen during the oestrous cycle
contribute to the preservation of the physiological circadian fluctuation of blood
pressure. In a study by Mercuro et al, less than 10% of post-menopausal women
studied had a peak- to- trough variation in blood pressure (1998). However,
following oestrogen replacement therapy, the expected reduction in blood pressure at
night was restored. Furthermore, in normally cycling female rats, the variation in the
circadian system was shown to be greatest during proestrous at which stage in the
oestrous cycle rats were also shown to be most active (Takezawa et al, 1994).
Interestingly, we found in our study that although activity in each of the three groups
studied increased at night, ovx female mice treated with either oestrogen or placebo
were less active than normally cycling female mice. As the level of oestrogen used to
supplement the oestrogen treated mice was equivalent to that during prooestrous it
may have been expected that these mice would have been more active than either
normally cycling or placebo treated animals. It is possible that in the oestrogen
supplemented mice that the blunting of the increase of activity at night could be that
the level of oestrogen is fixed and such diurnal variations are enhanced by
fluctuations during the oestrous cycle. Alternatively, the reduced level of activity in
oestrogen and placebo treated mice could be due to the additional surgery that these
animals underwent, ovx and telemetry implantation as opposed to normally cycling
female mice which underwent the telemetry implantation surgery only. However,
this seems unlikely as the mice had recovered from ovx surgery, as determined by
weight and daily inspection to ensure animals were healthy and infection free, before
undergoing surgery for telemetry implantation.
In our study we also show that administration of the proprietary Organon ERB
selective antagonist, increased MABP measured over 24hrs in sham ovx mice yet
reduced MABP in ovx mice supplemented with oestrogen. This suggests therefore,
that in normally cycling female mice, oestrogen acts through ER8 to lower blood
pressure and chronic administration of oestrogen acts through ER8 to increase blood
pressure.
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Although this is the first study to show the effect of oestrogen in female mice on
blood pressure and to demonstrate a role for ER6 using the novel approach of a
specific ER6 antagonist, it is not the first time that a role for ER6 in the regulation of
blood pressure has been demonstrated. Zhu et al reported, using the 6ERKO mouse
as their experimental model, that loss of functional ERB leaa to an increase in blood
pressure, of -lOmmHg, in year old male and female mice, which were normally
cycling (Zhu Y et al, 2002). In our study we observed a similar increase in MABP,
8.6mmHg and 6.2mmHg day and night respectively, in normally cycling female
mice following treatment with the ERB antagonist. Furthermore, in rat, oestrogen
acting centrally reduced the arterial pressure response to stress (Chemay et al, 2003).
They demonstrated that these effects were in part mediated via NO which is known
to reduce sympathetic output when applied to the paraventricular nucleus of the
hypothalamus (PVN, reviewed in Kurkoff, 1999). This study was not designed to
attribute this effect of oestrogen specifically through the action of one of its
receptors. However, interestingly, immunoreactive ERB and mRNA have been
described in the neurones of the PVN (Shughrue and Merchenthaler, 2001).
Furthermore, ER gene expression has been demonstrated in neurones of the nucleus
tractus solitaries (NTS) and caudal ventrolateral medulla (CVN) (Simerly et al,
1990) where the activity of neurones in these areas are also known to be affected by
NO (reviewed in Kurkoff, 1999). The ERP antagonist used in this study is predicted
to be able to cross the blood brain barrier based on its physico- chemical properties,
such as solubility and lipophilicity. Therefore from our study it may be suggested
that the increase in blood pressure in mice which were normally cycling following
treatment with the ERp antagonist, may in part be due to the inhibition of ERB
acitivity in the PVN. The inhibition of ERB in the PVN, NTS and or CVM may result
in reduction in the release of NO.
The finding that the said ERP antagonist reduced MABP ir. ovx mice administered
oestrogen suggests that ERB is involved in the increase in blood pressure produced
by chronic administration of oestrogen. This is in sharp contrast to our finding in
sham ovx female mice and from that observed in the study by Zhu et al (2002) where
ERB reportedly has an antihypertensive effect. To date the role of ERB in regulating
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blood pressure has been restricted to mouse studies using either male or normally
cycling female mice and studying the role of the vasculature in blood pressure. It is
possible, that the higher concentration of oestrogen which results in an increase
blood pressure relative to sham ovx mice also alters the functioning of ER8 such that
it acts to increase blood pressure. As previously discussed oestrogen may act to
increase blood pressure by activating the RAS. The literature has not as yet identified
a specific role for ERs in regulation of the RAS. However, Stavreus- Evers et al,
reported that serum levels of angiotensinogen increased with increasing levels of
oestrogen and ERa expression in the liver which was blocked by the non-selective
ER antagonist ICI 182 780 (2001). To date expression of ER8 has not been detected
in the liver. Further investigation as to the mechanism by which chronic oestrogen
treatment may increase blood pressure via ER8 is required however it is possible that
it may be due to a dose-dependent effect of oestrogen on the RAS.
In this study we also investigated vascular function as this may be one of the
contributing factors through which oestrogen and ER6 may influence blood pressure.
The observed effect of oestrogen status and the ERp antagonist on blood pressure in
our study was mainly attributable to alterations in DBP which is indicative of
alterations in vascular resistance. Oestrogen has been reported to lead to the
alteration or modulation of ion fluxes, receptors on smooth muscle cells and
modulation of endothelium-derived factor production and activity (White et al, 1995,
Austin et al 1995). Therefore, we compared vascular responses in the mesenteric
artery from mice of different oestrogen status as well as assessing vascular function
in mice that had been treated with the said ERP selective antagonist.
We showed that the contractile response to PE was similar between normally cycling
female mice and those that had undergone ovx and treatment with placebo. However,
female mice that had undergone ovx and were then supplemented with oestrogen had
an enhanced contractile response to PE in comparison to those mice that were
normally cycling. The increase in vascular tone, either as a result of enhanced
vasoconstriction, impaired endothelium-dependent vasodilatation or a decreased
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vascular sensitivity to NO, following chronic oestrogen administration may be one of
the mechanisms by which blood pressure was increased in these animals.
The enhanced contractile response to PE following administration of exogenous
oestrogen in this study was supported by the findings of Colucci et al and Cheng et
al (Colucci et al, 1982 and Cheng et al, 1992) who reported that oestrogen treatment
of female rats lead to an increase in the sensitivity to catecholamines in both isolated
aorta and mesenteric arteries. It was suggested that the enhanced contractile response
to catecholamines following oestrogen treatment may be explained by an increase in
the affinity of vascular a-adrenergic receptors (Colucci et al, 1982), and by the
inhibition of uptake, which is involved in the termination of catecholamine action, by
estradiol (Salt, 1972, Hamlet et al, 1980, Gisclard et al, 1987). Alternatively, as
shown by Bento and Moraes, oestrogen pre-treatment increased the number of ai-
adrenoceptors and the amount of intracellular calcium available for contraction
(1992). Future experiments would include determining the effect of oestrogen on the
contractile response to other contractile agents such as 5-HT or thromboxane
analogues. This would provide some insight into whether the enhanced response
following chronic oestrogen treatment was specifically due to enhancement of the a-
adrenoceptor mediated response or due to sensitisation of contractile proteins. If the
response was found to be specific to adrenoceptors, further experiments to elucidate
the exact mechanism would be required. One such experiment could be to determine
whether the increase in a- adrenoceptor sensitivity was due to the blocking of
uptake. This could be tested by measuring the a- adrenergic response in the presence
of cocaine, an uptake inhibitor. If the contractile response was not further enhanced
by the presence of cocaine, or less so than vessels from sham ovx or those mice
which were treated with placebo it would suggest that the increased sensitivity to the
adrenoceptor agonist was due to oestrogen blocking uptake.
Another factor may be the concentration of oestrogen used to supplement animals
and the stage of the oestrous cycle in which the sham ovx animals were at time of
being euthanised. As discussed earlier, the plasma concentration of oestrogen
achieved following supplementation (0.05mg/pellet) was 50pgml_1, which is closer to
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the higher concentrations of oestrogen during the mouse oestrous cycle. In contrast
the sham ovx animals included in this study were in stages of the oestrous cycle
when concentrations of oestrogen were low. A study by Bolego et al reported that
aorta isolated from female rats treated with low dose oestradiol (5pgkg_1), which was
equivalent to the levels of oestrogen during proestrous, had increased levels of basal
NO whilst administration of high dose oestradiol (lOOpgkg1) inhibited the release of
basal NO whilst also increasing the release of endothelium derived vasoconstrictor
substances (1997).
It is difficult to draw comparisons between this study and ours as although the low
dose they selected was physiological, it was equivalent to that used to supplement the
animals in our study. The higher dose, at which alterations in vascular function
occurred, was pharmacological. In contrast, we observed similar effects with
different concentrations of oestrogen within physiological limits. We cannot
determine from this study whether the difference in vascular response was due to low
levels of oestrogen, as the animals in our study which were normally cycling were at
stages of the oestrous cycle when oestrogen levels were low, or due to the
fluctuations in oestrogen during the oestrous cycle. Further investigation to assess the
contractile response to PE in vessels obtained from mice during different stages of
their oestrous cycle would provide further insight.
Endothelial cells control vascular tone in response to physiological stimuli- sheer
stress, pressure or pharmacological stimuli, through the synthesis and release of
vasoactive agents that affect the contraction of the underlying vascular smooth
muscle cells. To assess endothelial function and whether this could provide an
explanation for the effect of oestrogen on blood pressure and indeed the
vasoconstrictor response, we studied both endothelium -dependent and -independent
vasodilation.
We found that the contractile response to PE was unaltered by the presence of
L-NAME in normally cycling female mice and ovx mice administered either placebo
or oestrogen. This suggests that in first order mesenteric arteries from female mice,
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NO is not the main mediator of basal vascular tone. However, literature has reported
that vasorelaxation of mouse mesenteric arteries results from activation of both the
NO and COX pathways (Cooke et al, 2003a and Chataigneau et al, 1999). An
explanation for the observation may be the difference in the sex of the animals
studied as our studies in contrast to those were carried out in female mice.
Interestingly, the involvement of these pathways has been suggested to be influenced
by oestrogen status as endothelium- dependent relaxation of mesenteric arteries from
pregnant mice, which have high levels of oestrogen, require inhibitors of both NO
and COX pathways before the relaxation response is attenuated (Cooke et al,
2003b). This is in contrast to mesenteric arteries from non- pregnant mice, in which
the endothelium- dependent vasodilatory response can be blocked by inhibitors of
the NO pathway alone (Cooke et al, 2003b). Furthermore, the relative contributions
of endothelium- derived vasodilators have been reported to vary with the size of the
vascular bed studied. It was demonstrated in the cerebral vascular bed of the rat that
oestrogen treatment increased endothelial NO production, in larger cerebral arteries,
with no apparent effect on COX pathways whereas, in smaller cerebral arteries
prostanoids play a more prominent role (You et al, 1999 and Ospina et al, 2003).
Interestingly, we demonstrated that incubation with indomeihacin slightly increased
the contractile response to PE in mesenteric arteries from ovx mice treated with
oestrogen. This suggests that chronic oestrogen treatment lead to an increase in the
release of vasodilator prostanoids from the endothelium. However, this was not
sufficient to counteract the mechanism by which oestrogen increases vascular
sensitivity to PE. These findings suggest that as oestrogen acts to increase the release
of vasodilator prostanoids from the endothelium and the response to PE was
unaltered by the presence of L-NAME, the increased sensitivity to PE cannot be
explained by a reduction in the levels of basal NO or alteration of prostanoid levels.
Although decreased levels of basal NO were shown not to be an explanation for the
potentiated response to PE following oestrogen supplementation, the relaxation
response to ACh and SNP were found to be reduced in vessels from these mice
relative to those from sham ovx and placebo treated mice, which were not different
to each other. As the response to SNP was reduced to a similar degree to that of
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ACh, this suggests that the ability of vascular smooth muscle cells to relax in
response to NO was impaired following ovariectomy and oestrogen supplementation.
This may be due to down regulation or desensitisation of the components of the
signalling pathway of NO in VSMC such as guanylate cyclase (GC) and cGMP
following chronic oestrogen treatment. Such a hypothesis is supported by the report
that incubation of cultured PC 12 cells with oestrogen decreased cGMP levels (Chen
et al, 2001). This was attributed to a reduction in soluble guanylate cyclase as the
activation of cGMP in response to SNP was reduced whilst that to ANP was
unaffected. Therefore, future studies on the vasculature of our mice such as western
analysis to quantify the expression of soluble guanlyl cyclase, would be required to
determine whether such a mechanism for oestrogen to reduce the sensitivity of
vascular smooth muscle cells to NO could exist.
Although less likely, other possibilities for the reduction in the response to ACh
could be due to alterations in the release of endothelium derived hyperpolarizing
factor (EDHF). In this study we did not test the relaxant response to ACh in the
presence of the NOS inhibitor L-NAME and therefore it is not possible to conclude
that the relaxation response to ACh in the animals studied was solely due to
alterations in the stimulated release of NO. It is also possible that the reduction in
response to ACh was due to oestrogen reducing the release of, or smooth muscle
sensitivity to, EDHF. Further experiments to determine whether oestrogen has
modulated the release of NO, prostanoids or EDHF could be ascertained by
determining the relaxant response to ACh in vessels in the presence of both
indomethacin and L-NAME and whether such a relaxant response could be inhibited
by charybdotoxin (ChTX), which would block the EDHF response. A role for
oestrogen in regulating EDHF was demonstrated by Golding and Kepler, as they
showed that EDHF mediated dilations in the cerebral artery were nonexistent in
female rats which had undergone chronic oestrogen administration following ovx
and endogenous oestrogen in intact female rats. This effect of oestrogen was
confirmed by the observation that EDHF relaxation was enhanced in rats which had
undergone ovx. Although there are some contradictory reports in the literature,
demonstrating that oestrogen treatment enhanced relaxation induced by EDHF (Liu
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et al, 2001), once again there are also indications that the cellular modes of action of
EDHF show both tissue and species variability (Garland et al, 1995).
The observation in this study that treatment of sham ovx and ovx mice supplemented
with oestrogen, with the ER6 selective antagonist lead to an increase and decrease in
blood pressure respectively, may in part be attributed to alterations in vascular
reactivity of these animals.
In normally cycling female mice, the ERG selective antagonist did not alter the
contractile response to PE or basal levels of NO or prostanoids in the mesenteric
artery. However, the study by Zhu et al, which reported an increase in MABP in both
male and female, normally cycling, GERKO mice also reported that ERG attenuated
vascular contraction as aorta isolated from these mice had an increased contractile
response (2002). Therefore they suggested that the increase in MABP in the GERKO
mouse may at least in part be attributed to an increase in vascular tone. However, it is
possible that the conflicting findings between the studies are due to differences in
experimental approach between the selective ERG antagonist, in our study, to that of
a knock out mouse model. In addition, although blood pressure studies by Zhu et al,
were carried out in both male and female mice, the vascular study was done in aortic
vessels from male mice. Therefore, it is difficult to compare results between our
study and that of Zhu et al due to differences in both the sex of the mice and vascular
bed studied. Although their paper reports an increase in the response to PE in
denuded vessels, supplementary data revealed that this was only in aortic vessels in
which the endothelium had been removed. Therefore similar to our findings in
female endothelium intact first order mesenteric rings, they report that the contractile
response to PE between WT and GERKO mice in endothelium intact aortic rings
from male mice was not different. Although, this was not further discussed in the
paper this would suggest that the reactivity of the endothelium is altered such that it
would mask differences in vascular smooth muscle function which would only
become apparent when the endothelium was removed. Furthermore, endothelial
function was not determined by the more typical method of L-NAME or
indomethacin to determine the basal release of NO or prostanoids or determining the
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endothelium- dependent and -independent vasorelaxation responses using ACh or
SNP but rather to the vasodilatory response to acute administration of oestrogen.
In contrast to that observed in normally cycling female mice, treatment of female
mice supplemented with oestrogen with the said ER6 antagonist lead to a reduction
in MABP, restoring BP to levels seen in sham ovx mice. We demonstrated that the
sensitivity of VSMC of vessels obtained from these mice to PE was reduced when
compared to vessels from mice which did not receive the antagonist suggesting that
the reduction in blood pressure may be in part due to a reduction in vascular tone. To
determine whether this effect of the ER6 antagonist was due to alterations in the
basal release of either NO or constrictor prostanoids, the response to PE was
determined in the presence of L-NAME and indomethacin. We reported, similar to
the observation in ovx mice supplemented with oestrogen which did not receive the
antagonist, that incubation with L-NAME did not alter the contractile response to PE.
Therefore, the increased sensitivity to PE in vessels in mice treated with the ERB
antagonist remained in the presence of L-NAME and suggested that ERB does not
modify the release of basal NO at least in the female mouse mesenteric vascular bed.
However, we demonstrated that treatment of oestrogen supplemented mice with the
ERB antagonist abolished the enhanced sensitivity to PE in the presence of
indomethacin observed in vessels from those mice which did not receive the
antagonist. This suggests therefore, that ERB may mediate the release of vasodilatory
prostanoids by chronic administration of oestrogen. Therefore, the reduction in
sensitivity to PE in vessels from oestrogen treated female mice following treatment
with the ERB selective antagonist was not due to an increase in the basal release of
NO or in the release of vasoldilatory prostanoids through ERB.
However, the relaxation response to ACh and SNP was increased following
treatment with the ERB selective antagonist. We reported that chronic oestrogen
supplementation reduced the vasodilatory response similarly to both ACh and SNP
thereby suggesting a reduction in vascular smooth muscle sensitivity to NO which
may be attributed to a reduction in soluble guanylate cyclase or activity of cGMP.
Therefore it is possible that in mice supplemented with oestrogen, ERB attenuates
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signalling of NO through the GC pathway, as following treatment with the antagonist
the relaxant responses to ACh and SNP were restored. It is possible to suggest
therefore that ER6 in female mice supplemented with oestrogen, can modulate
vascular tone by reducing sensitivity to NO.
In conclusion, the major finding of this chapter was that oestrogen supplementation
of ovx mice increased blood pressure when compared to that of female mice which
were normally cycling. Ovx mice treated with placebo had a reduced bp relative to
normally cycling mice. The increase in MABP in oestrogen supplemented mice may
be attributed in part to an increase in vascular sensitivity to PE and a decrease in
endothelium-dependent and independent vasodilatation. Neither decreased NO, nor
increased constrictor PG, bioavailability can account for these effects of oestrogen in
the vessels. In addition, it was shown that all of the effects of oestrogen
supplementation on bp and vascular function were reversed in mice treated
concurrently with the ER6 selective antagonist.
In contrast to the above, the ER6 antagonist increased, rather than reduced BP, in
normally cycling female mice, although there was no accompanying change in
vascular function.
The opposite effects of the ER6 selective antagonist on MABP in normally cycling
female mice and those ovx and treated with oestrogen, suggests that different levels
of oestrogen, or indeed, chronically sustained elevated levels of oestrogen, produce
opposing effects whilst acting through the same receptor, perhaps due to




As pre-menopausal women had a lower incidence of cardiovascular disease than either
post-menopausal women or age- matched men, it was proposed that oestrogens
protected against cardiovascular disease (Sullivan et al, 1990, Benetos et al, 1999).
However, randomised controlled clinical studies have suggested not only that HRT
provides no benefit but that in the first year of treatment there is an increased risk of
cardiovascular events (Hulley et al, 1998, WHI 2002). A number of studies using a
variety of animal models have reported that oestrogens, via actions on both the
vasculature and heart, are cardioprotective.
When I started the studies described in this thesis, experiments of the effects of
oestrogen on the cardiovascular system were largely focussed upon the use of mice with
targeted disruption of the ERa and ERB genes. The use of these mice as animal models
for oestrogen research had progressed despite a lack of knowledge about the cell specific
pattern of expression of the two ERs in the mouse cardiovascular system. At that time
research using ERKO and pERKO mice and their wild typ^ control littermates had
mainly focused on the effects of oestrogen on the vasculature, specifically vascular
injury (Iafrati et al, 1997, Karas et al, 1999) and vascular tone (Rubanyi et al, 1997,
Nilsson et al, 2000). These studies had demonstrated that chronic oestrogen
supplementation may attenuate vascular smooth muscle cell proliferation via ERa or
ERP (Iafrati et al, 1997, Karas et al, 1999) and that endogenous oestrogen in male mice
increased the basal release of NO via ERa (Rubanyi et al, 1997). However, it was only
recently that characterisation of the role of ERp in mediating the effects of oestrogen in
the vasculature began. Nilsson et al (2001), in contrast to Rubanyi et al (1997), studied
the relaxant response to acute administration of oestrogen and reported that oestrogen
acting through ERp negatively regulated the release of NO. Therefore, a distinct lack of
clarity existed as to the individual effects of ERs in regulating vascular tone due, in part,
to differences in the experimental design employed in the different studies. Furthermore,
correlating with the onset of our study, the literature reported that a polymorphism in the
human gene encoding ERp was associated with hypertension in Japanese women
(Ogawa et al, 2000). Therefore, the purpose of this study was to determine whether
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oestrogens and in particular oestrogens acting through ERp modify vascular function
and contributes to the regulation of blood pressure.
In our initial investigations of the distribution and cellular localization of ERs in the
cardiovascular system of WT mice we demonstrated that ERp, but not ERa, could be
immunolocalized to the nuclei of cardiomyocytes and nuclei of endothelial and vascular
smooth muscle cells of vessels from both aortic and mesenteric vascular beds. In
addition, cellular localisation and tissue distribution within the cardiovascular system
was the same for both male and female mice. The pattern of distribution of ERp was
similar to that reported in the rat (Andersson et al 2001, Rodrigo et al, 2002). More
recently, in support of our findings, Liang et al demonstrated that ERp was expressed in
mouse aorta by both immunohistochemistry (Liang et al, 2001) and Western blotting
(Liang et al, 2003). Although in their original study Liang et al, in agreement with our
observations, demonstrated that ERa was not expressed in mouse aorta (2001), they
were able to detect it in protein extracts using Western blotting (2003) and therefore, this
is something that we may wish to pursue in the future. Recently, Forster et al (2004), in
contrast to our findings, reported that they were unable to detect ERp in mouse hearts by
either immunohistochemistry or Western blotting. The literature is rather conflicting as
regards expression of ERp in the heart with some studies reporting expression only in
the nucleus of cardiomyocytes (Saunders et al, 1997) and others, restricted specifically
to the mitochondria (Taylor et al, 2000). However, in support of our initial findings we
were able to confirm that immunoreactive ERP was expressed in the nuclei of
cardiomyocytes using a second antibody which was directed against a different region of
the ERp protein.
Having determined that ERp was expressed in the vasculature we aimed to investigate
the physiological role of ERp in mediating the effects of oestrogen in both male and
female mice. In male mice, we studied the role of ERp in mediating the effects of
endogenous oestrogen in both young and aged animals using the BERKO model. We
demonstrated that loss of functional ERp lead to an increase in vascular contractility to
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PE in both young and aged animals. The enhanced vasoconstricting response to PE in
young pERKO mice relative to age-matched WT controls could in part be attributed to
impaired endothelial vasodilatation, as both the basal release of NO and the relaxation
response to ACh was reduced in the vasculature of pERKO mice. This suggested that
oestrogen acting through ERp increased the bioavailability of NO. The studies described
in this thesis were not designed to determine the exact mechanism by which this may
occur. However, since our study several mechanisms have been suggested, from
localisation of ERp in caveolae leading to activation of eNOS (Chambliss et al, 2002),
induction of iNOS expression (Zhu et al, 2002) and by activating anti-oxidant enzymes
(Tamir et al, 2002, Montano et al, 2004). Whether such mechanisms applied to our
model could be determined by measuring the levels of eNOS by Western blotting and by
measuring tissue levels of NO. In vessels from aged animals, the loss of functional ERp
also resulted in enhanced sensitivity to PE. However, in contrast to young pERKO mice,
there was no difference in the basal release of NO between aged WT and pERKO mice.
This suggested that the enhanced vascular contractility in pERKO mice may also be due
to a direct effect of ERp on vascular smooth muscle cells, poss'bly via the regulation of
ion flux. As the contractile response to KC1 was similar between all the groups studied it
was unlikely that the enhanced contractile response was due to alterations in Ca2+ influx.
However, it has been demonstrated that oestrogen can regulate the expression of
subunits of K+ channels such that it enhances K+ efflux (Benkusky et al, 2002).
Therefore it is possible that, in pERKO mice, the loss of ERp lead to impaired function
of K+ channels and subsequently K+ efflux leading to enhanced vasoconstriction.
Whether ERp is the receptor responsible for the effect of oestrogen on K+ channel
subunits and if this could be a mechanism by which vasculature contractility is enhanced
following the loss of ERp could be investigated by measuring the expression of the K+
channel subunit in both WT and pERKO mice. Preliminary studies using RT-PCR and
toxinhistochemistry, carried out by a collaborating lab, demonstrated that loss of
functional ERp in our colony of PERKO mice lead to a trend developing for a reduction
in the expression of the subunit of the K+ channel in both brain and aorta. However due
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to the low numbers of animals studied this did not reach significance. It would be
interesting to be able to complete this study and determine whether the trend for a
reduction in K+ channel expression would reach significance. Although we demonstrated
that loss of functional ERp lead to enhanced vascular tone and impaired vasodilatation
similar to the observations by Zhu et al (2002), in contrast, we did not find that impaired
vascular function in the PERKO mouse lead to an increase in blood pressure. This may
be due to the different techniques used to measure blood pressure between our studies.
However, it was also possible that it was due to variations between the PERKO mouse
model used in our studies. Whilst determining the expression of ERP in the mouse
cardiovascular system we found that we were able to detect immunoreactive ERp in the
pERKO mouse using antibodies directed against the hinge domain and the C-terminus of
the protein. However, we also concluded that in these mice in which targeted disruption
of an exon encoding the DNA binding domain has been undertaken the ERp protein they
expressed did not function in the same way as the WT protein as female PERKO mice
presented with the same ovarian phenotype as described by Krege et al (1998). Western
analyses of tissues from these mice are underway to elucidate what regions of the ERp
protein are expressed in the variant strain of pERKO mouse used in our study. However,
it seems possible that this may provide an explanation for the differences observed
between our study and that of Zhu et al (2002).
Due to the recent advances in the development of selective ER agonists and antagonists
and the expression of residual ERp protein in the pERKO mouse we decided to change
our approach to studying the role of ERp. Through collaboration with Organon we were
able to use an ERp selective antagonist to investigate the influence of oestrogen, and the
role of ERp, on vascular function and in the regulation of blood pressure, as assessed by
radiotelemetry. In this study we found that in WT female mice, chronic oestrogen
supplementation increased MABP when compared to both normally cycling and placebo
treated female mice. As discussed in Section 5.4, this could be due to effects of
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oestrogen on the RAS and this is currently being investigated in our lab by measuring
plasma renin activity and angiotensin concentration. However, as the increase in MABP
in this group of mice studied could be attributed to the concurrent increase in DBP it
suggests that an increase in vascular tone could also be one of the mechanisms by which
blood pressure was increased. Interestingly, the increase in blood pressure in the
oestrogen treated group was reflected in the vascular study of first order mesenteric
arteries where chronic oestrogen treatment resulted in a leftward shift of the PE CRC.
Whilst investigating whether this was due to a reduction in basal NO, we revealed not
only that basal NO was not the main vasodilator in the mesenteric artery of female mice
but also that chronic oestrogen treatment lead to an increased release of vasodilating
prostanoids from the endothelium. These findings were in contrast to those observed in
the male study where NO was the main vasodilator and that prostanoids released from
the endothelium lead to vasoconstriction. The explanation for this may not only be the
sex difference in the animals studied but also the vascular bed as these have been
reported to effect the release of vasoactive factors from the endothelium (Huang et al,
2001 and Sun et al, 1999, Ospina et al, 2003). Results from the second arm of the
vascular study in which aortic vessels from each of the groups studied has yet to be
analysed. This should provide insight into whether the differences in the basal release of
vasodilator between our two studies was indeed due to differences in gender or simply in
the vascular bed studied. Despite oestrogen supplementation increasing the release of
vasodilating prostanoids from the endothelium, it was not sufficient to attenuate the
enhanced vascular tone. The response to both endothelium- dependent and -independent
vasodilators was reduced in a similar manner in vessels from oestrogen supplemented
mice relative to those from normally cycling and placebo treated animals. This
suggested that chronic oestrogen supplementation reduced the ability of vascular smooth
muscle cells to relax to NO. Therefore, in addition to the effect of oestrogen on the
response to PE and that this is not attenuated by blocking either NO or prostanoids, it is
possible that oestrogen treatment alters vascular smooth muscle cell function. Studies by
Colucci (1982) and Bento and Moraes (1992) suggest oestrogen may increase the
affinity or number of vascular a-adrenergic receptors. Ongoing experiments in our lab
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will determine whether the enhanced vasoconstriction to PE is due to effects of
oestrogen on adrenoceptors by studying the contractile response to different contractile
agents. Preliminary data presents a trend for oestrogen treatment to shift the CRC to
5-HT to the left of normally cycling female mice. This is similar to that observed with
PE and therefore suggests that enhanced vascular tone is not specific to adrenoceptors
and subsequently that oestrogen may either increase the sensitivity of contractile
proteins or as previously discussed alter ion flux which could be investigated by
contracting vessels in the presence of a K+ channel blocker.
In female mice which were normally cycling, treatment with the ER6 antagonist lead to
an increase in MABP. This was similar to the finding by Zhu et al, (2002) in which
female I3ERKO mice demonstrated a similar increase in MABP relative to WT females.
Although the increase in MABP following treatment with the said antagonist was due to
an increase in DBP we found that the increase in MABP was not reflected in vascular
function of these mice. Therefore, results from ongoing experiments in the lab of levels
of plasma renin activity in these animals may provide useful insight into the regulation
of blood pressure in these animals. In sharp contrast, the treatment of mice supplemented
with oestrogen with the ER6 antagonist lead to a reduction in MABP. The vascular
response to PE was also reduced in these animals despite the release of vasodilating
prostanoids being attenuated. The vascular response to ACh and SNP was also improved
suggesting that the ability of vascular smooth muscles to relax in response to NO is
improved by blocking ER6. These findings suggest that the effects on the vasculature
are independent of the endothelium and due to alterations in vascular smooth muscle cell
function. Therefore, it will be interesting to test this hypothesis by determining whether
the responses are similar in endothelium denuded vessels. Again it seems likely the
reduction in vascular tone following treatment of mice supplemented with oestrogen and
treated with the ER8 antagonist, is not due to an affect on vascular adrenoceptors, as
preliminary studies in our lab indicate that the contractile response to 5-HT in vessels
from female mice supplemented with oestrogen are shifted to the right in vessels from
animals that had also been treated with said antagonist. The opposite effects of the ER8
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antagonist on MABP in normally cycling female mice and those ovx and treated with
oestrogen, suggests that different levels of oestrogen, or indeed, chronically sustained
elevated levels of oestrogen, produce opposing effects whilst acting through the same
receptor, perhaps due to modification of receptor expression under these different
conditions. Therefore, it will be interesting to determine whether expression of ERa and
ERB is altered by differences in oestrogen concentrations. In addition, to further improve
our understanding of the physiological significance of changes in ER expression by
oestrogen, the actions of these receptors during different oestrogen status could be
investigated through the use of ER selective agonists.
The hypothesis of this thesis was that oestrogen acting through ERp modifies vascular
function and contributes to the regulation of blood pressure. In summary, our findings
are that ERp, which is expressed in the myocardium and vasculature of both male and
female mice, influences vascular function. In male mice, through the use of the 6ERKO,
we demonstrated that ERB mediates the effects of oestrogen as the loss of functional
ERB lead to enhanced vascular contractility and impaired endothelial function. However,
the increase in vascular tone and impaired endothelial vasodilatation were not implicated
in the regulation of MABP. In female mice we found that oestrogen supplementation led
to an increase in blood pressure when compared to that of female mice which were
normally cycling, and those treated with placebo. This may be attributed in part to an
increase in vascular sensitivity to PE and a decrease in endothelium-dependent and
independent vasodilatation. ERB may influence blood pressure by altering vascular
function as the effects of oestrogen on blood pressure and vascular function were
reversed in oestrogen supplemented mice treated concurrently with the ERB selective
receptor antagonist. By contrast, the said antagonist increased rather than reduced blood
pressure in normally cycling female mice while vascular function was unaltered. This
suggests that different levels of oestrogen, or indeed, chronically sustained elevated
levels of oestrogen, produce opposing effects while acting through the same receptor.
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